Catalogue

Transcription

Catalogue
Catalogue
Catalogue
Chemical Reference Substances
Infrared Reference Spectra
Biological Reference Preparations
List No. 48
December 2006
© European Pharmacopoeia - Catalogue, December 2006
i
Catalogue
I. TERMS OF SUPPLY
All items listed in this catalogue are supplied strictly on
the basis of these Terms of Supply, whose provisions shall
have effect notwithstanding any inconsistent provision
contained in any document received from a purchaser.
1. Quality and purpose of items supplied
All chemical substances or biological preparations listed
in this catalogue are supplied exclusively as European
Pharmacopoeia Chemical Reference Substances,
Biological Reference Preparations or Reference Spectra
(Ph. Eur. CRS, BRP or RS) for use as reference standards
in tests and assays carried out in accordance with
the official methods of the European Pharmacopoeia
(Ph. Eur.) and for no other purpose.
The Council of Europe accordingly makes no representation, contractual statement, or expression of opinion
concerning the quality or safety of any item supplied, the
presence of any defect in it, or its fitness for any particular purpose except that of use as a Ph. Eur. CRS, BRP or
RS in tests and assays carried out in accordance with the
official methods of the Ph. Eur. by professional persons
having technical skill and at their own discretion and
risk. It is for the purchasers of any such item who are
responsible for persons in a workplace to determine independently the risks associated with the item according
to the conditions of use and to take appropriate safety
measures, including provision of appropriate information
to persons working with the substance. Any liability of
the Council of Europe for injury, loss or damage arising
from the supply or use of any such item is in any event
hereby excluded to the fullest extent permitted by law;
in particular, no liability is accepted for loss of profits or
indirect or consequential loss.
2. Prices
2.1. PRICE LIST
Prices are identified for each product in the list starting
on page 1.
However, please note that prices and package sizes are
subject to change without notice.
The European Directorate for the Quality of Medicines
(EDQM) does not operate a discount policy. The sale
prices are exclusive of duties and taxes and are given
in Euros. It is the responsibility of the buyer (or the
recipient of the delivery if different from the buyer) to
contact the national fiscal or customs authorities to pay
the duties and taxes. In no event shall the said duties and
taxes be paid by the Council of Europe (EDQM).
In the European Union (EU), there is no VAT identification number for organisations with diplomatic status.
The Council of Europe (EDQM) therefore has no VAT
identification number and is not subject to duties and
taxes.
The goods remain the property of the Council of Europe
(EDQM) until the invoice has been paid in full. Catalogue
items are not returnable for exchange or refund.
2.2. DELIVERY AND RELATED COSTS
on a DDU (Incoterms 2000) basis, namely, delivered
duty unpaid insurance included. Where the shipment
is identified below as airport consignment (see section
Delivery charges), the goods are shipped to the buyer
on a CIP (Incoterms 2000) basis, namely carriage and
insurance included.
— The Council of Europe (EDQM) delivers the goods to
the buyer not cleared for import and not unloaded by
any means of transport.
— The Council of Europe (EDQM) bears the cost and risks
of packing, transport to the delivery site and insurance.
— In no event shall the Council of Europe (EDQM) be
held responsible for any deterioration of the goods due
to their delayed delivery by the carrier.
— The buyer is responsible for the cost of import
customs clearance, for paying the duties and taxes
required in the country of import and for unloading
the goods.
Where the shipping costs are paid by the customer,
the goods are shipped to the buyer on an EX Works
(Incoterms 2000) basis, with neither carriage nor
insurance included. Therefore, the Council of
Europe (EDQM) takes no responsibility in any case of
deterioration or loss of goods.
— The buyer shall be entirely responsible if the goods
are held up at customs at the time of import into
the buyer’s country. In no event shall the Council of
Europe (EDQM) be able to provide any assistance.
Delivery charges
The extra charges are applied per shipment. A shipment
comprises only the reference standards that can be
shipped under the same conditions. Consequently, goods
requiring specific packaging (eg ice, dry-ice), dangerous
goods or controlled substances will be invoiced separately
from the rest of the order and extra charges will be
incurred. As one order could include several shipments,
the Council of Europe (EDQM) advises its customers
to re-group their orders by type of shipment so the
customers can better track the progress of a complete
order and to save money in shipping charges.
Where the buyer requests shipping conditions other than
those recommended in our catalogue, or another carrier,
the Council of Europe (EDQM) takes no responsibility in
any case of deterioration of the goods or loss of parcel.
Extra charges (postage and packaging) will be applied in
the following cases. Please note that prices are subject to
change without notice.
a) Shipment at ambient temperature
— France: no extra charge, price is inclusive of
packaging and postage. At the client’s request, express
courier delivery is charged at 18 EUR per shipment
— EU: 18 EUR per shipment
— Other European countries: 80 EUR per shipment
— Outside Europe: 120 EUR per shipment
(Note: for India, South America and Africa, our
shipment is by airport consignment only)
Unless otherwise stated below or specifically agreed
with the customer, the goods are shipped to the buyer
— Shipping costs paid by the customer: 10 EUR per
shipment
ii
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
b) Shipment under ice (+ 5 °C): sent in cooled freight
containers, either by express courier or by airfreight
(Note: for all countries inside the EU (with the
exception of Cyprus) our shipment is on a ‘door to
door’ basis. For all other countries (and the exceptions
above), our shipment is by airport consignment only)
— EU: 50 EUR per shipment
— Other European countries: 70 EUR per shipment
— Outside Europe: 120 EUR per shipment
— Shipping costs paid by the customer: 20 EUR per
shipment
c) Shipment under ice (- 20 °C): sent in cooled freight
containers, either by express courier or by airfreight
g) Dangerous goods in excepted quantities: sent by
carrier chosen by EDQM
(Note: for countries inside the EU (with the exception
of Cyprus and Malta), our shipment is on a ‘door to
door’ basis. For all other countries (and the exceptions
above), our shipment is by airport consignment only,
and an express courier delivery cannot be used.)
— EU: 50 EUR per shipment
— Other European countries: 125 EUR per shipment
— Outside Europe: 125 EUR per shipment
h) Dangerous goods sent by road: carrier chosen by
EDQM
— EU: 150 EUR per item (‘door to door’)
— Other European countries: 180 EUR per item (‘door
(Note: for all countries inside the EU (with the
to door’)
exception of Cyprus) our shipment is on a ‘door to
door’ basis. For all other countries (and the exceptions — Outside Europe: cannot be sent
above), our shipment is by airport consignment only)
i) Precursors (controlled drugs: sent by carrier chosen
— EU: 50 EUR per shipment
by EDQM)
— Other European countries: 70 EUR per shipment
— Outside Europe: 120 EUR per shipment
— Shipping costs paid by the customer: 20 EUR per
shipment
d) Shipment under dry-ice: sent in cooled freight
containers (dry-ice), either by express courier or by
airfreight
(Note: for all countries inside the EU (with the
exception of Cyprus and Malta) our shipment is on
a ‘door to door’ basis. For all other countries (and
the exceptions above), our shipment is by airport
consignment only)
— EU: 90 EUR per shipment
— Other European countries: 120 EUR per shipment
— Outside Europe: 200 EUR per shipment
— Shipping costs paid by the customer: 55 EUR per
shipment
e) Hepatitis C virus BRP, B19 virus DNA for NAT: dry
ice + dangerous goods – from 5 to 100 vials (from 1
to 20 sales units), sent by carrier chosen by EDQM.
For orders of over 100 vials (20 sales units): prices on
request
(Note: for countries outside France, our shipment is
by airport consignment only)
— EU: 250 EUR per shipment
(Note for countries outside the EU, our shipment is by
airport consignment only)
— France: no extra charge, price is inclusive of
packaging and postage. At the client’s request, express
courier delivery is charged at 18 EUR per shipment
— EU: 18 EUR per shipment
— Other European countries: 160 EUR per shipment
— Outside Europe: 160 EUR per shipment
NB: these extra charges include packaging, shipping
and management of permits
j) Psychotropic substances (controlled drugs: sent by
carrier chosen by EDQM)
(Note for countries outside France, our shipment is by
airport consignment only)
— France: no extra charge, price is inclusive of
packaging and postage. At the client’s request, express
courier delivery is charged at 18 EUR per shipment
— EU (except France): 110 EUR per shipment
— Outside EU: 160 EUR per shipment
NB: these extra charges include packaging, shipping
and management of permits
k) Narcotics (controlled drugs: sent by carrier chosen by
EDQM)
(Note for countries outside France, our shipment is by
airport consignment only)
— Other European countries: 250 EUR per shipment
— France: 50 EUR per shipment
— Outside Europe: 250 EUR per shipment
— EU (except France): 110 EUR per shipment
f) Dangerous goods: sent by airfreight chosen by EDQM
— Outside EU: 160 EUR per shipment
(Note: for countries outside France, our shipment is
by airport consignment only)
NB: these extra charges include packaging, shipping
and management of permits
— EU: 150 EUR per item
l) Reference spectra
— Other European countries: 180 EUR per item
— France: no extra charge, price is inclusive of
packaging and postage. At the client’s request, express
courier delivery is charged at 18 EUR per shipment
— Outside Europe: 250 EUR per item
© European Pharmacopoeia - Catalogue, December 2006
iii
Catalogue
— EU: 18 EUR per shipment
— Other countries: 50 EUR per shipment
— Shipping costs paid by the customer: 10 EUR per
shipment
3. How do I order?
The reference standards are supplied by the EDQM.
3.1. ORDER FORM
Please send your order using the CRS order form (see
page xv of this catalogue) or by sending an official
purchase order on company letterhead to the EDQM.
The order form may be downloaded from www.pheur.org
under Reference Standards (Ph. Eur. Reference
Standards).
Fax: +33 (0)3 88 41 27 71
for the attention of Sales Section
E-mail: [email protected]
Letter: Council of Europe, European Directorate for
the Quality of Medicines, Sales Section, 7 allée
Kastner, CS 30026, F-67081 Strasbourg, France
Unfortunately, we will not be able to process any orders
received without the above information.
3.2. QUANTITIES
A Reference Standard may include several vials/ampoules
(see Sales unit in the catalogue). In such instances do not
order in terms of the total number of vials/ampoules but
in sales units.
Example: to obtain 4 vials of Calcitonin, you have to
order:
Reference C0200000, Quantity 2.
It is the policy of EDQM to limit the purchase quantities of
the same reference standards where stock levels are low.
The EDQM will do everything possible to ensure all
orders are dispatched in their entirety, but when
quantities of CRSs or BRPs are limited, the EDQM will try
to dispatch orders in such a way that as many customers
as possible will receive at least some of the limited
quantities.
3.3. SPECIAL DOCUMENTATION
3.3.1. For all products
It is the responsibility of the customer to check if a
Customers are financially responsible for duplicate orders special permit is needed in the importing country for the
in the following cases:
given product or if, for the given product, no importation
at all is allowed. All necessary documentation has to be
— confirmation orders that are not clearly marked as
provided with the order (especially as regards biological
being a confirmation of an order that has already
products). For customers in China: an additional form
been sent to the Council of Europe (EDQM)
has to be completed and to accompany each Reference
— submission of the same order multiple times (i.e., via Standard order (see example on page xix of this
fax, e-mail, mail or any combination thereof)
catalogue).
Please note that we do not accept orders by telephone.
3.3.2. Controlled drugs
If you are using any other documentation other than the
official CRS order form please ensure you have included:
— 3.3.2.1. Psychotropic substances and narcotics
of the Vienna Convention
— details of the Invoicing/Billing address including
name of company, post code, town, country and
telephone number
As our premises are located in France, the reference
to “*psy” and “*narc” given in the catalogue, only
refers to the French legislation.
— details of the Delivery/Dispatch address (if different)
including name of company, post code, town,
country (please note STREET ADDRESS ONLY, no
P.O. Boxes)
France: to order a psychotropic substance, the
form has to be sent exclusively by mail, with the
appropriate licence to hold such a substance.
— contact name, telephone number, fax number and
e-mail address: an e-mail address is required for order
confirmation and shipping notification purposes
— VAT number (mandatory within the European
Union)
— your order reference/purchase order reference
— item order code
— official name of the Reference Standard as set out in
this catalogue
— sales/unit quantity
— name and account number of the carrier (if you wish
to use your own)
If orders are received without the official name of the
Reference Standard and the full item order code (as set
out in the catalogue) the EDQM takes no responsibility for
an incorrect item being dispatched.
iv
Other countries: to order a psychotropic substance,
the form has to be sent exclusively by mail. These
substances are subject to import and export control
in certain countries. It is the responsibility of the
customer to obtain any necessary documents to
comply with the laws of the importing country.
An import permit (in French or with a certified
French translation attached) must be valid for at least
6 months from the date of its receipt by the Council
of Europe (EDQM).
— 3.3.2.2. Chemical precursors of narcotics (Vienna
Convention)
Countries from the EU: the order of a substance(s)
frequently used for the illegal production of narcotics
and psychotropic substances (reference “*Drug
precursor” in the catalogue) has to be accompanied
by the end user declaration form stating the use(s)
of the substance(s) in line with the current European
form (see example on page xvii of the catalogue).
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
Other countries: it is the responsibility of the
customer to obtain any necessary documents to
comply with the laws of the importing country.
An import permit (in French or with a certified
French translation attached) must be valid for at least
6 months from the date of its receipt by the Council
of Europe (EDQM).
Special charges are required (see 2.2.h and 2.2.i).
For certain countries, especially those having strict
monetary regulations, new clients and large orders,
we reserve the right to require pre-payment. In case of
doubt, please contact us at [email protected]. Payment
by letter of credit is not accepted.
5. Regulatory procedures and SH/NDP
(harmonised system – nomenclature for
customs clearance of goods)
Export permits for psychotropic drugs and precursors In the event of special requirements in the buyer’s
country, the buyer shall obtain the import authorisations
are required before the goods can be dispatched.
and resolve any regulatory matters before the goods
3.4. ORDER PROCESSING AND INVOICING
are ordered and shipped. The buyer shall be entirely
responsible if the goods are held up at customs at the
On receiving the completed order, the EDQM aims to
time of import into the buyer’s country. In no event shall
invoice and dispatch all orders within 2-3 working days
the Council of Europe (EDQM) be able to provide any
with the exception of:
assistance.
— orders for controlled drugs,
Origin of the goods: Diplomatic, Council of EuropeFrance.
— shipments to be made under ice (these are
dispatched only on Mondays and Tuesdays)
SH/NDP 000009.
or dry-ice (these are dispatched only on Mondays),
The SH/NDP is strictly limited to export operations out of
— orders where pre-payment is required.
France.
Please note :
The importer shall be personally responsible for the
tariff classification in the country of import and will
— For all customers from the EU, except France, all
assume the ensuing regulatory, fiscal, health and safety
psychotropic drugs will be invoiced separately from
obligations.
the rest of your order and extra charges will be
incurred (see 2.2.h).
6. Complaints
— For all customers outside the EU, all psychotropic
Complaints related to delivery
drugs and precursors will be invoiced separately from
Any delays in delivery do not entitle the buyer to cancel
the rest of your order and in all cases extra charges
the sale, refuse the goods or claim damages.
will be incurred (see 2.2.h and 2.2.i).
Complaints can be made by the buyer upon delivery of
— For all customers from the EU, all orders for
goods only if the goods do not correspond quantitatively
precursors need to be accompanied by the valid
or qualitatively (if the package containing the goods is
End User Declaration. The End User Declaration for
precursors is included on page xvii of this catalogue. badly damaged).
Complaints must be made to the carrier in writing at the
Delays in shipping will occur if all documentation
time of delivery.
is not available when your order is placed. For this
reason we kindly ask customers to order controlled
A copy of the complaints must be sent to the Council of
drugs separately from other reference standards.
Europe (EDQM) (by e-mail or fax) no later than 12 hours
after the complaints were made.
4. Payment
Payment can be made by cheque made payable to the
Council of Europe/EDQM and be sent to the above
address (see 3.1) or by bank transfer.
Société Générale, 255, route de Mittelhausbergen, 67200
Strasbourg, France
IBAN Account Number for International Transfers:
(FR 76) 30003 02360 00550034256 76
National transfers: 30003 02360 00550034256 76
SWIFT:
SOGEFRPP
You can also pay by credit card (Visa, Eurocard,
Mastercard or American Express) by writing down the
card number, the expiry date, the card holder’s name and
not forgetting the card holder’s signature. Please note
that we do not accept credit card numbers by telephone.
In all cases, the payment should be net of charge for
the Council of Europe and invoices should be paid
within 30 days from the date of invoice. Any other fees,
such as customs duties, taxes, or tariffs are also the
responsibility of the customer.
© European Pharmacopoeia - Catalogue, December 2006
Complaints related to the order
Complaints can be made by the buyer upon delivery of
goods only if the goods do not correspond quantitatively
with the initial order.
Any complaints should be sent within 48 hours of the
time of delivery of the goods in the original package.
For airport deliveries, any complaint should be sent
within a week of the time of delivery at the airport.
If the complaint made at the time of delivery is shown to
be justified because the package and the goods are badly
damaged or because an error clearly has been made, the
Council of Europe (EDQM) will be free to choose between
issuing a credit note, refunding the customer or making
another delivery of similar goods.
In the event of complaints, shipping costs and other
costs (customs) to return goods to the Council of Europe
(EDQM) will be borne by the buyer.
In no event shall the customer return goods to the
Council of Europe (EDQM) unless the Council of Europe
v
Catalogue
(EDQM) has been notified and has given its written
consent.
II. EDQM LONG-TERM STORAGE
CONDITIONS
We will not accept or exchange any returned goods unless
See the relevant column in the list starting on page 1.
the customer complies with the terms and conditions and
the above procedure.
7. Responsibility
The Council of Europe (EDQM) cannot be held responsible for failure to meet the requirements of the legislation of the country where the goods are delivered. It is
the customer’s responsibility to check with the local authorities to make sure that the goods or services that they
intend to order can be imported or used in that country.
III. IDENTIFICATION OF
REFERENCE STANDARDS
The names of the reference standards printed in this
catalogue are those used in the official monographs of the
Ph. Eur. (English version) in alphabetical order (name in
italics followed by CRS or BRP).
IV. USE OF REFERENCE
The customer is solely responsible for the choice of
STANDARDS
products, their storage from the time of delivery and their
use. In no event shall the Council of Europe (EDQM) be
The reference standards of the Ph. Eur. are established
liable for any consequent damage.
and distributed following the general principle of ISO
The Council of Europe (EDQM) guarantees that the goods standard 34.
have been submitted to the carrier in perfect condition.
The specificity of pharmacopoeial reference standards
This is the only guarantee given by the Council of
has been officially recognised in the introduction of the
Europe (EDQM). No other guarantees, whether express
revision of ISO standard ISO 34 - General requirements
or implied, are given by the Council of Europe (EDQM).
for the competence of reference material producers In particular, the Council of Europe (EDQM) does not
(Second Edition 2000): “Pharmacopoeial standards
guarantee that the goods will meet the customer’s
and substances are established and distributed by
specific expectations.
pharmacopoeial authorities following the general
The Council of Europe (EDQM) cannot be held
responsible for the contract not being fulfilled in the
event of goods being out of stock or unavailable, force
majeure, disturbances or total or partial strike action
affecting in particular postal services and means of
transport, and flood or fire.
8. Disputes
In accordance with the provisions of article 21 of the
General Agreement on the Privileges and Immunities
of the Council of Europe, all disputes between the
Council of Europe (EDQM) and the customer as regards
the application of this contract shall be submitted, if
a mutual agreement cannot be reached between the
parties, to arbitration as laid down in Order No. 481 of
the Secretary General, approved by the Committee of
Ministers.
Answers to Your Questions
Reference Standards - Questions about orders, billing,
and shipping information.
Helpdesk: http://www.pheur.org/hd
Fax: +33 (0)3 88 41 27 71
Flight details - Questions about dispatch of CRS orders
only.
Helpdesk: http://www.pheur.org/hd
E-mail: [email protected]
Fax: +33 (0)3 88 41 27 71
principle of this guide. It should be noted, however,
that a different approach is used by the pharmacopoeial
authorities to give the user the information provided by
certificate of analysis and the expiration dates. Also, the
uncertainty of their assigned values is not stated since
it is negligible in relation to the defined limits of the
method-specific assays of the pharmacopoeias for which
they are used.”
The reference standards are specially selected and verified
batches, suitable for use as prescribed in the Pharmacopoeia.
The column ‘Monograph’ lists the monograph(s) and/or
general method(s) of analysis for which the reference
standard is intended. The monograph number requires
four digits (for example monograph 0076), a general
chapter requires five digits (for example the text 5.4 is
indicated with the number 50400, the method 2.5.1 is
indicated with the number 20501). These numbers are
available on the top of the monograph, and correspond to
the identification number of the document.
Suitability for purposes other than those prescribed in
the Ph. Eur. monographs is left up to the user. Each vial
supplied contains a quantity sufficient for the prescribed
use.
A vial or an ampoule is considered as an ‘immediate use’
reference standard. It is recommended that the vial or
ampoule is used in the same series of analysis.
Monographs - Questions about monographs
It is recommended to purchase only a sufficient amount
for immediate use and to use the reference standards as
soon as possible.
Helpdesk: http://www.pheur.org/hd
Fax: +33 (0)3 88 41 27 71
The stability of the contents of opened vials or ampoules
cannot be guaranteed.
An electronic version of the Reference Standards
Catalogue (using Adobe Acrobat version 5) and other
information is available on our website www.pheur.org
In specific cases, for reasons related to filling or labelling,
sub-batches 1.1, 1.2, 1.3, etc., are obtained from the same
batch of bulk material. (Note: the previous classification
vi
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
of the sub-batches 1a, 1b, 1c, will be gradually replaced
with 1.1, 1.2, 1.3, etc.)
provided with the previous batch. An example of a BVS is
included on pages xx and xxi of this catalogue.
However, all necessary precautions are taken in order to
guarantee that the quality and the specifications of the
sub-batches do not differ from one to another.
For reference standards supplied in sealed glass
ampoules the following technique is suitable for opening
the ampoule: tap the ampoule gently to collect the
material at the lower end; score the ampoule with a file;
heat a glass rod to white heat and apply firmly to the file
mark; if a crack is not produced, deepen and extend the
file mark, reheat the glass rod and apply again.
Since CRSs and BRPs are officially certified by the
European Pharmacopoeia Commission, which adopts
the reports establishing their suitability for the intended
use, it should be noted that neither certificates of
analysis nor data not relevant to the use of the products
as defined by the Ph. Eur. monograph are provided with
the reference standard. In the same way, no expiry date
is indicated because the reference standards comply
with the requirements of the corresponding monograph
and are monitored regularly. The ‘Information’ column
of the catalogue indicates an official date on which the
batch is no longer valid as a CRS/BRP for all batches
that have just been replaced. Hence “batch 1 valid until
30 June 2006” means that batch 1 is no longer official as
of 1 July 2006.
Toxic substances. The potential toxicity of certain
reference standards is such that special precautions are
needed during use to avoid contact.
Such substances should be manipulated in a glove box,
otherwise protective gloves, eye protection and a mask
should be worn.
Biological preparations and blood products. These
preparations should be regarded as potentially hazardous
to health and should be used and disposed of according to
your own Laboratory safety practices.
Safety Data Sheets
Where no drying conditions are stated, the substance is
to be used as received.
For the CRS with an assigned content, the stated content
is expressed on an ‘as is’ basis.
The reference standards database on our website is now
updated daily with information on availability. Other
information available includes details on the origin,
assigned value and batch validity.
A batch validity statement (BVS) for the reference
standards is now available. It enables the user of a
reference standard to print a validity statement directly
from the reference standards database on the EDQM
website (http://crs.pheur.org/). This tool will help users
to assure the traceability of validity dates and leaflets
© European Pharmacopoeia - Catalogue, December 2006
Safety data sheets are available on the website or on
request.
Information provided by the Ph. Eur. on the safety data
sheets is compiled from information provided in the
usual way by suppliers or manufacturers of the products
and has not been independently verified by Ph. Eur. staff.
The accuracy of such information cannot therefore be
guaranteed.
V. LEAFLET
In specific cases, an explanatory leaflet is sent with the
product. See the relevant column in the list starting
on page 1 (where nothing is stated, no leaflet is needed
for the given product). Leaflets are also available on the
website.
vii
Catalogue
I. CONDITIONS GÉNÉRALES
La fourniture des articles contenus dans le présent catalogue est effectuée conformément aux termes des Conditions Générales : les dispositions des Conditions Générales s’appliquent, nonobstant toute disposition contraire
contenue dans tout document reçu d’un acquéreur.
1. Qualité et usage des articles fournis
Toute substance chimique ou toute préparation biologique inscrite dans ce catalogue est exclusivement
fournie au titre, soit de Substance Chimique de Référence, soit de Préparation Biologique de Référence, ou
bien encore de Spectre de Référence de la Pharmacopée
Européenne (SCR, PBR, SR Ph. Eur.). Ces produits sont
utilisés en tant qu’étalons de référence dans les essais
et les dosages réalisés conformément aux prescriptions
des méthodes officielles de la Pharmacopée Européenne
(Ph. Eur.) et à aucune autre fin.
Les produits demeurent la propriété du Conseil de
l’Europe (DEQM) jusqu’au complet paiement de la
facture. Les produits ne sont ni échangés ni repris.
2.2. LIVRAISON ET SUPPLÉMENTS SPÉCIAUX
Sauf accord particulier, la livraison des produits est
réalisée en DDU (Incoterms 2000) à l’acheteur, c’est-àdire en « rendu droits et taxes non acquittés assurance
incluse». Pour les envois en rendu aéroport (voir section
Frais de livraison), la livraison des produits est réalisée en
CIP (Incoterms 2000) à l’acheteur, c’est-à-dire en « port
payé assurance incluse».
—
Le Conseil de l’Europe (DEQM) livre à l’acheteur
le produit non dédouané à l’importation et non
déchargé à l’arrivée de tout véhicule de transport.
—
Le Conseil de l’Europe (DEQM) supporte les frais et
risques liés à l’emballage, le transport jusqu’au lieu
de livraison et l’assurance.
—
Il s’ensuit que le Conseil de l’Europe n’émet aucun avis,
ne fait aucune déclaration et n’assume aucune garantie
concernant la qualité ou la sécurité des articles fournis,
l’absence d’un quelconque défaut ou leur aptitude à
toute autre fin, excepté dans le cadre de leur usage au
—
titre de SCR, PBR, SR Ph. Eur. dans les essais et dosages
réalisés conformément aux prescriptions des méthodes
officielles de la Ph. Eur. par des personnes spécialisées
disposant d’une compétence technique, et à leurs risques
et périls. Il appartient aux acquéreurs de tels articles, qui
sont responsables des personnes à leur poste de travail,
de vérifier, à titre personnel, les risques inhérents à
l’article selon les conditions d’utilisation et de prendre les
mesures de sécurité appropriées à l’égard des personnes
travaillant avec la substance. Le Conseil de l’Europe
décline, dans les limites autorisées par la loi, toute
responsabilité à l’égard de tout dommage, de tout sinistre
ou de tout préjudice liés à la fourniture ou à l’utilisation
—
d’un tel article. Le Conseil de l’Europe n’assume
notamment aucune responsabilité relative au manque à
gagner ou à toute autre perte indirecte.
2. Prix
2.1. LISTE DES PRIX
Les prix sont indiqués pour chaque produit dans la liste
débutant page 1.
Toutefois, veuillez noter que les prix et les quantités
unitaires peuvent changer sans préavis.
La Direction Européenne de la Qualité du Médicament
(DEQM) ne pratique pas de politique de remise de prix.
Les prix s’entendent hors droits et taxes. Ils sont indiqués
en euros. Il appartient à l’acheteur (ou le preneur s’il est
différent de l’acheteur) de contacter, selon son statut, son
autorité fiscale ou douanière nationale pour le paiement
des droits et des taxes dont il serait redevable au titre
de la présente commande. Lesdits droits et taxes ne
pourront être pris en charge par le Conseil de l’Europe
(DEQM) en aucune façon.
Dans l’Union Européenne (UE), le régime diplomatique
ne possède pas de numéro d’identification TVA. Aussi,
le Conseil de l’Europe (DEQM) n’a pas de numéro
d’identification TVA et est un non-assujetti exonéré de
droits et de taxes.
viii
En aucun cas, le Conseil de l’Europe (DEQM)
ne saurait être responsable d’une éventuelle
détérioration des produits du fait de leur retrait
tardif auprès du transporteur.
Restent à la charge de l’acheteur : les frais
des formalités d’importation et de mise à la
consommation, les droits et les taxes dont il serait
redevable dans son pays, le déchargement de la
marchandise.
Quand les coûts d’expédition sont à la charge de
l’acheteur, la livraison des produits est réalisée
en EX Works (Incoterm 2000) à l’acheteur, ni
les frais de port, ni l’assurance ne sont inclus.
Par conséquent, le Conseil de l’Europe (DEQM)
ne saurait être tenu pour responsable en cas de
détérioration des produits ou de perte du paquet.
En cas de blocage douanier au moment de
l’importation dans le pays de l’acheteur, ce dernier
assumera la responsabilité pleine et entière. Le
Conseil de l’Europe (DEQM) ne pourra en aucun cas
intervenir dans une quelconque assistance.
Frais de livraison
Un supplément spécial est ajouté par envoi. Un envoi
comprend uniquement les étalons de référence qui
peuvent être expédiés dans les mêmes conditions. Ainsi,
les produits nécessitant un emballage particulier (glace,
carboglace), les produits dangereux ou les substances
contrôlées seront facturés séparément du reste de la
commande, et les suppléments spéciaux seront ajoutés.
Comme une commande peut faire l’objet de plusieurs
envois, le Conseil de l’Europe (DEQM) conseille à ses
clients de regrouper leurs commandes en fonction du
type d’envoi, ainsi les clients pourront mieux suivre la
progression de leur commande complète et économiser
des frais d’expédition.
Si un acheteur demande des conditions d’envois autres
que celles recommandées dans notre catalogue, ou un
autre transporteur, le Conseil de l’Europe (DEQM) ne
saurait être tenu responsable en cas de détérioration des
produits ou de perte du paquet.
Un supplément spécial (emballage et expédition) est
demandé dans les cas suivants. Veuillez noter que les prix
peuvent changer sans préavis.
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
a) Envoi à température ambiante
— UE : 250 EUR par envoi
— France : pas de supplément spécial, le prix s’entend
emballage et expédition par la poste compris. Sur
demande du client, un envoi express est facturé
18 EUR par envoi
— Autres pays d’Europe : 250 EUR par envoi
— UE : 18 EUR par envoi
— Autres pays d’Europe : 80 EUR par envoi
— Hors Europe : 250 EUR par envoi
f) Marchandises dangereuses : expédiées par un
transitaire choisi par la DEQM
(Pour les pays hors France, la livraison est en rendu
aéroport uniquement)
— Hors Europe : 120 EUR par envoi (Pour l’Inde,
l’Amérique du Sud et l’Afrique, la livraison est en
rendu aéroport uniquement)
— UE : 150 EUR par article
— Coûts d’expédition à la charge de l’acheteur : 10 EUR
par envoi
— Hors Europe : 250 EUR par article
b) Envoi sous glace (+ 5 °C) : expédiés par express ou
par transitaire, en conteneurs réfrigérés
g) Matières dangereuses en quantités exemptées :
expédiées par un transporteur choisi par la DEQM
(Pour tous les pays de l’UE (à l’exception de Chypre)
la livraison est en rendu domicile. Pour ces derniers
et tous les autres, la livraison est en rendu aéroport
uniquement)
— UE : 50 EUR par envoi
— Autres pays d’Europe : 70 EUR par envoi
— Hors Europe : 120 EUR par envoi
— Coûts d’expédition à la charge de l’acheteur : 20 EUR
par envoi
c) Envoi sous glace (- 20 °C) : expédiés par express ou
par transitaire, en conteneurs réfrigérés
(Pour tous les pays de l’UE (à l’exception de Chypre)
la livraison est en rendu domicile. Pour ces derniers
et tous les autres, la livraison est en rendu aéroport
uniquement)
— UE : 50 EUR par envoi
— Autres pays d’Europe : 70 EUR par envoi
— Hors Europe : 120 EUR par envoi
— Coûts d’expédition à la charge de l’acheteur : 20 EUR
par envoi
d) Envoi sous carboglace : par express ou par transitaire,
en conteneurs réfrigérés
(Pour tous les pays de l’UE (à l’exception de Chypre
et Malte) la livraison est en rendu domicile. Pour ces
derniers et tous les autres, la livraison est en rendu
aéroport uniquement)
— UE : 90 EUR par envoi
— Autres pays d’Europe : 120 EUR par envoi
— Hors Europe : 200 EUR par envoi
— Coûts d’expédition à la charge de l’acheteur : 55 EUR
par envoi
e) Hepatitis C virus BRP, B19 virus DNA for NAT:
carboglace + marchandises dangereuses – de 5 à
100 flacons (de 1 à 20 unités de vente), expédiés
par un transporteur choisi par la DEQM. Pour les
commandes supérieures à 100 flacons (20 unités de
vente) : prix sur demande
(Pour les pays hors France, la livraison est en rendu
aéroport uniquement)
© European Pharmacopoeia - Catalogue, December 2006
— Autres pays d’Europe : 180 EUR par article
(Pour tous les pays de l’UE (à l’exception de Chypre
et Malte) la livraison est en rendu domicile. Pour ces
derniers et tous les autres, la livraison est en rendu
aéroport uniquement) et ces étalons de référence ne
peuvent être expédiés en express.
— UE : 50 EUR par envoi
— Autres pays d’Europe : 125 EUR par envoi
— Hors Europe : 125 EUR par envoi
h) Matières dangereuses expédiées uniquement par route
par un transporteur choisi par la DEQM
— UE : 150 EUR par article (rendu domicile)
— Autres pays d’Europe : 180 EUR par article (rendu
domicile)
— Hors Europe : ne peut pas être expédié
i) Précurseurs chimiques de stupéfiants (substances
contrôlées : expédiées par un transporteur choisi par
la DEQM)
(Pour les pays hors UE, la livraison est en rendu
aéroport uniquement)
— France : pas de supplément spécial, le prix s’entend
emballage et expédition par la poste compris. Sur
demande du client un envoi express est facturé
18 EUR par envoi
— UE : 18 EUR par envoi
— Autres pays d’Europe : 160 EUR par envoi
— Hors Europe : 160 EUR par envoi
NB : ces suppléments s’entendent emballage, port et
gestion des permis officiels d’exportation
j) Psychotropes (substances contrôlées : expédiées par
un transporteur choisi par la DEQM)
(Pour les pays hors France, la livraison est en rendu
aéroport uniquement)
— France : pas de supplément spécial, le prix s’entend
emballage et expédition par la poste compris. Sur
demande du client un envoi express est facturé
18 EUR par envoi
— UE (hors France) : 110 EUR par envoi
— Hors UE : 160 EUR par envoi
ix
Catalogue
NB : ces suppléments s’entendent emballage, port et
gestion des permis officiels d’exportation
k) Stupéfiants (substances contrôlées : expédiées par un
transporteur choisi par la DEQM)
(Pour les pays hors France, la livraison est en rendu
aéroport uniquement)
— France : 50 EUR par envoi
— UE (hors France) : 110 EUR par envoi
— Hors UE : 160 EUR par envoi
NB : ces suppléments s’entendent emballage, port et
gestion des permis officiels d’exportation
— adresse de facturation incluant le nom de la société,
le code postal, la ville, le pays et le numéro de
téléphone
— adresse de livraison (si différente) incluant le nom de
la société, le code postal, la ville, le pays et le numéro
de téléphone (attention ADRESSE COMPLÈTE, pas
de boîte postale)
— nom du contact, numéro de téléphone, numéro
de fax et adresse e-mail: une adresse e-mail est
indispensable pour recevoir une confirmation de
commande et l’avis d’expédition du paquet
— numéro TVA (obligatoire dans l’Union Européenne)
— votre numéro/référence de commande
l) Spectres de référence
— code article
— France : pas de supplément spécial, le prix s’entend
emballage et expédition par la poste compris. Sur
demande du client un envoi express est facturé
18 EUR par envoi
— nom officiel de l’étalon de référence tel qu’indiqué
dans le catalogue
— UE : 18 EUR par envoi
— nom et numéro de compte du transporteur si vous
désirez utiliser le vôtre
— Autres pays : 50 EUR par envoi
— nombre d’unités de vente
3. Comment commander
Si les bons de commandes ne comportent pas le nom
officiel de l’étalon de référence et le code complet (tel
qu’indiqué dans le catalogue), la DEQM ne saurait être
tenue pour responsable en cas d’envoi d’un mauvais
article.
Les étalons de référence sont fournis par la DEQM.
Malheureusement, il ne nous sera pas possible de traiter
les commandes ne contenant pas ces informations.
3.1. BON DE COMMANDE
3.2. QUANTITÉS
Veuillez envoyer votre commande en utilisant le bon
de commande SCR (voir page xvi du catalogue) ou en
envoyant un bon de commande officiel à l’en-tête de votre
société à la DEQM. Le bon de commande est également
disponible pour téléchargement sur notre site
www.pheur.org sous Reference Standards (Ph. Eur.
Reference Standards).
Un étalon de référence peut être constitué de plusieurs
flacons ou ampoules (voir colonne Sale Unit dans le
catalogue) ; dans ce cas ne pas commander en nombre de
flacons ou ampoules totaux mais en unités de vente.
— Coûts d’expédition à la charge de l’acheteur : 10 EUR
par envoi.
Fax : +33 (0)3 88 41 27 71
à l’attention de la Section Ventes
E-mail : [email protected]
Courrier : Conseil de l’Europe, Direction Européenne de
la Qualité du Médicament, à l’attention de la
Section Ventes, 7 allée Kastner, CS 30026,
F-67081 Strasbourg, France
Les acheteurs sont financièrement responsables des
commandes reçues en double dans les cas suivants :
— confirmation de commande non clairement indiquée
en tant que confirmation d’une commande déjà
envoyée au Conseil de l’Europe (DEQM)
Exemple : pour recevoir 4 flacons de calcitonine, il faut
commander :
référence C0200000, quantité 2.
La politique de la DEQM est de limiter la quantité d’achat
d’un même étalon de référence quand les niveaux de
stock sont bas.
La DEQM fera tout son possible pour assurer que toutes
les commandes soient expédiées en totalité. Cependant,
quand les stocks sont limités, la DEQM préparera
les commandes de façon que le plus grand nombre
d’utilisateurs reçoivent au moins une partie des quantités
limitées.
3.3. DOCUMENTATION SPÉCIALE
3.3.1. Pour tout produit
Il est de la responsabilité du client de s’assurer
que l’importation du produit n’est pas soumise à
une autorisation spéciale ou qu’une interdiction
d’importation du produit est en vigueur dans son
Veuillez noter que nous n’acceptons pas de commandes pays. Tous les documents nécessaires à l’importation
doivent être joints à la commande (spécialement pour
par téléphone.
les produits biologiques). Pour importer en Chine,
Si vous n’utilisez pas le bon de commande SCR officiel,
un formulaire additionnel doit être complété et doit
assurez-vous que les informations suivantes sont fournies accompagner chaque commande d’étalons de référence
sur votre bon de commande :
(voir modèle inclus dans ce catalogue à la page xix).
— envoi d’une même commande à plusieurs reprises
(c.-à-d. par fax, e-mail, courrier ou n’importe quelle
combinaison citée ci-dessus)
x
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
3.3.2. Substances contrôlées
Veuillez noter :
— 3.3.2.1. Psychotropes et stupéfiants de la Convention
de Vienne
Etant donné que nos locaux se situent sur le
territoire français, les mentions « *psy » et « *narc »
portées dans le catalogue se réfèrent uniquement à la
législation française.
— Pour tous les clients de l’UE, excepté la France,
toutes les substances psychotropes seront facturées
séparément des autres substances et un supplément
spécial sera facturé (voir 2.2.h).
France : la commande d’une substance psychotrope
doit être adressée exclusivement par courrier
accompagnée d’une copie de l’autorisation
de détention ou d’une copie de la déclaration
d’ouverture d’établissement pharmaceutique.
Autres pays : la commande d’une substance
psychotrope doit être adressée exclusivement par
courrier. Ces substances faisant l’objet d’un contrôle
à l’importation et à l’exportation dans certains pays, il
est de la responsabilité du client de se conformer à la
législation du pays importateur et d’obtenir tous les
documents nécessaires.
Un permis d’importation (en français ou avec une
traduction certifiée en français jointe) doit être valide
au moins 6 mois à compter de la date de réception du
permis par le Conseil de l’Europe (DEQM).
— 3.3.2.2. Précurseurs chimiques de stupéfiants
(Convention de Vienne)
Pays de l’UE : toute commande de substances
fréquemment utilisées pour la fabrication illicite
de stupéfiants et de substances psychotropes
(mention «*Drug precursor» dans le catalogue) doit
être accompagnée d’une déclaration d’usage final
spécifiant le ou les usages de la (des) substance(s)
établie selon le modèle européen en vigueur inclus
dans ce catalogue page xviii.
Autres pays : il est de la responsabilité du client de
se conformer à la législation du pays importateur
et d’obtenir tous les documents nécessaires à
l’importation.
Un permis d’importation (en français ou avec une
traduction certifiée en français jointe) doit être valide
au moins 6 mois à compter de la date de réception du
permis par le Conseil de l’Europe (DEQM).
Un supplément spécial est demandé (voir 2.2.h et
2.2.i).
Les permis d’export pour les substances psychotropes
et pour les précurseurs sont nécessaires avant de
pouvoir réaliser l’envoi.
3.4. TRAITEMENT DE LA COMMANDE ET FACTURATION
A réception d’une commande complète, la DEQM
s’efforce de facturer et d’expédier la commande en
2-3 jours ouvrés à l’exception :
— Pour tous les clients hors UE, toutes les substances
psychotropes et tous les précurseurs seront facturés
séparément des autres substances et dans tous les
cas un supplément spécial sera facturé (voir 2.2.h et
2.2.i).
— Pour tous les clients de l’UE, toute commande de
précurseurs doit être accompagnée de la déclaration
d’usage final valide. Un modèle est inclus dans ce
catalogue à la page xviii.
Des retards dans l’expédition des produits seront
inévitables si l’ensemble de la documentation n’est
pas fourni lors de la commande. C’est pourquoi nous
demandons que toutes les substances contrôlées
soient commandées séparément des autres étalons de
référence.
4. Règlement
Le règlement peut s’effectuer par chèque à l’ordre du
Conseil de l’Europe/DEQM et être envoyé à l’adresse cidessus (voir 3.1) ou par transfert bancaire.
Société Générale, 255, route de Mittelhausbergen, 67200
Strasbourg, France
IBAN Account Number for International Transfers:
(FR 76) 30003 02360 00550034256 76
National transfers: 30003 02360 00550034256 76
SWIFT:
SOGEFRPP
Il est également possible de régler par carte de crédit
(Visa, Eurocard, Mastercard ou American Express) en
indiquant le numéro de la carte, la date d’expiration,
le nom du titulaire de la carte et en n’oubliant pas
la signature du titulaire. Veuillez noter que nous ne
prenons pas de numéro de carte bancaire par téléphone.
Dans tous les cas, le règlement doit être net de frais pour
le Conseil de l’Europe et les factures sont payables à
30 jours date de facture. Tout autre frais, tels que droits
de douane ou taxes sont à la charge de l’acheteur.
Pour certains pays, notamment ceux ayant des
réglementations monétaires strictes, pour de nouveaux
clients, pour d’importantes commandes, nous nous
réservons le droit de demander un paiement par
avance. En cas de doute, veuillez nous contacter à
[email protected]. Le règlement par lettre de crédit n’est
pas accepté.
5. Procédures réglementaires et SH/NDP
En cas de disposition particulière dans le pays de
l’acheteur, ce dernier devra détenir les autorisations
— des commandes de substances contrôlées,
d’importation et avoir réglé les éventuelles questions
réglementaires avant la commande et l’expédition des
— des envois effectués sous glace (ceux-ci ne sont
produits. En cas de blocage douanier au moment de
réalisés que les lundis et mardis) et carboglace (ceux- l’importation dans le pays de l’acheteur, ce dernier
ci ne sont réalisés que les lundis),
assumera la responsabilité pleine et entière. Le Conseil de
l’Europe (DEQM) ne pourra en aucun cas intervenir dans
— des commandes pour lesquelles un prépaiement est
une quelconque assistance.
requis.
© European Pharmacopoeia - Catalogue, December 2006
xi
Catalogue
Origine des produits : Diplomatique, Conseil de l’Europe la législation du pays où les produits sont livrés. Il
appartient au client de vérifier auprès des autorités
- France.
locales les possibilités d’importation ou d’utilisation des
SH/NDP 000009.
produits ou services qu’il envisage de commander.
Le NDP-SH est strictement limité aux opérations
Le client est seul responsable du choix des produits, de
d’exportation de la France.
leur conservation à compter de la livraison et de leur
L’importateur fera son affaire personnelle pour la
utilisation. En aucun cas le Conseil de l’Europe (DEQM)
classification tarifaire dans son pays et assumera les
ne pourrait être tenu responsable de tout dommage
obligations réglementaires, fiscales, sanitaires et
intervenant de ce fait.
sécuritaires qui en découlent.
Le Conseil de l’Europe (DEQM) garantit que les produits
sont en parfait état lors de la remise au transporteur. Ceci
6. Réclamation
est la seule garantie consentie par le Conseil de l’Europe
(DEQM). Aucune autre garantie expresse ou tacite n’est
Réclamations liées à la livraison
accordée. En particulier, le Conseil de l’Europe (DEQM)
Les retards éventuels ne donnent pas droit à l’acheteur
ne saurait garantir que les produits répondent aux
d’annuler la vente, de refuser la marchandise ou de
attentes spécifiques du client.
réclamer des dommages et intérêts.
Le Conseil de l’Europe (DEQM) ne saurait être tenu pour
L’acheteur ne peut émettre des réserves lors de la
responsable de l’inexécution du contrat conclu en cas de
livraison des produits qu’en cas de livraison non
rupture de stock ou indisponibilité du produit, de force
conforme quantitativement et qualitativement (au cas
majeure, de perturbation ou grève totale ou partielle
où le paquet contenant les produits serait fortement
notamment des services postaux et moyens de transport,
endommagé).
d’inondation ou d’incendie.
Ces réserves doivent être faites par écrit auprès du
8. Litiges
transporteur lors de la livraison.
Une copie de ces réserves doit être envoyée au Conseil de En conformité avec les dispositions de l’article 21 de
l’Europe (DEQM) (par courrier électronique ou télécopie) l’accord général sur les privilèges et immunités du
Conseil de l’Europe, tout litige entre le Conseil de
au plus tard 12 heures après que ces réserves ont été
l’Europe (DEQM) et le client relatif à l’application des
faites.
présentes conditions générales sera soumis, à défaut de
Réclamations liées à la commande
règlement amiable entre les deux parties à un arbitrage
selon les modalités déterminées par l’Arrêté N° 481 du
Le client ne peut faire de réclamation lors de la livraison
Secrétaire Général, approuvé par le Comité des Ministres.
des produits qu’en cas de non conformité quantitative par
rapport à sa commande initiale.
Pour tout renseignement concernant :
Etalons de référence – Renseignements concernant les
Toute éventuelle réclamation devra être transmise dans
commandes, la facturation et l’expédition
les 48 heures à compter de la réception du produit dans
Helpdesk: http://www.pheur.org/hd
son emballage d’origine.
Fax: +33 (0)3 88 41 27 71
Concernant les envois en rendu aéroport, toute
Détails des vols - Questions concernant les expéditions
éventuelle réclamation devra être transmise dans
(uniquement pour les commandes SCR)
la semaine à compter de la date d’arrivée du colis à
Helpdesk: http://www.pheur.org/hd
l’aéroport.
E-mail: [email protected]
S’il est prouvé que les réserves ou réclamations faites au
Fax: +33 (0)3 88 41 27 71
moment de la livraison sont dues au fait que le paquet
et les produits sont fortement endommagés, ou qu’il y a
Monographies - Questions concernant les monographies
erreur manifeste, le Conseil de l’Europe (DEQM), à son
Helpdesk: http://www.pheur.org/hd
choix, établira un avoir ou remboursera au client le prix
Fax: +33 (0)3 88 41 27 71
payé ou effectuera une nouvelle livraison de produits
similaires.
La version électronique du catalogue des étalons de
référence (nécessite Adobe Acrobat version 5) ainsi que
En cas de réclamation, les frais de transport et autres
d’autres informations sont disponibles sur notre site
frais (douane) pour le retour des produits au Conseil de
www.pheur.org
l’Europe (DEQM) sont à la charge de l’acheteur.
L’acheteur ne peut en aucun cas retourner les produits
au Conseil de l’Europe (DEQM) sans en avoir averti celuici et obtenu son accord écrit.
II. CONDITIONS DE STOCKAGE
LONG TERME À LA DEQM
Aucun retour de produits ne sera accepté et nous ne
procéderons à aucun échange si les conditions énoncées
et la procédure ci-dessus n’ont pas été respectées.
Voir colonne spécifique (Storage) dans la liste débutant
page 1.
7. Responsabilité
III. IDENTIFICATION DES ÉTALONS
DE RÉFÉRENCE
La responsabilité du Conseil de l’Europe (DEQM)
ne saurait être engagée en cas de non-respect de
La dénomination des étalons de référence reprise dans
ce catalogue correspond au nom anglais utilisé dans les
xii
© European Pharmacopoeia - Catalogue, December 2006
Catalogue
monographies officielles de la Ph. Eur. et classé par ordre
alphabétique (nom en italique suivi de SCR ou PBR).
IV. UTILISATION DES ÉTALONS DE
RÉFÉRENCE
Les étalons de référence de la Ph. Eur. sont établis et
distribués selon le principe général de la norme ISO 34.
La spécificité des étalons de référence des pharmacopées
a été officiellement reconnue dans l’introduction de
la révision de la norme ISO 34 - Exigences générales
pour la compétence des producteurs de matériaux de
référence - deuxième édition 2000) : « Les étalons et les
substances de référence des pharmacopées sont établis
et distribués par les autorités de pharmacopée selon le
principe général de ce guide. Il convient toutefois de
noter que chaque autorité de pharmacopée adopte une
approche différente pour transmettre aux utilisateurs
les informations fournies par le certificat d’analyse et les
dates d’expiration. L’incertitude sur les valeurs assignées
aux étalons et substances de référence est négligeable par
rapport aux limites définies dans les dosages (méthodes
spécifiques) des pharmacopées pour lesquelles elles sont
utilisées. En conséquence, cette incertitude n’est pas
mentionnée. »
Les étalons de référence sont des lots spécialement
sélectionnés et vérifiés, appropriés à l’usage prescrit dans
la Pharmacopée.
La colonne « Monograph » liste la(les) monographie(s)
et/ou la(les) méthode(s) analytique(s) générale(s) dans
lesquelles sont utilisés les étalons de référence. Les
numéros de monographie comportent quatre digits
(par exemple la monographie 0076), les chapitres
généraux comportent cinq digits (par exemple le texte
5.4 est indiqué par le nombre 50400, la méthode 2.5.1
est indiquée par le nombre 20501). Ces nombres sont
disponibles au début de la monographie et correspondent
au numéro d’identification du document.
L’utilisation de ces produits pour d’autres usages que
ceux prescrits dans la monographie de la Ph. Eur. relève
de la responsabilité de l’utilisateur. Chaque flacon
ou ampoule fourni contient une quantité de produit
suffisante pour l’utilisation prescrite.
Un flacon ou une ampoule est considéré comme un
étalon de référence à « utilisation immédiate ». Nous
recommandons que le contenu d’un flacon ou d’une
ampoule soit utilisé dans la même série d’analyses.
Il convient de ne commander que la quantité nécessaire
pour le besoin immédiat et d’utiliser les étalons de
référence dans les meilleurs délais possibles.
La stabilité du contenu des flacons ouverts ne peut être
garantie.
Dans des cas spécifiques, un lot peut faire l’objet
d’une présentation en sous-lots 1.1, 1.2, 1.3, etc. pour
des raisons de remplissage ou d’étiquetage. (Note :
l’ancienne numérotation des sous-lots 1a, 1b, 1c sera
progressivement remplacée par 1.1, 1.2, 1.3, etc.)
qui adopte les rapports d’études les ayant qualifiés pour
leur usage, il n’est fourni avec les étalons de référence ni
certificat d’analyse, ni données autres que celles requises
pour l’utilisation prévue par la monographie de la Ph.
Eur. De la même façon, il n’est pas indiqué de date de
péremption car les étalons de référence sont conformes
aux exigences de la monographie correspondante et
font l’objet de vérifications régulières. Dans la colonne
Information du catalogue est rendue officielle la date
de fin de validité comme SCR/PBR des lots qui viennent
d’être remplacés. Ainsi «batch 1 valid until 30 June 2006»
signifie que le lot 1 n’est plus officiel à partir du
1er juillet 2006.
Lorsqu’il n’est pas fait mention de conditions de
dessiccation, les substances et préparations sont à utiliser
en l’état.
Pour les SCR avec une valeur assignée, la valeur est
exprimée sur la substance « telle quelle ».
La disponibilité des étalons dans la base de données des
étalons de référence sur notre site internet est mise à
jour quotidiennement. Des informations sur l’origine,
la valeur assignée et la validité du lot sont également
disponibles.
Une déclaration de validité de lot (BVS) pour les étalons
de référence est maintenant disponible. L’utilisateur
d’étalons de référence peut imprimer cette déclaration
de validité à partir de la base de données Reference
Standards du site internet de la DEQM (http://crs.
pheur.org/). Cet outil aidera les utilisateurs à assurer la
traçabilité des dates de validité et des notices distribuées
avec le lot précédent. Un exemple de BVS est inclus dans
ce catalogue pages xx et xxi.
Pour les étalons de référence conditionnés en ampoules
de verre scellées, la procédure à suivre pour l’ouverture
est la suivante : tapoter doucement l’ampoule pour
rassembler son contenu dans le fond ; faire une entaille
sur l’ampoule avec une lime ; chauffer à blanc une tige
de verre et l’appuyer fermement sur l’entaille ; s’il ne se
produit pas de cassure, approfondir et agrandir l’entaille,
chauffer à nouveau la tige et recommencer.
Substances toxiques. Certains étalons de référence
sont très toxiques et doivent être manipulés avec des
précautions particulières afin d’éviter tout contact.
Il est recommandé de manipuler ces substances dans
une boîte à gants ou, à défaut, en portant des gants, une
protection oculaire et un masque.
Préparations biologiques et produits du sang. Ces
préparations sont à considérer comme potentiellement
dangereuses pour la santé et doivent être utilisées et
détruites conformément aux pratiques de sécurité de
votre propre laboratoire.
Fiches de données de sécurité
Les fiches de données de sécurité sont disponibles sur
notre site internet ou sur demande.
Les renseignements présentés dans les fiches de données
de sécurité et fournis par la Ph. Eur. proviennent
Toutefois, toutes les précautions sont prises pour garantir
des informations transmises habituellement par le
l’homogénéité de qualité et des spécifications des sousfournisseur ou fabricant du produit. Elles n’ont pas été
lots entre eux.
vérifiées indépendamment par les agents de la Ph. Eur.
Les SCR et PBR étant des produits faisant l’objet d’une
L’exactitude de ces renseignements ne peut donc être
certification officielle par la Commission de la Ph. Eur.
garantie.
© European Pharmacopoeia - Catalogue, December 2006
xiii
Catalogue
V. NOTICE
Dans certains cas, une notice explicative est envoyée avec
le produit. Voir colonne spécifique (Leaflet) dans la liste
débutant page 1 (si aucune indication n’est mentionnée,
il n’y a pas de notice pour le produit concerné). Les
notices sont également disponibles sur notre site
internet.
xiv
© European Pharmacopoeia - Catalogue, December 2006
Council of Europe
European Directorate for the Quality of Medicines
CRS Order Form
Tel: +33 (0)3 88 41 30 30
7 allée Kastner, CS 30026, F-67081 Strasbourg (France)
website: http://www.pheur.org
Helpdesk: http://www.pheur.org/site/page_521.php
SIRET: 778860080010
APE
Code APE:990Z
VAT N°: Not applicable to Council of Europe - diplomatic privilege.
Fax: + 33 (0)3 88 41 27 71
BILLING ADDRESS
Your Client Code
Company Name*
Invoice Address*
DELIVERY ADDRESS
City*
PostCode*
Country*
City*
PostCode*
Country*
Contact Name*
VAT N°(* in Europe)
Tel*
E-mail
Contact Name*
VAT N°(* in Europe)
Tel*
Email
(Please complete if different from invoicing address)
Company Name*
Delivery Address*
Fax
Fax
All items marked with an asterisk (*) are mandatory
Your Order Reference* [reference]
Reference*
Date*
Item*
Unit Price
(1) A CRS/BRP may include several individual vials (see sale unit in catalogue), in such instances do not order in terms of total number
of vials.
Total Goods/€
DELIVERY CHARGES and PRICES
The price should not be regarded as representing the selling price of a commercial product. The prices quoted in our catalogue are
exclusive of duties and taxes. Extra handling charges may be applied. Please see our catalogue for details.
CONDITIONS OF SALE
We sell on our standard terms of business. For details please see our catalogue.
Payment
I would like to pay now. I will automatically receive an invoice/receipt
I enclose a cheque made payable to Council of Europe/EDQM
I wish to pay by credit card
Visa N°
Expiry Date
I will pay on receipt on a invoice
Euro/Mastercard N°
Name
American Express N°
Signature
Quantity(1)*
Total
Conseil de l’Europe
Direction Européenne de la Qualité du Médicament
Bon de Commande SCR
Tél: +33 (0)3 88 41 30 30
7 allée Kastner, CS 30026, F-67081 Strasbourg (France)
site internet : http://www.pheur.org
Helpdesk : http://www.pheur.org/site/page_521.php
SIRET : 778860080010
APE Code APE:990Z
N° TVA : non applicable au Conseil de l’Europe - régime diplomatique
Fax : + 33 (0)3 88 41 27 71
ADRESSE DE FACTURATION
Votre Code Client
Nom de la société*
Adresse de facturation*
ADRESSE DE LIVRAISON
Ville*
Code postal*
Pays*
Ville*
Code postal*
Pays*
Nom du Contact*
TVA N°(* en Europe)
Tél*
E-mail
Nom du Contact*
TVA N°(* en Europe)
Tél*
E-mail
(Veuillez compléter si différent de l’adresse de facturation)
Nom de la Société*
Adresse de livraison*
Fax
Fax
Les informations marquées du symbole*sont obligatoires.
Votre N° de Commande* [référence]
Référence*
Date*
Item*
Prix unitaire
Total Produits €
(1) Une SCR/PBR peut être constituée de plusieurs flacons, dans ce cas ne pas commander en nombre de flacons totaux.
FRAIS DE LIVRAISON et PRIX
Le prix n’est pas à considérer comme le prix de vente d’un produit commercial. Les prix indiqués dans notre catalogue s’entendent hors
droits et taxes. Des frais de livraison peuvent s’appliquer. Voir notre catalogue pour plus de détails.
CONDITIONS DE VENTE
Les conditions générales de vente sont celles figurant dans notre catalogue.
Paiement
Je désire payer maintenant, je recevrai automatiquement une facture acquittée
Je joins un chèque à l’ordre du Conseil de l’Europe/DEQM
Visa N°
Je désire payer par carte de crédit
Euro/Mastercard N°
Expire à fin :
Je réglerai à réception de facture
Nom
Quantité(1)*
American Express N°
Signature
Total
COMPANY LETTERHEAD
CUSTOMER DECLARATION OF SPECIFIC USE(S) OF THE SCHEDULED
CATEGORY 1 OR 2 SUBSTANCE (INDIVIDUAL TRANSACTIONS)
I, We,
Name ……………………………………………………………………………………………
Address ………………………………………………………………………………………….
Authorisation/Licence/Registration No. or reference1 …………………………………………..
Issued on …………..…………….…. by ………………………………………………………
(name and address of authority)
and valid until/without expiry1………………………………......................................................
have ordered from:
Name ……………………………………………………………………………………………
Address ………………………………………………………………………………………….
the following substances (name and CN code2) …………………………………………… ..
(quantity) ……………………… .....................................................
The substance will be used solely for …………………………………………………………..
We confirm that the substance referred to above will only be re-sold or otherwise supplied to a
customer on the condition that the customer will furnish a similar declaration of use or, for category
2 substances, a declaration relating to multiple transactions.
Signed …………………………………….
Name ……………………………………
(block capitals)
Position …………………………………...
Date …………………………………….
1
2
Delete as appropriate
Combined Nomenclature code
EN-TÊTE DE LA SOCIÉTÉ
DÉCLARATION DU CLIENT SPÉCIFIANT L’USAGE OU LES USAGES DE LA
SUBSTANCE RELEVANT DES CATÉGORIES 1 OU 2
(TRANSACTIONS INDIVIDUELLES)
Nous,
Nom……………………………………………………………………………………………………
Adresse
………………………………………………………………………………………………………....
Référence à l’autorisation/l’agrément/l’enregistrement1 ……………………………………………...
Délivré le …………..…………….…. par ……………………………………………………………
(nom et adresse de l’autorité)
et valable jusqu’au/sans limite de temps1………………………………….. ........................................
avons commandé à :
Nom……………………………………………………………………………………………………
Adresse …………………………………………………………………………………………….….
La substance suivante (dénomination et code NC2) .. ……………………………………………....
(quantité)........................................................................................................
La substance sera utilisée exclusivement pour ………………………...…………………………..
Nous certifions que la substance visée ci-dessus ne sera revendue ou transférée à un client qu’à la
condition que ce client fournisse une déclaration d’utilisation conforme à ce modèle ou, pour les
substances de catégorie 2, une déclaration relative à des transactions multiples.
Signature………………………………………..
Nom …………..………………………………
(en majuscules)
Quantité …………………………………...
Date …………………………………….
1
2
Biffer la mention inutile
Code de la nomenclature combinée
COMPANY LETTERHEAD
IMPORT OF EUROPEAN PHARMACOPOEIA
REFERENCE STANDARDS INTO CHINA
I, We,
Name ………………………………………………………………………………….……………….
Address
…………………………………………………………………………………………………………
…………………………………………………………………………………………………………
Hereby confirm that:
-
The substances below are not controlled in China1
We have all the import authorisations/licences for the import of the substances below into
China1
We have the authorisations/licences to pay in Euro currency1
List of substances
Name
CRS Code
Quantity
The Council of Europe (EDQM) cannot be held responsible for failure to meet the requirements of
the legislation of China. It is the customer’s responsibility to check with the local authorities to
make sure that the goods they intend to order can be imported into or used in China.
I, We, agree
If the parcel is held up by the Chinese customs or is unable to clear customs
- To pay the invoice in full
- To bear any shipping or other costs (customs) incurred to return goods to the Council of
Europe (EDQM).
Signed …………………………………….
Name ……………………………………
(block capitals)
Position …………………………………...
Date …………………………………….
1
Delete as appropriate
http://crs.pheur.org/db/4DCGI/www_BVS
BATCH VALIDITY STATEMENT
EUROPEAN PHARMACOPOEIA REFERENCE STANDARDS (CRS) & (BRP)
This Batch Validity Statement has to be used in conjunction
with Ph. Eur. general chapter 01/2007:51200 Reference Standards.
European Directorate for the Quality of Medicines (EDQM) – Council of Europe
Postal address: B.P. 907 - F 67029 Strasbourg Cedex 1
Phone: +33 (0)3 88 41 30 30
Fax: +33 (0)3 88 41 27 71
Internet : http://www.pheur.org
Name
Insulin (human)
Catalogue
code
I0310000
Batch
number*
3
Assigned
value
7.03 mg insulin + A21 desamido per vial
Validity
Batch 3 is valid at the printing date: 2006-8-22
Storage
conditions
The standard is intended for immediate use.
Recommended EDQM storage conditions for unopened containers :
-20°C
Safety data
Safety Data Sheet is available from the detailled view or upon request.
Leaflet
Click on the hyperlink to download the leaflet containing the
instructions for use, if available (Adobe Acrobat Reader version 5 or
higher, or the corresponding browser plug-in is needed to open the
file)
click to download the leaflet
* Sub-batches a, b, c are obtained from the same batch of bulk material and the quality does not differ from one
sub-batch to another.
This statement is valid at the date of printing : 2006-8-22
Legal notice:
The Council of Europe (EDQM) makes no representation or warranty with respect to the accuracy, completeness, or
currentness, of this electronic statement.
The Council of Europe (EDQM) shall not be liable on account of any potential errors or omissions.
1 sur 1
22/08/06 14:14
n/a
1
1
1
2
2
1
1
2
5
4
1
1
3
1
1
1
2
5
2
2
2
1
1
3
2
Y0000056 Aceclofenac - reference spectrum
Y0000085 Aceclofenac impurity F
Y0000086 Aceclofenac impurity H
Acenocoumarol
Acesulfame potassium
Acesulfame potassium impurity B
Acetazolamide
Acetylcholine chloride
Acetylcysteine
Acetylcysteine impurity C
Acetylcysteine impurity D
ß-Acetyldigoxin
ß-Acetyldigoxin for peak identification
Acetylsalicylic acid
N-Acetyltryptophan
N-Acetyltyrosine
Acholeplasma laidlawii BRP
Aciclovir
Aciclovir impurity A
A0050000
A0070000
A0070020
A0100000
Y0000002
A0150000
A0152000
A0153000
Y0000565
Y0000642
A0200000
A0208000
A0202000
Y0000693
A0220000
A0221000
A0225000 Acitretin
Y0000360 Acriflavinium monochloride
A0230000 Adenine
A0230200 Adenosine
Y0000110 Adipic acid
A0300000 Adrenaline tartrate
A0325000 Alanine
© Council of Europe, all rights reserved 2006
n/a
1
1
1
1
1
1
Batch
1
2
Acamprosate calcium - reference spectrum
Acamprosate impurity A
Acarbose
Acarbose for identification
Acarbose for peak identification
Acebutolol hydrochloride
Acebutolol impurity B
Reference Standard
Y0000127 Acebutolol impurity C
Y0000128 Acebutolol impurity I
Order
Code
Y0000055
Y0000116
Y0000500
Y0000354
Y0000427
A0040000
Y0000359
Catalogue No. 48-2006/4
100 mg
1 mg
50 mg
50 mg
50 mg
200 mg
50 mg
20 mg
50 mg
10 mg
100 mg
50 mg
50 mg
10 mg
10 mg
30 mg
10 mg
100 mg
125 mg
200 mg
1 ml
75 mg
15 mg
n/a
20 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0871
0871
1585
1585
2089
2089
2089
0871
0871
Monograph
1
Batch 1 is valid until 28 February 2007
2-[(2-amino-6-oxo-1,6-dihydro-9§-purin-9-yl)methoxy]ethyl
acetate
99.7% CœŒHœÿO– ; Batch 1 is valid until 28 February 2007
90.9% CŒÕHŒÿNœOÿSœ; N,N'-diacetyl-L-cystine
N,£-diacetyl-L-cysteine
Batch 1 is valid until 30 April 2006
5-chloro-6-methyl-1,2,3-oxathiazin-4(3§)-one 2,2-dioxide
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-80°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
c
a
a
a
f
f
a
a
a
d
a
a
l
a
a
a
a
79 79 79 79 79 79 79 79 79 120 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 l
79 a
79 a
79 a
79 a
79 a
79 a
1385
+5°C
g
2043
Yes
+5°C
a
0800,1486
+5°C
a
1486
+5°C
a
1586
+5°C
a
0254,0285,0732
+5°C
g
0614,0752
+5°C
a
For extra charges please see 2.2
0698,0699
1282
1282
0454
1485,1971
0967
0967
0967
2168
2168
0309
1383
1384
20607
0968
0968
1281
benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate 1281
[[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl]
1281
oxy]acetyl]oxy]acetic acid
Information
Unit Sale
Quantity Unit
n/a
1
50 mg
1 3-aminopropane-1-sulphonic acid
100.1 mg 1 100.1 mg per vial of Cœ—H÷–NOŒ‡
10 mg
1
40 mg
1
50 mg
1
10 mg
1 N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]
propoxy]phenyl]acetamide (diacetolol)
20 mg
1 N-(3-acetyl-4-hydroxyphenyl)butanamide
0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl]
butanamide
6 December 2006
Allopurinol impurity D
Allopurinol impurity E
Allylstrychnine bromide
Almagate
Almagate - reference spectrum
Alprazolam - * psy
Alprenolol hydrochloride
Alprostadil
Altizide
Alverine citrate
Alverine for peak identification
Alverine impurity D
Amantadine hydrochloride
Ambroxol hydrochloride
Amfetamine sulphate - reference spectrum
Amidotrizoic acid dihydrate
Amikacin
Amikacin impurity A
© Council of Europe, all rights reserved 2006
A0365900 Amikacin sulphate
A0370000 Amiloride hydrochloride
A0350040
A0350050
A0351000
Y0000235
Y0000255
A0357000
A0360000
Y0000054
Y0000606
New Y0000687
New Y0000595
New Y0000607
A0363000
A0363700
A0900000
A0365000
A0368000
A0368010
2
1
2
1
1
1
n/a
1
1
1
1
1
1
1
1
2
n/a
1
1
1
2
2
A0350020 Allopurinol impurity B
A0350030 Allopurinol impurity C
1
1
4
n/a
2
n/a
1
1
Batch
1
2
2
Albendazole
Alcuronium chloride
Alfacalcidol
Alfacalcidol - reference spectrum
Alfadex
Alfentanil hydrochloride - reference spectrum
Alfuzosin hydrochloride
Alfuzosin impurity A
Reference Standard
A0349000 Allantoin
A0350000 Allopurinol
New A0350010 Allopurinol impurity A
Order
Code
A0325100
A0325200
A0325450
A0325451
A1225000
A0325500
A0325800
A0325801
Catalogue No. 48-2006/4
200 mg
100 mg
10 mg
20 mg
10 mg
25 mg
n/a
125 mg
100 mg
50 mg
5 mg
5 mg
0.125 mg
10 mg
100 mg
125 mg
n/a
100 mg
200 mg
10 mg
10 mg
10 mg
60 mg
50 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
2
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
Leaflet Storage
a
a
a
a
a
a
l
j
a
a
a
a
a
a
a
a
l
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
300 c
79 l
79 a
79 l
79 a
79 a
For extra charges please see 2.2
0576
0576
1285
2010
2010
1065
0628,0876
1488
0370
2156
2156
2156
0463
1489
0368
0873
1289
1289,1290
0576
0576
1288
0576
0576
1386
1285
1286
1286
1070,1487
1062
1287
1287
Monograph
93.1% CœœH÷–N—OŒ–
86% CœœH÷–N—OŒ–;
4-O-(3-amino-3-desoxy-alpha-D-glucopyranosyl)-6-O-(6-amino-6
-desoxy-alpha-D-glucopyranosyl)-N1-[(2S)-4-amino-2hydroxybutanoyl]-2-desoxy-L-streptamine
89.0% CœœH÷ŸN—OœŒSœ
1290
0651
N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine
99.2% CœÕH–÷O—
13.4% carbonic acid
99.9% C—H÷N÷O
5-amino-1H-pyrazole-4-carboxamide ; Batch 1 is valid until 28
February 2007
5-formylamino-1H-pyrazole-4-carboxamide
N-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide ; Batch 1 is
valid until 31 May 2006
ethyl 5-amino-1H-pyrazole-4-carboxylate
ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate
Information
Unit Sale
Quantity Unit
50 mg
1
100 mg 1
5 mg
1 99.9% CœŸH÷÷Oœ ; Batch 3 is valid until 30 April 2006
n/a
1
150 mg 1 89.5% [CÿHŒÕ0—]
n/a
1
50 mg
1
20 mg
1 N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)
(methyl)-amino]propyl]furan-2-carboxamide
6 December 2006
1
1
1
1
Y0000130
A0590000
A0590002
A0590004
500 mg
500 mg
100 mg
1
1
3
2
3
2
3
1
n/a
4
4
Y0000005 Amphotericin B
A1000000 Ampicillin (anhydrous)
A1100000 Ampicillin trihydrate
A1200000
A1210000
Y0000172
A1220000
A1230000
© Council of Europe, all rights reserved 2006
Anhydrotetracycline hydrochloride
Antazoline hydrochloride
Apomorphine hydrochloride - reference spectrum
Alpha-apo-oxytetracycline
Beta-apo-oxytetracycline
n/a
n/a
10 mg
50 mg
n/a
20 mg
20 mg
150 mg
500 mg
250 mg
n/a
150 mg
n/a
n/a
3
n/a
20 mg
50 mg
40 mg
10 mg
20 mg
100 mg
20 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
94.2% CœœHœœNœOŸ
960 IU per mg
98.0% CŒÿHŒ„N–O÷S
85.4% CŒÿHŒ„N–O—S
99.9% CœÿH–ŒClNœO‡S
[(2RS)-1-ethylpyrrolidin-2-yl]methanamine
4-amino-N-[[(2RS)-1-ethylpyrrolidin-2-yl]methyl]-5-(ethyl
sulphonyl)-2-hydroxybenzamine
Batch 2 is valid until 28 February 2007
(2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)
methanone
(2-butyl-benzofuran-3-yl)-(4-hydroxyphenyl)methanone
Information
Unit Sale
Quantity Unit
10 mg
1 methyl-3,5-diamino-6-chloropyrazine-2-carboxylate
60 mg
1
50 mg
1
100 mg 1
125 mg 1
20 mg
1 (3¢£)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione;
(3-aminoglutethimide)
10 mg
1 3,3'-[diazenediyldi(4,1-phenylene)]bis(3-ethylpiperidine-2,6dione); (azoglutethimide)
A0600000 Amitriptyline hydrochloride - reference spectrum
Y0000049 Amlodipine besilate
Y0000302 Ammonio methacrylate copolymer(type A) - reference
spectrum
Y0000303 Ammonio methacrylate copolymer(type B) - reference
spectrum
A0650000 Amobarbital - * psy
A0700000 Amobarbital sodium - * psy
A0800000 Amoxicillin trihydrate
Amiodarone impurity E
Amisulpride
Amisulpride impurity A
Amisulpride impurity B
1
3
1
A0560000 5-Amino-2,4,6-tri-iodo-N-methylisophthalamic acid
A0575000 Amiodarone hydrochloride
Y0000129 Amiodarone impurity D
2
1
1
1
1
1
Batch
1
Amiloride impurity A
4-Aminobenzoic acid
Aminocaproic acid
7-Aminodesacetoxycephalosporanic acid
Aminoglutethimide
Aminoglutethimide impurity A
Reference Standard
A0496020 Aminoglutethimide impurity D
Order
Code
Y0000020
Y0000173
A0420000
A0460000
A0496000
A0496005
Catalogue No. 48-2006/4
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
l
a
a
a
c
a
j
j
a
l
l
a
l
a
a
a
a
a
g
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
For extra charges please see 2.2
0594
0166
0167,0168,0260,
0577,0578,0813,
1140,1653
1292,20702
0167,0168,0578,
1168,1169
0168,0260,0577,
0578,0808,2211,
2212
0210,0211,1654
0972
0136
0198
0198
2082
0464
1491
2081
0803
1490
1490
1490
0751
0803
0803
1291
0651
1687
0874
0708,0813
1291
1291
Monograph
6 December 2006
1
2
2
1
Y0000304
A1271000
Y0000079
Y0000080
Aspartic acid
Astemizole
Atenolol
Atenolol for column validation
Atracurium besilate
Atracurium for impurity F identification
Atracurium for peak identification
Atropine sulphate
Atropine - reference spectrum
Atropine for system suitability
Azaperone
Azathioprine
Azelastine hydrochloride
Azelastine impurity B
Azelastine impurity D
Azelastine impurity E
Azithromycin
Azithromycin for peak identification
Azithromycin for system suitability
Azithromycin impurity A
Azithromycin impurity B
A1330000
A1335000
A1340000
A1341000
Y0000424
Y0000503
Y0000504
A1400000
Y0000231
Y0000230
Y0000029
A1500000
Y0000326
Y0000327
Y0000328
Y0000329
Y0000306
Y0000637
Y0000641
Y0000307
Y0000308
© Council of Europe, all rights reserved 2006
2
n/a
1
2
3
Ascorbic acid
Ascorbyl palmitate - reference spectrum
Asparagine monohydrate
Aspartame
Aspartame impurity A
A1300000
A1315000
Y0000305
A1320000
A1321000
2
1
2
5
1
1
1
3
n/a
1
1
1
1
1
1
1
1
1
1
1
2
1
Y0000081 Articaine impurity E
Arginine aspartate
Arginine hydrochloride
Articaine hydrochloride
Articaine impurity A
2
1
2
Batch
Order
Reference Standard
Code
A1250000 Aprotinin solution BRP
A1269000 L-Arabinitol
A1270000 Arginine
Catalogue No. 48-2006/4
50 mg
150 mg
100 mg
100 mg
120 mg
5 mg
5 mg
50 mg
n/a
0.4 mg
50 mg
100 mg
25 mg
5 mg
5 mg
5 mg
120 mg
15 mg
0.05 mg
10 mg
0.04 mg
100 mg
n/a
60 mg
40 mg
10 mg
10 mg
20 mg
50 mg
100 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
4
6-demethylazithromycin
3-deoxyazithromycin
1-benzoyl-2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]diazane
4-(4-chlorobenzyl)phthalazin-1(2H)-one
3-(4-chlorobenzilidene)isobenzofuran-1(3H)-one
93.2% C–‡HŸœNœOŒœ
98.9% Cÿ—H‡œNœOŒ‡Sœ
2-(5-benzyl-3,6-dioxopiperazin-2-yl) acetic acid
(diketopiperazine) ; Batch 2 is valid until 31 December 2005
Batch 1 is valid until 30 September 2006
methyl3-[[2-(propylamino)acetyl]amino]-4-methylthiophene-2carboxylate
methyl 4-methyl-3-[[( 2RS)-2-[(1-methylethyl)amino]
propanoyl]amino] thiophene-2-carboxylate
Vitamin C
Batch 1 is valid until 31 October 2006
Information
Unit Sale
Quantity Unit
0.5 ml
1 About 27 Ph. Eur. Units per ml
10 mg
1
50 mg
1 Batch 1 is valid until 31 October 2006
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
f
f
f
a
l
a
a
a
a
a
a
a
a
a
a
a
a
a
l
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
For extra charges please see 2.2
0750,0797
1067
0703
0703
1970
1970
1970
0068,2056
2056
2056
1708
0369
1633
1633
1633
1633
1649
1649
1649
1649
1649
0253,0958
0807
2086
0973
0973
1688
0579,0580
1381
0806,0930,1654,
2114
2096
0805,0885,0998
1688
1688
Monograph
6 December 2006
Benserazide hydrochloride
Benserazide impurity A
Benzarone
Benzathine benzylpenicillin
B0477000
B0477010
B0490000
B0500000
© Council of Europe, all rights reserved 2006
B0950000 Betadex
Y0000391 Betahistine dihydrochloride
B0990000 Betahistine mesilate
Benzbromarone - reference spectrum
Benzethonium chloride
Benzocaine
Benzophenone
Benzyl alcohol
Benzyl benzoate - reference spectrum
S-Benzylmercaptoacetyltriglycin
Benzylpenicillin potassium
Benzylpenicillin sodium
Beclometasone dipropionate monohydrate
Beclometasone dipropionate for system suitability
Beclometasone dipropionate for peak identification
Bendroflumethiazide
Bendroflumethiazide impurity A
Benfluorex hydrochloride
Benfluorex hydrochloride for system suitability
Benperidol
Y0000351
Y0000352
Y0000469
B0400000
Y0000564
Y0000044
Y0000043
B0470000
B0505000
B0550000
B0600000
New Y0000647
Y0000167
B0670000
B0680000
B0700000
B0900000
3
2
1
1
1
1
n/a
3
Bacampicillin hydrochloride
Bacitracin zinc
Baclofen
Baclofen impurity A
Bambuterol hydrochloride
Barbital - * psy
Basic butylated methacrylate copolymer -reference spectrum
Beclometasone dipropionate anhydrous
B0070000
B0100000
B0200000
B0200050
B0250000
B0300000
Y0000295
B0305000
4
1
1
n/a
1
1
1
1
n/a
1
1
7
1
1
1
2
1
1
1
1
1
1
1
1
1
Batch
Order
Reference Standard
Code
Y0000285 B19 virus DNA for NAT testing BRP
Catalogue No. 48-2006/4
200 mg
50 mg
100 mg
n/a
100 mg
50 mg
40 mg
50 mg
n/a
10 mg
50 mg
200 mg
1
1
1
1
1
1
1
1
1
1
1
1
5
88.4% [CÿHŒÕO—]Ÿ ; Batch 3 is valid until 31 March 2006
99.4% CŒÿHŒŸNœNaO÷S; Penicillin G sodium
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
-20°C
Leaflet Storage
a
a
a
l
a
a
a
a
l
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
j
l
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
242 e
For extra charges please see 2.2
1393
0974
0011,1088
1784
0256
0705
1372
0113,0148,0149
0113,0114,0148,
0149
1070,1487,1804
1665
1071
Information
Unit Sale
Monograph
Quantity Unit
150 mg 5 B19 virus DNA content logŒÕ 5.8 IU per ml for plasma pool testing See leaflet,0557,
by NAT
1527,1646
92.9%
CœŒHœ‡ClN–OŸS
120 mg 1
0808,0852
150 mg 1 62.9 IU per mg
0465,0466,20702
50 mg
1
0653
50 mg
1 (¢£)-4-amino-3-(4-chlorophenyl)butyric acid lactam
0653
100 mg 1
1293
500 mg 1
0170
n/a
1
1975
150 mg 1 99.1% Cœ‡H–ŸClOŸ
0654,0809,1449,
1709
10 mg
1
1709
10 mg
1
0654,1709
10 mg
1
0654,1709
100 mg 1
0370
5 mg
1
0370
50 mg
1
1601
360 mg 1
1601
100 mg 1
1010,1172,1254,
1708
50 mg
1
1173
20 mg
1 (¢£)-2-amino-3-hydroxypropanohydrazide
1173
10 mg
1
1393
125 mg 1 90.7% C÷‡H—ÿNÿO‡Sœ
0373
24.1% CŒÿHœÕNœ (N,N' - dibenzylethylenediamine)
6 December 2006
1,3-bis(2-acetyl-3-hydroxyphenoxy)-2-propanol
Bisacodyl
Bisacodyl for peak identification
Bisacodyl for system suitability
Bleomycin sulphate
Bromazepam - * psy
Bromazepam for system suitability - * psy
Bromhexine hydrochloride
Bromhexine impurity C
Bromocriptine mesilate
Bromocriptine mesilate for system suitability
Bromperidol
Bromperidol decanoate
Brompheniramine maleate
Brotizolam - * psy
Brotizolam impurity B
© Council of Europe, all rights reserved 2006
B1155000 Brucella melitensis Rev. 1 strain BRP - * Biotox
B1157300 Budesonide
B1143000
New Y0000645
B1145000
Y0000200
B1150000
New Y0000677
B1152000
B1152050
B1153000
Y0000468
Y0000470
Y0000434 Boldine
B1142000 Bordetella pertussis mouse antiserum BRP
B1130000
New B1140000
Y0000608
Y0000694
B1141000
1
3
3
1
2
2
2
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
3
2
2
1
2
1
1
2
1
1
1
Betamethasone acetate
Betamethasone dipropionate
Betamethasone sodium phosphate
Betamethasone-17-valerate
Betamethasone-21-valerate
Betaxolol hydrochloride
Betaxolol impurity A
Bezafibrate
Bifonazole
Bifonazole impurity B
Biotin
Biperiden hydrochloride
Biperiden impurity A
B1030000
B1040000
B1045000
B1054000
B1055000
B1103000
B1103100
B1115000
B1110000
B1110004
B1116000
B1120000
B1121000
Batch
4
Reference Standard
Order
Code
B1000000 Betamethasone
Catalogue No. 48-2006/4
1 mg
110 mg
60 mg
10 mg
100 mg
10 mg
30 mg
5 mg
100 mg
60 mg
100 mg
10 mg
10 mg
30 mg
0.5 mg
50 mg
50 mg
10 mg
5 mg
7 mg
100 mg
100 mg
100 mg
100 mg
15 mg
60 mg
10 mg
100 mg
100 mg
10 mg
50 mg
60 mg
30 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Monograph
1396
See leaflet,20716
0562
0595
0595
0595
0976,20702
6
99.8% Cœ—H–÷Oÿ
0793
1075
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
f
a
j
j
a
a
g
g
a
a
a
j
a
a
c
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 90 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0778,0879
0879
0706
N-(2-aminobenzyl)-N-methylcyclohexanamine
0706
0596
0596
0616,1178
1397,1431
0977,1196
2197
2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3- 2197
a][1,4]diazepine (demethylbrotizolam)
8910 IU per vial; bleomycin Aœ : 67.0%; Bleomycin Bœ : 29.2%;
demethylbleomycin Aœ : 2.6%
99.4% CŒ„HœŒNO÷
Anti-PT: 19.5 ELU/vial Anti-FHA: 69 ELU/vial
Anti-69k: 17 ELU/vial Anti-Fim 2/3: 28 ELU/vial
Batch 1 is valid until 31 December 2006
0312,0354,0388,
0561
0548,0975
0809
Batch 2 is valid until 30 April 2006
0549,0810
0322,0811
0811
1072
(¢£)-3-(4-ethylphenoxy)-1-[(1-methylethyl)amido]propan-2-ol 1072
1394
1395
Bifonazole impurity B trifluoroacetate
1395
Vitamin H
1073
1074
(1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl- 1074
3-(piperidin-1-yl)propan-1-ol (endo form)
Information
Unit Sale
Quantity Unit
75 mg
1 Batch 3 is valid until 31 May 2006
6 December 2006
© Council of Europe, all rights reserved 2006
n/a
n/a
3
C0226000 Calcitriol - reference spectrum
C0249000 Calcium ascorbate - reference spectrum
C0250000 Calcium folinate
1
3
1
n/a
n/a
1
n/a
7
1
3
6
Cabergoline
Caffeine
Calcifediol
Calcifediol - reference spectrum
Calcipotriol (anhydrous) - reference spectrum
Calcipotriol monohydrate
Calcipotriol monohydrate - reference spectrum
Calcitonin (salmon)
Y0000472
C0100000
C0166000
C0166001
Y0000499
Y0000473
Y0000474
C0200000
n/a
n/a
1
n/a
1
1
1
1
1
3
1
1
1
1
1
1
2
1
2
2
Batch
Y0000632 Calcitonin-Gly
C0200010 N-acetyl-cys1-calcitonin
C0225000 Calcitriol
Buprenorphine - reference spectrum
Buprenorphine hydrochloride - reference spectrum
Buserelin
Buserelin - Reference spectrum
D-His-Buserelin
Buspirone hydrochloride
Buspirone for system suitability
Busulfan
Butyl parahydroxybenzoate
Butylhydroxyanisole
Butylhydroxytoluene
Bumetanide
Bumetanide impurity A
Bumetanide impurity B
Bupivacaine hydrochloride
Bupivacaine impurity B
Bupivacaine impurity E
B1160490
B1160500
B1168000
Y0000357
B1168020
Y0000131
Y0000471
B1170000
B1217000
B1212000
B1215000
B1158000
Y0000309
Y0000310
B1160000
Y0000088
New Y0000089
Order
Reference Standard
Code
B1156000 Bufexamac
B1157400 Buflomedil hydrochloride
B1157410 Buflomedil impurity B
Catalogue No. 48-2006/4
n/a
n/a
125 mg
0.4 ml
0.1 mg
10 mg
100 mg
100 mg
5 mg
n/a
n/a
5 mg
n/a
0.98 mg
n/a
n/a
4.92 mg
n/a
0.5 mg
5 mg
2 mg
50 mg
50 mg
50 mg
50 mg
150 mg
5 mg
5 mg
100 mg
20 mg
20
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
7
84.6% CœÕHœŒCaNŸOŸ
0.98 mg per vial of CŒ÷—Hœ÷ÕN÷÷O÷‡Sœ ; Batch 6 is valid until 31
October 2006
About 0.9 mg per ml
Batch 2 is valid until 31 March 2006
100.0% CœŸH÷÷O– ; Batch 5 is valid until 28 February 2007
Batch 4 is valid until 31 December 2005
93.9% CœŸH÷ÕO–
95.6% CœŸH÷÷Oœ
99.8% CœÿH–ŸN—Oœ
Plastic additive 07
4.92 mg per vial of CÿÕH‡ÿNŒÿOŒ–
(2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide ; Batch 1 is
valid until 30 April 2007
3-nitro-4-phenoxy-5-sulphamoylbenzoic acid
3-amino-4-phenoxy-5-sulphamoylbenzoic acid
Information
Unit Sale
Quantity Unit
100 mg 1
100 mg 1
20 mg
1 4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1one
Yes
+5°C
-20°C
-20°C
-20°C
-20°C
+5°C
-20°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
l
l
a
c
c
c
c
g
c
l
l
f
l
c
l
l
c
l
c
g
g
a
a
a
a
a
a
a
g
g
G
79 79 79 1000 79 79 79 79 79 79 79 150 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
For extra charges please see 2.2
0883
1182
0978,1606
0471
0471
0883
1180
1181
1077
1077
1077
1711
1711
0542
0881, 1216
0880
0581,30103,30105,
30106,30107
1773
0267,0268
1295
1295
2011
2011,2284
2284
0471
1076
1076
1076
0541
0541
0541
1179
1398
1398
Monograph
6 December 2006
1
1
3
1
3
1
1
2
1
3
5
Calcium levulinate dihydrate
Calcium oxalate monohydrate
Calcium pantothenate
Camphor (racemic)
Canrenone
Caprylic acid
Capsaicin
Captopril
Carbachol
Carbamazepine
Carbamazepine impurity A
Carbasalate calcium - reference spectrum
Carbenicillin sodium
Carbidopa
Carbimazole
Carbocisteine
Carbon dioxide - reference spectrum
Carboplatin - reference spectrum
Carboprost trometamol
Carboprost trometamol - reference spectrum
Carisoprodol
Carisoprodol impurity A
Carmustine - reference spectrum
Carmustine impurity A
Carteolol hydrochloride - reference spectrum
Carteolol for system suitability
Carvedilol - reference spectrum
Carvedilol impurity C
C0340000
C0350000
C0400000
C0405000
C0410000
C0426000
Y0000671
C0430000
Y0000113
C0450000
Y0000033
C0451000
C0455000
C0460000
C0465000
C0470000
C0499900
C0550000
Y0000475
Y0000536
Y0000035
Y0000036
C0580004
C0580010
Y0000192
Y0000193
Y0000075
Y0000103
2
C0630000 Cefaclor
© Council of Europe, all rights reserved 2006
2
C0600000 Casein BRP
n/a
1
n/a
1
n/a
1
n/a
2
1
1
1
n/a
n/a
1
n/a
1
1
1
1
Batch
Order
Reference Standard
Code
C0299000 Calcium glucoheptonate
C0300000 Calcium gluconate
Catalogue No. 48-2006/4
100000
mg
450 mg
n/a
20 mg
n/a
30 mg
n/a
10 mg
n/a
50 mg
50 mg
100 mg
50 mg
n/a
n/a
40 mg
n/a
50 mg
10 mg
250 mg
500 mg
60 mg
50 mg
50 mg
200 mg
50 mg
10 mg
50 mg
200 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Information
8
95.0% CŒ—HŒ÷ClN–O÷S
(2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9Hcarbazol-4-yloxy)propan-2-ol
1,3-bis(2-chloroethyl)urea
(2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)carbamate
99.9% CŒ—HŒœNœO ; Batch 2 is valid until 31 August 2006
10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
(10,11-dihydrocarbamazepine) ; Batch 4 is valid until 28 February
2007
Batch 3 is valid until 30 June 2006
98.6 % CŒ‡HœŸNO–
Batch 2 is valid until 31 May 2006
Loss of 12.1% m/m
Batch 2 is valid until 31 July 2006
Unit Sale
Quantity Unit
60 mg
1
100 mg 1 Calcium digluconate
0986
0350
1187
1187
1972
1972
1745
1745
1185
812,956
0755
0884
0885
0375
1081
1712
1712
1689
1689
Yes
Yes
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
-20°C
+4°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
a
l
c
l
a
l
a
a
a
a
l
l
c
l
a
a
l
a
a
a
a
a
a
g
a
a
a
a
79 131 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
1399
0172,0658,0979,
1047,1399
1296
20234
0470
0655
0688
1401,1471
1859,2336,2337
1079
1971
0543
0543
Monograph
6 December 2006
Delta-3-Cefaclor
Cefadroxil
Cefalexin monohydrate
Cefalotin sodium
Cefalotin for impurity B identification
Cefamandole nafate
Reference Standard
3
3
2
2
1
1
1
n/a
C0691000 Ceftriaxone sodium
C0692000 Ceftriaxone impurity A
C0694990 Cefuroxime axetil
C0695000 Cefuroxime sodium
Y0000311 Celiprolol hydrochloride
Y0000312 Celiprolol impurity I
Y0000239 Celiprolol for peak identification
C0698000 Cellulose acetate - reference spectrum
© Council of Europe, all rights reserved 2006
2
1
1
2
1
n/a
1
4
1
2
3
1
1
2
Cefazolin
Cefepime dihydrochloride monohydrate
Cefepime dihydrochloride monohydrate for system suitability
Cefixime
Cefoperazone dihydrate
Cefoperazone sodium - reference spectrum
Cefotaxime acid
Cefotaxime sodium
Cefotaxime sodium for peak identification
Cefoxitin sodium
Cefradine
1
1
1
2
2
2
2
1
1
Batch
Y0000568 Cefradine for peak identification
C0690500 Ceftazidime
C0690510 Ceftazidime impurity A
C0682800
Y0000633
Y0000634
C0684000
C0684750
C0684800
Y0000420
New C0685000
Y0000506
C0688000
C0690000
Y0000240 Cefapirin sodium
C0682400 Cefatrizine propylene glycol
C0682410 Cefatrizine impurity A
Order
Code
C0640000
C0650000
C0675000
C0682000
Y0000505
C0682300
Catalogue No. 48-2006/4
80 mg
10 mg
60 mg
150 mg
10 mg
0.02 mg
20 mg
n/a
6 mg
200 mg
15 mg
15 mg
200 mg
100 mg
n/a
80 mg
30 mg
10 mg
250 mg
300 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
9
1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea
85.5% CœœHœœNÿOŸSœ
83.1% CœœHœœNÿOŸSœ;
(6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2-[(1-carboxy-1-methyl
ethoxy)imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)-methyl]-5thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylate
(delta-2-ceftazidime) ; Batch 1 is valid until 30 June 2006
90.4% CŒ‡HŒÿN‡NaœOŸS– ; Batch 2 is valid until 31 August 2006
E-isomer
96.9% CœÕHœœN÷OŒÕS
96.6% CŒÿHŒ—N÷NaO‡S
98.4% CŒÿHŒÿN–NaOŸSœ
94.2% CŒÿHŒ„N–O÷S (Cefradine)
1.8% CŒÿHŒŸN–O÷S (Cefalexin)
94.3% CŒÿHŒŸN—OŸSœ
Batch 3 is valid until 31 May 2007
88.4% CŒÿHŒ—N—OŸSœ
93.6% Cœ—HœŸN„O‡Sœ
Information
Unit Sale
Quantity Unit
30 mg
1
250 mg 1 93.7% CŒÿHŒŸN–O—S
150 mg 1 94.1% CŒÿHŒŸN–O÷S
100 mg 1 98.8% CŒÿHŒ—NœNaOÿSœ
10 mg
1
125 mg 1 94.4% CŒ„HŒŸNÿNaOÿSœ (cefamandole nafate) corresponding to:
85.2% CŒ‡HŒ‡NÿO—Sœ (cefamandole) 4.4% CŒ‡HŒ‡NÿO—Sœ
(cefamandole free acid)
100 mg 1 98.5% CŒŸHŒÿN–NaOÿSœ
150 mg 1 81.8% CŒ‡HŒ‡NÿO—Sœ
60 mg
1 7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4-yl)sulfanyl]-methyl-8oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (7-ACA
triazole)
150 mg 1 99.4% CŒ÷HŒ÷N‡O÷S–
150 mg 1 95.2% CŒ„HœÿClœNÿO—Sœ
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
c
a
l
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 c
79 a
79 a
79 a
79 a
79 a
0991
+5°C
a
0991
+5°C
a
1300
+5°C
a
0988,0992
+5°C
a
1632
+5°C
a
1632
+5°C
a
1632
Yes
+5°C
a
0887
l
For extra charges please see 2.2
0988
2126
2126
1188
1404
1404
0989
0708,0989
0989
0990
0167,0168,0578,
0708,0814
0814
1405
1405
1650
1403
1403
0986
0260,0577,0813
0708
0987
0987
1402
Monograph
6 December 2006
Cetyl palmitate 15
Cetyl palmitate 95
Cetylpyridinium chloride
Chenodeoxycholic acid
Chitosan hydrochloride
Chlorambucil
Chloramphenicol
Chloramphenicol dipalmitate
Chloramphenicol disodium disuccinate
Chloramphenicol palmitate isomer
Chloramphenicol sodium succinate
Chlorcyclizine hydrochloride
Chlordiazepoxide - * psy
Chlordiazepoxide hydrochloride - * psy
Chlordiazepoxide impurity A
Chlorhexidine
Chlorhexidine diacetate
Chlorhexidine dihydrochloride
Chlorhexidine for performance test
Chlorogenic acid
Chloromethylnitroimidazole
(2-Chlorophenyl)diphenylmethanol
1-(4-Chlorophenyl)-1-phenylethanol
Chloroquine sulphate
Chlorothiazide
Chlorphenamine maleate
Y0000073
Y0000074
C1000000
C1050000
Y0000104
C1100000
C1200000
C1300000
C1350000
C1400000
C1425000
C1435000
C1450000
C1500000
Y0000476
C1510000
C1520000
C1540000
C1530000
Y0000569
C1600000
C1605000
C2223030
C1650000
C1700000
C1800000
© Council of Europe, all rights reserved 2006
3
3
n/a
1
Cetirizine dihydrochloride
Cetirizine impurity A
Cetostearyl isononanoate - reference spectrum
Cetyl alcohol
C0980650
C0980651
C0984100
C0990000
1
5
1
3
1
1
4
2
1
4
1
1
1
1
1
1
1
2
1
3
1
1
1
1
1
1
n/a
n/a
2
Batch
Order
Reference Standard
Code
C0698005 Cellulose acetate butyrate - reference spectrum
C0698020 Cellulose acetate phthalate - reference spectrum
C0700000 Cephaëline hydrochloride
Catalogue No. 48-2006/4
100 mg
20 mg
20 mg
200 mg
100 mg
100 mg
50 mg
10 mg
50 mg
30 mg
20 mg
60 mg
50 mg
50 mg
125 mg
30 mg
100 mg
500 mg
100 mg
25 mg
100 mg
1500 mg
100 mg
50 mg
100 mg
10 mg
100 mg
10 mg
n/a
250 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
Unit Sale
Quantity Unit
n/a
1
n/a
1
10 mg
1
10
Batch 4 is valid until 31 January 2006
Clemastine fumarate impurity C
Batch 2 is valid until 31 July 2006
96.9% CŒÿHŒ‡O„
Batch 1 is valid until 28 February 2006
7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
4-oxide
91.1% CŒ„HŒ‡ClœNœNaœOŒŒ
100% CŒÿH–÷O
(RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine
Information
Yes
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
c
a
a
a
g
g
a
a
a
a
a
a
a
a
g
a
a
a
a
a
a
j
j
a
a
a
l
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 l
79 l
79 a
For extra charges please see 2.2
0658
0657
0659
0657,0658,0659
0897,1823,1824,
1866
0369
0757
1190
0544,0545
0385,0394
0386,0977,1084,
1196
1406
0314
0080,0081,0093,
0094,1530,1875
1084
1084
1085
0540,0702,0801,
0802,0847,0969,
1411
1906
1906
0379
1189,1275
1774
0137
0071,0473,0709
0473
0709
0473
0709
1086
0656,1974
0474
0474,0656
Monograph
6 December 2006
1
1
1
1
4
1
5
4
6
4
Y0000479 Chlorpromazine impurity D
Chlorpromazine impurity E
Chlorpropamide
Chlorpropamide impurity B
Chlorprothixene hydrochloride
Chlortalidone
Chlortalidone impurity B
Y0000508
C1905000
C1905020
C1915000
C1950000
C1950020
C2000000 Chlortetracycline hydrochloride
C2100000 Cholecalciferol
C2150000 Cholecalciferol for performance test
Ciclopirox impurity B
Ciclopirox olamine
Ciclosporin
Ciclosporin for system suitability
Cilastatin sodium
Cilazapril
© Council of Europe, all rights reserved 2006
C2162702
C2162700
C2163000
Y0000361
C2170000
C2174000
2
1
2
1
2
1
2
1
1
1
2
1
1
1
1
2
1
1
C1900000 Chlorpromazine hydrochloride
Y0000507 Chlorpromazine impurity A
Cholesterol
Cholic acid
Chondroitin sulphate sodium
Chondroitin sulphate sodium (marine)
Chymotrypsin BRP
Cladribine
Cladribine for peak identification
Cladribine impurity C
Ciclopirox
Ciclopirox impurity A
1
Y0000437 Chlorphenamine impurity C
C2155000
C2158000
Y0000280
Y0000593
C2160000
New Y0000639
New Y0000609
New Y0000610
Y0000040
C2162701
1
Batch
Order
Reference Standard
Code
Y0000436 Chlorphenamine impurity A
Catalogue No. 48-2006/4
20 mg
150 mg
120 mg
5 mg
10 mg
50 mg
60 mg
60 mg
250 mg
100 mg
100 mg
50 mg
10 mg
5 mg
100 mg
20 mg
1 ml
500 mg
100 mg
10 mg
100 mg
50 mg
50 mg
50 mg
10 mg
10 mg
200 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0475
1087
1087
0815,1365
0546
0546
0475
0475,20303
0475
0386
0386
Monograph
11
98.8% CÿœHŒŒŒNŒŒOŒœ
1302
0994
0994
1408
1499
Yes
Yes
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
g
a
a
a
a
a
a
a
a
a
b
b
b
a
a
c
c
a
a
a
a
g
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
2-(4-chloro-3-sulfamoylbenzoyl)benzoic acid ; Batch 4 is valid
until 31 December 2005
89.7% CœœHœ÷ClœNœO‡
0173
5.5% Cœ—Hœ—ClNœO‡
100% CœŸH÷÷O; Vitamin D3 ; Batch 5 is valid until 28 February 2007 0072,0574,0575,
0598,1192,1193
0072,0082,0574,
0575,0598
99.2% CœŸH÷ÿO
0993
1189,1275
100% HœO(CŒ÷HŒ„NNaœOŒ÷S)¨
2064
2064
6.01 microkatals per mg
0476,0694
99.1% CŒÕHŒœClN—O–
2174
2174
2-chloro-7H-purin-6-amine
21-74
1407
(¢£)-2-(3-cyclohexyl-5-methyl-4,5-dihydroisoxazol-5-yl)acetic
1302,1407
acid
6-cyclohexyl-4-methyl-2§-pyran-2-one
1302,1407
1,3-Dipropylurea
2.0% E-isomer
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1amine S-oxide (chlorpromazine sulphoxide)
3-(2-chloro-10H-phenothiazin-10-yl)-N-methypropan-1-amine
(demethylchlorpromazine)
2-chloro-10H-phenothiazine
Information
Unit Sale
Quantity Unit
10 mg
1 2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino)
ethyl]butanenitrile
10 mg
1 (3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1amine
6 December 2006
1
1
1
1
1
1
1
1
3
1
4
Cimetidine
Cimetidine hydrochloride
Cinchocaine hydrochloride
Cineole
Cinnarizine
Ciprofibrate
Ciprofibrate for system suitability
Ciprofloxacin
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride for peak identification
Ciprofloxacin impurity A
Cisapride monohydrate
Cisapride tartrate
Cisplatin
Citric acid (anhydrous)
Citric acid monohydrate
Clarithromycin
Clarithromycin for peak identification
Clazuril for system suitability
Clazuril for veterinary use - reference spectrum
Clebopride malate
Clemastine fumarate
Clenbuterol hydrochloride
Clenbuterol impurity B
Clindamycin hydrochloride
Clindamycin phosphate
Clioquinol
Clobazam - reference spectrum
Clobazam impurity A
C2175000
C2175500
C2177000
Y0000176
C2180000
Y0000362
Y0000363
Y0000198
C2190000
Y0000199
C2190050
C2205000
C2205100
C2210000
A1202000
C2219000
Y0000320
Y0000321
Y0000269
Y0000262
C2221000
C2223000
C2248000
C2248010
C2250000
C2269000
Y0000364
Y0000205
Y0000241
© Council of Europe, all rights reserved 2006
1
C2174005 Cilazapril impurity D
3
2
1
n/a
1
1
1
2
1
1
2
1
1
n/a
1
1
1
1
1
Batch
Order
Reference Standard
Code
C2174002 Cilazapril impurity A
Catalogue No. 48-2006/4
200 mg
250 mg
5 mg
n/a
10 mg
30 mg
100 mg
150 mg
50 mg
50 mg
160 mg
30 mg
10 mg
n/a
100 mg
100 mg
50 mg
20 mg
50 mg
100 mg
60 mg
180 mg
100 mg
5 mg
5 mg
20 mg
100 mg
10 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
12
7-chloro-5-phenyl-1,5-dihydro-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione
1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]
ethanone (clenbuterol ketone)
93.3% CŒ‡H–÷ClœNœO—S
95.7% CŒ‡H–÷ClNœO‡PS ; Batch 1 is valid until 31 January 2006
97.5% C–‡Hÿ„NOŒ– ; Batch 1 is valid until 30 November 2006
100% [PtClœ(NH–)œ]
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
g
l
a
a
a
g
a
a
a
a
a
l
a
a
a
a
a
a
a
g
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0582,0583,0996
0996
2111
1974
1974
0995
1503
0599
0455
0456
1651
1651
1714
1714
1303
1190
1409
1409
0756
1500
1088
1973
0816
2013
2013
1089
93.6% CŒŸHŒ„ClFN–O–
0888,1353
0888,1089
7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3- 0888,1089
carboxylic acid (fluoroquinolonic acid) ; Batch 3 is valid until 30
April 2006
Information
Unit Sale
Monograph
Quantity Unit
25 mg
1 1,1-dimethylethyl(1S,9S)-9-[[(S)-1-ethoxycarbonyl-3-phenylpro 1499
pyl]amino]-10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine
-1-caboxylate
25 mg
1 (1S,9S)-9-[[(R)-1-ethoxycarbonyl-3-phenylpropyl]amino]-101499
oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic
acid
6 December 2006
Clozapine
Cocaine hydrochloride - reference spectrum
Cocoyl caprylocaprate
Codeine - reference spectrum
Codeine impurity A (methylcodeine)
© Council of Europe, all rights reserved 2006
1
n/a
1
n/a
2
2
3
1
1
1
C2460000
Y0000162
C2480000
C2500000
Y0000334
C2430000
C2450000
C2425600
C2424500
C2424550
1
1
1
1
n/a
1
1
1
1
Clomipramine impurity F
Clonazepam - * psy
Clonazepam impurity A
Clonazepam impurity B
Clonazepam - reference spectrum
Clonidine hydrochloride
Closantel sodium dihydrate
Closantel for system suitability
Clostridia (multi-component) rabbit antiserum(for
vaccines-vet.use)BRP
Clostridium tetani guinea pig antiserum (for vaccines human use) BRP
Clostridium tetani guinea pig antiserum (for vaccines - vet.
use) BRP
Clostridium tetani rabbit antiserum (for vaccines - vet. use)
BRP
Clotrimazole
Cloxacillin sodium
Y0000134
C2385000
C2385010
C2385015
Y0000286
C2400000
Y0000392
Y0000393
C2424400
1
1
1
1
1
1
1
2
1
1
1
Batch
1
Clobetasol propionate
Clobetasol for peak identification
Clobetasol impurity J
Clobetasone butyrate
Clofazimine
Clofazimine for system suitability
Clofibrate
Clomifene citrate
Clomifene citrate for performance test
Clomipramine hydrochloride
Clomipramine impurity C
Reference Standard
Y0000133 Clomipramine impurity D
Order
Code
Y0000559
Y0000570
Y0000571
C2285000
Y0000313
Y0000358
C2300000
C2320000
C2332000
C2360000
Y0000132
Catalogue No. 48-2006/4
60 mg
n/a
40 mg
n/a
10 mg
100 mg
125 mg
1 mg
1 mg
1 mg
50 mg
25 mg
25 mg
n/a
100 mg
20 mg
20 mg
1 mg
1
1
1
1
1
1
1
1
1
3
1
1
1
1
1
1
1
1
13
7,8-didehydro-4,5 ¶-epoxy-3,6
¶-dimethoxy-17-methylmorphinan
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
-20°C
-20°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
c
c
a
j
a
a
l
a
a
a
c
a
79 79 79 79 79 79 79 90 90 90 90 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
0757
+5°C
g
0661,0663,0668,
+5°C
a
2260
1191
+5°C
g
0073
l
1411
+5°C
a
0074,0075,0076
l
0074,0075,0076,
+5°C
a
1412
For extra charges please see 2.2
See leaflet,0697
15 IU per vial
94.6% CŒ„HŒŸClN–NaO—S
See leaflet,0697
0889
1974
0890
0890
0890
0477
1716
1716
0362,0363,0364,
0697
20708
0889
2127
2127
2127
1090
2054
2054
0318
0997,1046
0997
0889
0889
Monograph
34 IU per vial
0.20 IU per vial (determined using toxin neutralisation test)
see information on the accompanying leaflet
2-Amino-2'-chloro-5-nitrobenzophenone
3-Amino-4-(2-chlorophenyl)-6-nitro-1§-quinolin-2-one
Information
Unit Sale
Quantity Unit
40 mg
1 99.6% Cœ—H–œClFO—
2 mg
1
0.4 mg
1
50 mg
1
150 mg 1
10 mg
1
0.5 ml
1
50 mg
1 44% of Z-isomer ; Batch 1 is valid until 31 December 2006
50 mg
1
100 mg 1
10 mg
1 94.5% Clomipramine impurity C;
3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1amine
10 mg
1 3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,Ndimethylpropan-1-amine
5 mg
1 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine
6 December 2006
Colistin sulphate for microbiological assay
Copovidone - reference spectrum
Cortisone acetate
Coumarin
Cotton wool. standard for neps
Crospovidone - reference spectrum
Crotamiton
Crotamiton impurity A
Cyanocobalamin
C2700000
C2725000
C2800000
Y0000438
C2900000
C2950000
C2970000
C2970005
C3000000
C3090000 Cyclizine hydrochloride
C3200000 Cyclobenzaprine hydrochloride
C3230000 Cyclohexa-1,4-dienylglycine
C3245000 Cyclopentolate hydrochloride
C3250000 Cyclophosphamide
C3280000 Cyproheptadine hydrochloride
C3283000 Cyproterone acetate
C3290000 Cysteine hydrochloride monohydrate
C3300000 Cystine
C3350000 Cytarabine
D0070000 Dalteparin sodium
Y0000600 Danaparoid sodium
D0100000 Dapsone
D0125000 Daunorubicin hydrochloride
D0120000 Daunorubicinone
D0160000 Deferoxamine mesilate
D0201000 Dehydrohexetidine
Y0000611 Dembrexine hydrochloride monohydrate
D0300000 Demeclocycline hydrochloride
© Council of Europe, all rights reserved 2006
Codeine hydrochloride dihydrate - reference spectrum
Codergocrine mesilate
Colchicine
Colchicine for system suitability
Colestyramine
Colistimethate sodium
Colistin sulphate (for LC assay)
Reference Standard
Order
Code
C2500100
C2510000
C2580000
Y0000209
Y0000374
C2600000
Y0000277
Catalogue No. 48-2006/4
1
1
1
1
1
1
2
1
1
1
2
1
2
3
2
2
1
1
4
n/a
1
2
4
2
n/a
5
1
1
n/a
1
1
1
1
1
3
Batch
50 mg
100 mg
80 mg
60 mg
50 mg
30 mg
30 mg
50 mg
100 mg
150 mg
250 mg
200 mg
100 mg
100 mg
10 mg
30 mg
50 mg
10 mg
100 mg
n/a
100 mg
30 mg
20 mg
n/a
250 mg
80 mg
1000 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
92.4% CœŒHœœClœNœO‡
14
98.0% CœŸH–ÕClNOŒÕ
Daunorubicin aglycone
Batch 1 is valid until 30 April 2006
Batch 1 is valid until 30 September 2006
98.9%CŒ–HŒŸNO(sum of E and Z-isomers); 2.9% Z-isomers
N-ethyl-N-(2-methylphenyl)but-3-enamide
Vitamin B12 ; Batch 3 is valid until 31 July 2006
99.9% C„HÿOœ
Information
Unit Sale
Quantity Unit
n/a
1
60 mg
1
50 mg
1
50 mg
1
10 mg
1
100 mg 1 12850 IU per mg
25 mg
1 33.7% colistin E2, 2.6% colistin E3, 3.3% colistin E1-I, 3.1%
colistin E1-7MOA, 44.2 % colistin E1.
25.0 mg of colistin sulphate per vial
25 mg
1 576 000 IU per vial; For microbiological assay only
Yes
Yes
+5°C
+5°C
Room
temp.
-20° C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
Leaflet Storage
a
l
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 l
79 a
79 a
79 a
79 a
79 a
79 a
0892
l
1194
-20°C
c
1194
-20°C
c
0269,0270,0547,
+5°C
a
0710,1505
1092
+5°C
a
0408,0464
+5°C
a
0814
+5°C
a
1093
+5°C
a
0711
+5°C
a
0817,0846
+5°C
a
1094
+5°C
g
0895
+5°C
a
0998
+5°C
a
0760
+5°C
a
0828
+5°C
a
2090
+5°C
b
0077
+5°C
a
0662
+5°C
a
0662
+5°C
a
0896
-20°C
a
1221
+5°C
a
2169
+5°C
a
0176
+5°C
a
For extra charges please see 2.2
0891
0321,0736,0767
2120
0036
1412
1416,2060
0758
0758
1775
0319,20702
0320
Monograph
6 December 2006
1
1
1
3
1
3
1
1
Dexamethasone isonicotinate
Dexamethasone isonicotinate for impurity C identification
Dexamethasone pivalate
Dexamethasone sodium phosphate
Dexchlorpheniramine maleate
Dexpanthenol
Dextran
Dextran 1
Dextran Vo
Dextran 4 for calibration
Dextran 10 for calibration
Dextran 40 for calibration
Dextran 70 for calibration
Dextran 250 for calibration
Y0000538
Y0000511
D0718000
D0720000
D0720800
D0730000
D0731000
D0731005
D0732000
D0733000
D0734000
D0735000
D0736000
D0737000
© Council of Europe, all rights reserved 2006
2
D0710000 Dexamethasone acetate
1
1
1
1
1
1
1
1
4
Y0000001 Detomidine hydrochloride
D0660020 Detomidine impurity B
New D0700000 Dexamethasone
Y0000509 Desogestrel
Y0000510 Desogestrel for system suitability
D0400000 Desoxycortone acetate
1
1
1
n/a
4
1
1
1
1
1
2
1
6
Y0000228
D0406000
D0406200
D0430000
D0431000
D0480000
D0500000
D0600000
D0630000
D0650000
Demethylflumazenil - reference spectrum
Deoxyminoxidil
Deptropine citrate
Dequalinium chloride
Dequalinium chloride for performance test
Desacetylvinblastine
Desipramine hydrochloride
Deslanoside
Desmethylmetrifonate
Desmopressin
2
Batch
Order
Reference Standard
Code
D0350000 N-Demethylerythromycin A
Catalogue No. 48-2006/4
10 mg
50 mg
50 mg
50 mg
50 mg
50 mg
10 mg
10 mg
50 mg
50 mg
60 mg
5 mg
25 mg
50 mg
100 mg
100 mg
20 mg
60 mg
50 mg
10 mg
250 mg
n/a
0.25 mg
60 mg
50 mg
50 mg
1 mg
100 mg
150 mg
30 mg
0.98 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
M™´¨
M™´¨
M™´¨
M™´¨
M™´¨
15
3050-Mö 3850
88000 - Mö 10450
30500- Mö 40900
58900- Mö 70300
121800- Mö 238200
Average molecule mass : 930-1000
Fraction with less than 3 glucose units : 8.0 to 10.5%
Fraction with more than 9 glucose units : 10.0 to 12.5%
(RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol
Batch 3 is valid until 30 April 2007
0.98 mg per vial of C÷ÿHÿ÷NŒ÷OŒœS ; Batch 5 is valid until 30
November 2006
99.9% CœœH–ÕO
98.8% C÷ŸHŸ÷OŒ„
Information
Unit Sale
Quantity Unit
10 mg
1 Batch 1 is valid until 31 March 2006
20239
20239
20239
20239
20239
20239
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
l
a
a
a
a
c
a
a
a
c
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
1717
1717
0322,0809,0850,
1327
1414
1414
0312,0388,0768,
1376,2237
0548,0933,0975,
2237
2237
2237
1327
0549,0735,0810
1196
0761
0999,1000,1001
1506
0179,0274,0490,
0552,1098
1917
0937
1308
1413
1413
1276
0481
0482
1133
0712
Monograph
6 December 2006
Dienestrol
Diethanolamine fusidate
Diethylcarbamazine citrate
Diethylene glycol (monoethyl ether) - reference spectrum
Diethyl phthalate
Diethylstilbestrol
Diethylstilbestrol dimethyl ether
Diethylstilbestrol monomethyl ether
Diflunisal
Digitoxin
Digoxigenin
Digoxin
Digoxin for peak identification
D1200000
D1250000
D1300000
Y0000217
D1410000
D1500000
D1600000
D1700000
D1750000
D1800000
Y0000640
D1900000
Y0000554
© Council of Europe, all rights reserved 2006
Dextran 40 for performance test
Dextran 60/70 for performance test
Dextromethorphan hydrobromide
Dextromethorphan impurity A
Dextropropoxyphene hydrochloride - reference spectrum
Diazepam - * psy
Diazepam for system suitability - * psy
Diazoxide
Dibenzocycloheptene
Dibenzosuberone
Dibrompropamidine diisetionate
Dibrompropamidine for system suitability
Dibutyl phthalate
Dichlorodiaminocyclohexaneplatinum
Diclazuril for system suitability
Diclazuril for veterinary use - reference spectrum
Diclofenac potassium
Diclofenac impurity A
Dicloxacillin sodium
Dicycloverine hydrochloride
Didanosine
Didanosine for system suitability
Didanosine impurity A
Didanosine impurity G
Reference Standard
Order
Code
D0738000
D0739000
D0740000
Y0000261
D0750000
D0940000
Y0000596
D0950000
D0970000
D1000000
Y0000480
Y0000481
D1010000
New Y0000275
Y0000259
Y0000264
D1039990
D1040000
D1050000
D1060000
Y0000439
Y0000440
Y0000441
Y0000442
Catalogue No. 48-2006/4
3
1
1
n/a
1
1
1
1
1
2
1
7
1
1
1
3
1
n/a
1
1
1
2
1
1
1
1
2
1
n/a
2
3
3
1
1
1
1
1
Batch
50 mg
250 mg
n/a
1 ml
100 mg
10 mg
10 mg
30 mg
250 mg
5 mg
30 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
16
98.5% C÷ŒHÿ÷OŒ÷ ; Batch 6 is valid until 30 June 2006
99.0% C÷ŒHÿ÷OŒ–
100% CŒ‡HœÕOœ. Dried at 100-105°C for 2 h
Information
Unit Sale
Quantity Unit
50 mg
1
50 mg
1
100 mg 1 Batch 2 is valid until 30 April 2006
5 mg
1 (S,13S,14S)-3-methoxymorphinan
n/a
1
30 mg
1
0.5 mg
1
50 mg
1
20 mg
1
100 mg 1
10 mg
1
20 mg
1
1 ml
1
10 mg
1 Batch 1 is valid until 30 April 2007
20 mg
1
n/a
1
100 mg 1
5 mg
1 1-(2,6-dichlorophenyl)indolin-2-one
250 mg 1 93.7% CŒ„HŒÿClœN–NaO—S
100 mg 1
10 mg
1
10 mg
1
10 mg
1 1,7-dihydro-6H-purin-6-one (hypoxanthine)
10 mg
1 9-(2,3-dideoxy-ß-D-glycero-pentofuranosyl)-9H-purin-6-amine
(2',3'-dideoxyadenosine)
150 mg 1 100% CŒ‡HŒ‡Oœ
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
g
l
a
a
a
a
a
a
f
f
f
79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 g
79 g
79 l
79 j
79 j
79 a
79 a
79 a
79 a
79 a
79 a
79 g
79 a
79 l
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
For extra charges please see 2.2
0483,0484
0798,0848
0271
1198
0897
0483,0484
0484
0484
0818,0864
0078,0079,0117
0079
0079
0079
20239
20239
0020
0020
0713
0022
0022
0550
0817
0464,0941
2300
2300
0762
2017
1718
1718
1508
1002,1281,1508
0661,0663,0668
1197
2200
2200
2200
2200
Monograph
6 December 2006
Dihydrotachysterol
Dihydrotachysterol for system suitability
Diltiazem hydrochloride
Diltiazem impurity A
Dimenhydrinate
(2,6-Dimethylphenoxy)acetone
N,N-Dimethylacetamide - reference spectrum
Dimethyl sulfoxide
Dimeticone
Dimetindene maleate
Dinoprost trometamol
Dinoprostone
Dinoprostone impurity C
Diosmin
Diosmin for system suitability
Diphenhydramine hydrochloride
Diphenhydramine impurity A
Diphenoxylate hydrochloride - reference spectrum
Diphtheria toxin BRP - * Biotox
Y0000544
Y0000482
D1980000
D1982000
D2000000
D2046000
Y0000234
D2050000
D2200000
D2205000
D2255000
D2250000
D2250015
Y0000094
Y0000095
D2600000
Y0000135
D2630000
Y0000258
D2700000 Diphtheria vaccine (adsorbed) BRP
Y0000376 Dipivefrine hydrochloride
Y0000394 Dipivefrine for system suitability
D2750100 Dipotassium clorazepate - reference spectrum
© Council of Europe, all rights reserved 2006
Dihydralazine for system suitability
Dihydralazine sulphate (hydrated) - reference spectrum
Dihydrocodeine hydrogen tartrate - reference spectrum
17 alpha-dihydroequilin
Dihydroergocristine mesilate
Dihydroergotamine mesilate
Dihydroergotamine tartrate
Dihydrostreptomycin sulphate
Reference Standard
Order
Code
Y0000232
D1940001
Y0000216
Y0000053
D1945000
D1950000
D1952000
D1954000
Catalogue No. 48-2006/4
3
1
1
n/a
1
2
1
2
n/a
1
1
1
n/a
2
2
1
1
2
1
1
1
3
1
1
n/a
n/a
1
1
3
2
n/a
Batch
32 mg
100 mg
10 mg
n/a
50 mg
5 mg
100 mg
10 mg
n/a
1 ml
100 mg
50 mg
n/a
1 ml
200 mg
50 mg
60 mg
100 mg
10 mg
5 mg
200 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1611
1611
0023,1190
0023
0819
See leaflet,0443
0601
1029
1667
0763
0138,1470
1417
1312
1311
1311,1488
2014
2014
1004,1199
1004
1310
1310
1776
1512
1416,2060
0551
0600
0485,20702
Monograph
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
Leaflet Storage
a
a
a
a
l
f
a
a
l
a
a
a
c
c
a
c
c
a
a
79 79 79 90 90 79 79 79 79 79 240 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 l
79 l
79 c
79 a
79 a
79 a
79 a
Nominal concentration of Diphtheria toxin: 1 Lf/ml (0.4μl/ml)
Yes
+5°C
Systemic toxicity: 77.6 LD—Õ/ml (determined in the subcutaneous
challenge test in guinea pigs)
Maximum intradermal toxicity: 75,000Lr/Lf (determined in the
guinea pig intradermal skin test)
Toxicity in the Vero cell assay: concentrations of 5x10-Î Lf/ml and
below cause cytotoxic effects.
160 IU per vial
See leaflet,20706
Yes
-20°C
c
1719
+5°C
g
1719
+5°C
g
0898
l
17
For extra charges please see 2.2
2-(diphenylmethoxy)-N-methylethanamine
98.2% Cœ÷H÷—NO‡
99.8% CœÕH–œO
(E)-7-[(1S,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]5-oxocyclopentyl]-hept-5-enoic acid (5-trans-PGEœ ; (5E)-PGEœ)
94.6% Cœ‡H–œOŒ—
Batch 1 is valid until 30 April 2006
99.8% dimeticone
(2¢,3£)-3-acetyloxy-5-[2-(dimethylamino)ethyl]-2-(4-methoxy
phenyl)-2,3-dihydro-1,5-benzothiazepin-4(5§)-one
Information
Unit Sale
Quantity Unit
10 mg
1
n/a
1
n/a
1
10 mg
1 98.2% CŒ‡HœœOœ
250 mg 1
100 mg 1
150 mg 1 100.0% CŸÕH‡ÕNŒÕOŒÿ. Dried at 100-105°C at constant weight
200 mg 1 820 IU per mg; International standard provided for an interim
period
10 mg
1 100.0% Cœ‡H÷ÿO
6 December 2006
Diprophylline
Dipyridamole
Dirithromycin
Disodium edetate
Disopyramide
Disopyramide phosphate
Disulfiram
Dithranol
Dithranol impurity C
Reference Standard
5
3
n/a
D2975000 Doxorubicin hydrochloride
D3000000 Doxycycline hyclate
Y0000163 Doxylamine hydrogen succinate - reference spectrum
© Council of Europe, all rights reserved 2006
1
1
1
n/a
2
2
Doxazosin mesilate
Doxazosin impurity D
Doxazosin impurity F
Doxepin hydrochloride - reference spectrum
Doxepin impurity A
Doxepin impurity B
Y0000553
Y0000551
Y0000552
D2964500
D2964510
D2964520
1
2
n/a
1
1
1
1
1
1
1
1
1
1
1
Dobutamine hydrochloride
Docosahexaenoic acid ethyl ester
Docusate sodium - reference spectrum
Dodecyl gallate
Domperidone
Domperidone maleate
Dopamine hydrochloride
Dopexamine dihydrochloride
Dopexamine impurity B
Dopexamine impurity F
Dosulepin hydrochloride
Dosulepin impurity A
3
1
1
1
1
1
1
1
1
2
Batch
D2963000 Doxapram hydrochloride
Y0000208 Doxapram impurity B
D2954000
D2954600
D2954500
Y0000365
D2955000
D2957000
D2960000
Y0000612
Y0000613
Y0000614
D2962000
D2962005
New D2953050 Dithranol impurity D
Order
Code
D2800000
D2850000
D2880000
D2900000
D2920000
D2922000
D2950000
D2953000
D2953025
Catalogue No. 48-2006/4
150 mg
100 mg
n/a
60 mg
10 mg
10 mg
n/a
20 mg
25 mg
50 mg
10 mg
100 mg
150 mg
n/a
30 mg
150 mg
150 mg
50 mg
10 mg
10 mg
10 mg
100 mg
50 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1201
1201
1200
2063,20429
1418
2078
1009
1008
0664,1200
1748
1748
1748
1314
1314
1007
0486
1199
1313
0232
1006
1005
0603
1007
1007
Monograph
18
1589
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
a
l
a
a
a
l
a
a
a
a
a
a
l
a
a
a
a
a
c
c
a
a
g
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 g
79 g
For extra charges please see 2.2
2125
2125
2125
1096
dibenzo[b,e]oxepin-11(6H)-one
1096
(11RS)-11-[3-(dimethylamino)propyl]-6,11-dihydrodibenzo[b,e] 1096
oxepin-11-ol
99.0% CœŸH–ÕClNOŒŒ
0714,0662,1590
85.6% CœœHœ÷NœO‡
0272,0820
(4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one
99.2% Cœ÷Hœ„N—O‡S
(E)-3-(6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-N,N'dimethylpropan-1-amine £-oxide
91.2% DHA ethyl ester
Information
Unit Sale
Quantity Unit
100 mg 1
50 mg
1
100 mg 1 97.4% C÷œHŸ‡NœOŒ÷
100 mg 1
100 mg 1
100 mg 1
100 mg 1
125 mg 1
20 mg
1 Dithranol-dimer
4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione ;
Batch 1 is valid until 31 May 2006
20 mg
1 94.9% CŒ÷HŒÕOœ; 1-hydroxyanthracen-9(10H)-one ; Batch 2 is valid
until 31 March 2007
6 December 2006
n/a
1
1
n/a
1
2
n/a
2
1
1
Y0000249 Ebastine - reference spectrum
Y0000247 Ebastine impurity C
Y0000248 Ebastine impurity D
Y0000270 Econazole - reference spectrum
Y0000254 Econazole for system suitability
E0050000 Econazole nitrate
Y0000296
E0085000
Y0000537
Y0000512
4-Epianhydrotetracycline hydrochloride
4-Epichlortetracycline hydrochloride
4-Epidemeclocycline hydrochloride
6-Epidoxycycline hydrochloride
4-Epioxytetracycline
Epirubicin hydrochloride
Enalapril for system suitability
Enalapril maleate
Enalaprilat dihydrate
Enalaprilat for system suitability
Enalaprilat impurity G
Enilconazole
Enilconazole impurity E
Endotoxin standard BRP
Enoxaparin sodium
Enoxolone
Enterokinase BRP
Ephedrine hydrochloride (racemic) - * Drug Precursor
Ephedrine hydrochloride - * Drug Precursor
© Council of Europe, all rights reserved 2006
E0400000
E0430000
E0440000
E0500000
E0530000
E0550000
E0110000
E0109000
Y0000615
Y0000629
New Y0000678
Y0000136
Y0000137
E0150000
E0180000
E0180500
E0200000
E0305000
E0300000
E0100000 Emetine hydrochloride
4
3
1
4
6
4
1
2
1
1
1
1
1
4
3
1
1
1
1
1
1
D3100000 Droperidol
Econazole nitrate - reference spectrum
Eicosapentaenoic acid ethyl ester
Emedastine difumarate
Emedastine impurity E
1
Batch
Order
Reference Standard
Code
Y0000160 Doxylamine impurity A
Catalogue No. 48-2006/4
10 mg
20 mg
20 mg
50 mg
40 mg
100 mg
20 mg
50 mg
100 mg
10 mg
0.005 mg
60 mg
20 mg
11 mg
200 mg
100 mg
500 mg
50 mg
150 mg
100 mg
n/a
150 mg
10 mg
10 mg
n/a
20 mg
100 mg
n/a
10 mg
10 mg
150 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1008,1009,1010,
1172
2015
2015
2015
1589
Monograph
19
82% CœœHœ÷NœO„ ; Batch 5 is valid until 31 January 2007
96.4% CœŸH–ÕClNOŒŒ ; Batch 3 is valid until 31 August 2006
Batch 2 is valid until 30 June 2006
(1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol
10000 IU per vial
Batch 2 is valid until 31 December 2005
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
c
a
a
a
a
a
a
a
a
a
a
a
i
i
a
l
a
a
a
l
a
a
l
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0080,0081,0093,
0094,1530,1875
1420
1420
1749
1749
1749
1720
1720
20614
0828,1097
1511
0350
0715
0487,0488,0489,
1367
0210,0211,1654
0173
0176
0272,0820
0198,0199
0662,0714,1590
2049
0665,2049
0513,0921,0935,
1017,1018
0665
97.6% EPA ethyl ester
2063,20429
2242
1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1yl)benzimidaz 2242
ole.
4-(diphenylmethoxy)piperidine
1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one
Information
Unit Sale
Quantity Unit
50 mg
1 N,N-dimethyl-2-[1(RS)-1-phenyl-1-(pyridin-4-yl)ethoxy]
ethanamine
6 December 2006
1
1
1
2
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin stearate
Erythropoietin BRP
Esketamine hydrochloride - reference spectrum
Esketamine impurity D - * narc
Estradiol benzoate
Estradiol benzoate impurity E
Estradiol butyrate
Estradiol hemihydrate
Estradiol for peak identification
Estradiol valerate
E1400000
E1500000
E1500800
E1515000
Y0000324
Y0000338
E1600000
Y0000201
Y0000045
E1620000
Y0000314
Y0000046
© Council of Europe, all rights reserved 2006
4
E1320000 Erythromycin C
n/a
1
1
1
1
2
1
1
2
E1310000 Erythromycin B
2
3
2
1
1
4
2
n/a
10 mg
250 mg
10 mg
10 mg
100 mg
10 mg
50 mg
100 mg
100 mg
50 mg
0.25 mg
50 mg
50 mg
50 mg
20 mg
100 mg
0.4 mg
1000 mg
250 mg
250 mg
6
Ergometrine maleate - * Drug Precursor
Ergosterol
Ergotamine tartrate - * Drug Precursor
Erysipelas ELISA coating antigen BRP
Erythritol
Erythromycin
Erythromycin A
500 mg
1
New Y0000712 Eq Influenza Subtype 2 American-like/South Africa Horse
Antiserum BRP
E0900000 Ergocalciferol
E1000000
E1100000
E1200000
Y0000051
Y0000177
E1300000
E1305000
1 mg
2
E0850022 Eq Influenza Subtype 2 European-like/Newmarket Horse
Antiserum BRP
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
See leaflet,0249
See leaflet,0249
See leaflet,0249
0210,0211,1654
1512
See leaflet,0249
Monograph
20
estra-1,3,5(10)-triene-3,17alpha-diol 3-benzoate
(2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
+5°C
-20°C
+5°C
-20°C
+5°C
-20°C
-20°C
-20°C
-20°C
-20°C
-20°C
+5°C
-20°C
-20°C
Leaflet Storage
l
k
a
a
a
a
a
a
a
a
a
b
a
a
i
c
i
c
a
a
a
c
c
c
c
79 79 79 79 79 79 79 79 150 79 79 79 79 79 79 79 79 90 79 79 79 79 90 90 90 Extra
Price
charges
79 a
79 c
90 c
6 December 2006
For extra charges please see 2.2
1742
1742
0139
0139
1614
0821,1203
0821
1614
0082,0574,0575,
0598,1192,1193
0223
0082
0224
0.5ml Freeze dried (0.367g protein)
See leaflet,0064
99.8% C÷HŒÕO÷
1803
960 IU per mg
0179,20702
96.7% C–ŸHÿŸNOŒ–
0179,0274,0293,
0490,0552,1098
99.0% Erythromycin B
0179,0274,0490,
0552,1098
97.6% C–ÿHÿ—NOŒ– ; Batch 3 is valid until 28 February 2006
0179,0274,0490,
0552,1098
0552
0274
0490
32500 IU per vial; 0.250 mg erythropoietin per vial; New unit sale : 1316
only ONE vial
99.8% Cœ‡H÷÷O; Vitamin D2 ; Batch 5 is valid until 28 February
2007
Information
Unit Sale
Quantity Unit
20 mg
1 86.8% CœœHœ—ClNœO‡ ; Batch 5 is valid until 31 May 2006
15 mg
1 99.7% CŒ‡HœÕOœ
1 mg
3 Assigned SRH antibody titre: 125 mmË +/-20%; Common
standard OIE
Strain A/eq/Newmarket/77
1 mg
3 Assigned SRH antibody titre: 180 mmË +/- 20%; Common
standard OIE
Strain A/eq/Newmarket/1/93
1 mg
3 Assigned SRH antibody titre: 155 mmË +/- 20%; Common
standard OIE
Strain A/eq/Newmarket/2/93
2
6
1
2
Batch
E0850021 Eq Influenza Subtype 2 American-like/Newmarket Horse
Antiserum BRP
Order
Reference Standard
Code
E0600000 4-Epitetracycline hydrochloride
Y0000052 Equilin
E0850010 Eq Influenza Subtype 1 Strain A/eq/Newmarket/77 Horse
Antiserum BRP
Catalogue No. 48-2006/4
Ethionamide
Ethosuximide
Ethosuximide impurity A
Ethyl acetate - reference spectrum
Ethylcellulose - reference spectrum
1-N-Ethylgaramine sulphate
1,1'-Ethylidenebistryptophan
Ethyl indole-3-carboxylate
Ethylmorphine hydrochloride - reference spectrum
Ethylnicotinamide
Ethyl parahydroxybenzoate
Etifenin
Etilefrine hydrochloride
Etilefrine impurity A
Etidronate disodium
Etodolac
Etodolac impurity H
Etofenamate
Etofenamate for peak identification
Etofenamate impurity G
Etofylline
Etomidate
Etomidate impurity B
Etoposide
Eugenol
Famotidine
E2000000
E2150000
E2250000
E2195000
E2195900
E2202000
E2205500
Y0000617
E2300000
E2400000
E2425000
E2450000
E2451000
E2451010
Y0000572
E2470000
E2470050
E2499900
E2499901
E2499914
E2500000
E2503000
E2503004
E2600000
E5000000
F0005000
© Council of Europe, all rights reserved 2006
Estriol
Estriol impurity A
Estrone
Etacrynic acid
Etamsylate
Ethacridine lactate monohydrate
Ethambutol hydrochloride
Ethanol (anhydrous) - reference spectrum
Ethanol 96% - reference spectrum
Ethinylestradiol
Reference Standard
Order
Code
E1680000
E1680005
E1700000
E1800000
E1830000
E1840000
E1850000
A1202800
E1860100
E1900000
Catalogue No. 48-2006/4
1
1
1
1
1
1
1
1
1
1
1
1
4
2
2
1
1
1
n/a
n/a
1
2
1
n/a
1
2
2
1
2
1
1
1
2
n/a
n/a
2
Batch
25 mg
75 mg
20 mg
5 mg
60 mg
10 mg
40 mg
15 mg
20 mg
100 mg
100 mg
25 mg
150 mg
500 μl
100 mg
100 mg
30 mg
50 mg
n/a
n/a
125 mg
5 mg
10 mg
n/a
150 mg
50 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Information
21
methyl 1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate
97.5% Cœ„H–œOŒ–
2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate
2-(7-ethylindol-3-yl)ethanol
2-ethylamino-1-(3-hydroxyphenyl)ethanone (etilefrone)
88.2% 1-N-Ethylgaramin sulphate
82.3% 1,1'-Ethylidenebistryptophan
2-ethyl-2-methylsuccinic acid
Unit Sale
Quantity Unit
50 mg
1
20 mg
1 9,11-didehydroestriol
15 mg
1 99.9% CŒ‡HœœOœ
100 mg 1
30 mg
1
50 mg
1
250 mg 1 99.1% CŒÕHœÿClœNœOœ
n/a
1
n/a
1
100 mg 1
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
l
l
a
a
a
l
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 l
79 l
79 g
For extra charges please see 2.2
1203
1203
1512
0457
1204
1591
0553
1318
1317
0140,0821,0926,
0940
0141
0764
0764
0899
0822
1351
1272,1383
2102
0491
0233
0409,0431,0900,
1262,1263,2134
0585
1205
1205
1778
1422
1422
1513
1513
1513
0492
1514
1514
0823
1100
1012
Monograph
6 December 2006
1
1
1
1
1
1
2
1
1
1
2
3
F0007000 Famotidine impurity B
Y0000409 Famotidine impurity D
Y0000556
Y0000660
F0030000
Y0000415
F0040000
F0040010
F0040020
F0041000
F0048000
F0048005
1
n/a
n/a
n/a
1
1
Fenoterol hydrobromide
Fenoterol hydrobromide - reference spectrum
Fentanyl - reference spectrum
Fentanyl citrate - reference spectrum
Fenticonazole nitrate
Fenticonazole impurity D
Ferrous gluconate
Finasteride
Finasteride for system suitability
Flecainide acetate
Flecainide impurity A
Flecainide impurity B
Flubendazole
Flubendazole for system suitability
Flucloxacillin sodium
F0050000
F0051000
F0054990
F0055000
F0060000
F0060040
F0100000
Y0000090
Y0000091
F0120000
F0120005
F0120010
Y0000138
Y0000139
F0150000
© Council of Europe, all rights reserved 2006
3
F0048035 Fenofibrate impurity G
1
1
1
6
1
1
1
1
1
3
F0048010 Fenofibrate impurity B
Febantel
Febantel for system suitability
Felodipine
Felypressin
Fenbendazole
Fenbendazole impurity A
Fenbendazole impurity B
Fenbufen
Fenofibrate
Fenofibrate impurity A
1
1
Batch
Order
Reference Standard
Code
Y0000382 Famotidine for system suitability
F0006000 Famotidine impurity A
Catalogue No. 48-2006/4
25 mg
25 mg
20 mg
250 mg
1000 mg
50 mg
100 mg
200 mg
50 mg
100 mg
n/a
n/a
n/a
50 mg
20 mg
25 mg
10 mg
10 mg
120 mg
0.994 mg
150 mg
20 mg
20 mg
100 mg
100 mg
20 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0901
0901
1210
1103
1211
1211
1322
1322
2176
2176
1013
1634
1208,1458
1208
1208
1209
1322
1322
1012
1012
1012
1012
Monograph
22
95.3% CŒ„HŒÿClFN–NaO—S ; Batch 5 is valid until 30 April 2006
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
c
a
a
a
a
a
a
l
l
l
a
a
a
a
a
a
a
c
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
1721
1721
0661,0663,0668
0493
1615
1615
1324
3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a-hexahydro 1324
imidazo[1,5-a]pyridine
(piperidin-2-yl)methanamine
1324
99.8% Cœ–H–ÿNœOœ
(¢£)-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-[4-(phenyl
suphanyl)benzyl]imidazolium nitrate
100.0% CœÕHœŒClO÷
(4-chlorophenyl)(4-hydroxyphenyl)methanone ; Batch 2 is valid
until 31 May 2006
2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid
(fenofibric acid)
1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl
propanoyl] oxy]-2-methylpropanoate
contains 4.0% m/m of the diastereoisomers
methyl(1§-benzimidazol-2-yl)carbamate
methyl[5(6)-chlorobenzimidazol-2-yl]carbamate
Information
Unit Sale
Quantity Unit
10 mg
1
10 mg
1 3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]-thio]
propanamide
10 mg
1 3,5-bis[2-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]
thio]-ethyl]-4§-1,2,4,6-thiatriazine1,1-dioxide
10 mg
1 3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphanyl]
propanamide
110 mg 1 99.9% CœÕHœœN÷OÿS
6 December 2006
1
3
n/a
1
1
n/a
1
1
1
3
1
1
n/a
1
3
4
3
1
2
1
Y0000078 Flupentixol impurity F
F0260000 Fluphenazine decanoate
Y0000009 Fluphenazine enantate
© Council of Europe, all rights reserved 2006
1
1
Y0000064 Flupentixol dihydrochloride
Y0000067 Flupentixol impurity D
Flumetasone pivalate
Flunarizine dihydrochloride
Flunarizine dihydrochloride - reference spectrum
Flunarizine dihydrochloride for system suitability
Flunitrazepam - * psy
Flunitrazepam - reference spectrum
Flunixin meglumine
Flunixin impurity B
Flunixin impurity C
Fluocinolone acetonide
Fluocortolone pivalate
Diacetylfluorescein
Fluoresceine sodium - reference spectrum
Fluorouracil
Fluoxetine hydrochloride
Fluoxetine impurity B (methyl(3-phenylpropyl)amine)
Fluoxetine impurity C
F0188500
F0189900
Y0000265
Y0000266
F0190000
Y0000169
Y0000443
Y0000444
Y0000445
F0200000
F0230000
Y0000454
F0245000
F0250000
F0253000
F0253020
F0253030
1
1
1
1
1
1
2
n/a
1
Batch
1
2
Fluconazole
Fluconazole for peak identification
Fluconazole impurity B
Fluconazole impurity C
Flucytosine
Fludarabine phosphate
Fludrocortisone acetate
Flumazenil - reference spectrum
Flumazenil impurity B
Reference Standard
F0189000 Flumequine
F0189020 Flumequine impurity B
Order
Code
Y0000557
Y0000558
Y0000573
Y0000574
F0175000
Y0000419
New F0180000
F0188000
Y0000335
Catalogue No. 48-2006/4
60 mg
100 mg
25 mg
120 mg
15 mg
100 mg
100 mg
n/a
20 mg
100 mg
n/a
10 mg
10 mg
50 mg
100 mg
100 mg
100 mg
n/a
50 mg
250 mg
5 mg
5 mg
60 mg
0.1 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2287
2287
2287
2287
0766
1781
0767
1326
1326
Monograph
23
2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9ylidene]propyl]piperazin-1-yl]ethoxy]ethanol
2-[4-[(EZ)-3-[(9RS)-2-(trifluoromethyl)-9H-thioxanthen-9-yl]
prop-2-enyl]piperazin-1-yl]ethanol
methyl(3-phenylpropyl)amine
(¢£)-methyl-[3-phenyl-3-(3-trifluoromethylphenoxy)-propyl]
amine ; Batch 2 is valid until 31 January 2006
99.6% Cœ÷HŒÿOŸ
2-methyl-3-(trifluoromethyl)aniline
ethyl 2-chloropyridine-3-carboxylate
100% Cœ÷H–ÕFœOÿ. Dried at 100-105°C for 2 hours
Batch 2 is valid until 31 October 2006
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
l
a
j
l
a
a
a
a
a
a
l
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 l
79 a
For extra charges please see 2.2
1014,1015
1014,1015
1693
1693
1693
1327
0816
1722
1722
1280
0717
1696
1696
1696
0494
1212
1213
1213
0611,0766
1104
1104
1104
1517
ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j] 1517
quinolizine-2-carboxylate (flumequine ethyl ester) ; Batch 1 is
valid until 30 June 2006
Information
Unit Sale
Quantity Unit
50 mg
1
10 mg
1
10 mg
1 94.6% CŒ—HŒ÷N„OF
5 mg
1
100 mg 1
100 mg 1 97.6% CŒÕHŒ–FN—OŸP
100 mg 1 Batch 1 is valid until 30 April 2007
n/a
1
5 mg
1 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]
benzodiazepine-3-carboxylic acid
6 December 2006
2
1
3
F0600000 Fumaric acid
F0700000 Furosemide
F0702000 Furosemide impurity A
© Council of Europe, all rights reserved 2006
1
1
1
1
7
2
1
1
2
1
1
n/a
n/a
1
1
F0550000 Fructose
Flutrimazole
Flutrimazole impurity B
Foeniculin for peak identification
Folic acid
Formoterol fumarate dihydrate
Formoterol fumarate dihydrate for impurity I identification
Formoterol fumarate for system suitability
Formylfolic acid
Foscarnet sodium hexahydrate
Foscarnet impurity B
Fosfomycin calcium - reference spectrum
Fosfomycin sodium - reference spectrum
Fosfomycin trometamol
Fosfomycin trometamol impurity A
F0290000
F0290010
Y0000386
F0300000
F0372000
Y0000339
Y0000340
F0380000
F0389000
F0389004
F0399900
F0399950
F0400000
F0400010
1
1
1
1
3
Flutamide
Flutamide impurity C
Fluticasone propionate
Fluticasone impurity D
F0285600
F0285603
Y0000284
Y0000221
1
1
1
n/a
1
1
1
1
Batch
F0450000 Framycetin sulphate
Fluphenazine dihydrochloride
Fluphenazine octanoate
Fluphenazine sulphoxide
Flurazepam monohydrochloride - reference spectrum
Flurbiprofen
Flurbiprofen impurity A
Fluspirilene
Fluspirilene impurity C
Reference Standard
Order
Code
F0280000
Y0000298
Y0000299
Y0000211
F0285200
F0285202
Y0000236
Y0000375
Catalogue No. 48-2006/4
100 mg
5 mg
100 mg
100 mg
25 mg
100 mg
60 mg
100 mg
250 mg
10 mg
10 mg
10 mg
30 mg
50 mg
10 mg
n/a
n/a
1500 mg
50 mg
50 mg
20 mg
100 mg
10 mg
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
24
2-chloro-4-(furfurylamino)-5-sulphamoylbenzoic acid
99.6% CŸHŒ‡NOŸP
1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium
(1,2-dihydroxypropyl)phosphonate
18060 IU per vial,
95.2% Cœ–H÷ÿNÿOŒ–,xHœSO÷
disodium (ethoxyoxydophosphanyl)formate
10-Formylfolic acid
(RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol
Star anise oil
91.5 % CŒ„HŒ„NŸOÿ
Batch 1 is valid until 30 November 2006
N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
99.1% Cœ—H–ŒF–O—S
S-methyl 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17apropionyloxy-androsta-1,4-diene-17ß-carbothioate
(S-methyl derivative)
Information
Unit Sale
Quantity Unit
50 mg
1
10 mg
1
10 mg
1
n/a
1
50 mg
1
20 mg
1 (2RS)-2-(biphenyl-4-yl)propanoic acid
20 mg
1
10 mg
1 8-[4,4-bis(4-fluorophenyl)butyl]-3-(hydroxymethyl)-1-phenyl
-1,3,8-triazaspiro[4.5]decan-4-one
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
a
a
c
a
a
l
l
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 l
79 a
79 a
79 a
79 a
For extra charges please see 2.2
0177,0178,0187,
0188,0204,0209,
1061,1570
0365,0902,1190,
1592
0391
0391
0180,0197,20702
1424
1424
0804
0067
1293,1724
1724
1724
0978,1606
1520
1520
1328
1329
1425
1425
1423
1423
1750
1750
0904,1014
1014,1015
1014,1015
0905
1519
1519
1723
1723
Monograph
6 December 2006
1
1
1
1
Y0000515
Y0000516
G0340000
G0342000
1
1
1
1
1
1
n/a
1
2
Y0000643 Glipizide impurity D
Y0000191 Human glucagon
G0350500 Glucose
G0355000 Glutamic acid
Y0000517
G0360000
G0400000
G0400002
G0400004
© Council of Europe, all rights reserved 2006
Glutathione
Glutethimide - * psy
Glycerol (85 per cent) - reference spectrum
Glycerol dibehenate
Glycerol distearate
1
Y0000523 Glipizide impurity C
Glimepiride
Glimepiride for system suitability
Glipizide
Glipizide impurity A
2
2
2
G0326000 Gliclazide
G0326004 Gliclazide impurity B
G0326012 Gliclazide impurity F
n/a
1
2
1
1
1
1
1
1
5
2
2
1
Batch
1
Fusidic acid - reference spectrum
Galactitol
Galactose
Gallamine triethiodide
Gammacyclodextrin
Gemcitabine hydrochloride
Gemcitabine impurity A
Gemfibrozil
Gemfibrozil for system suitability
Gentamicin sulphate
Gitoxin
Glibenclamide
Glibenclamide impurity A
Reference Standard
Y0000242 Glibenclamide impurity B
Order
Code
F1000000
G0049000
G0050000
G0100000
G0150000
Y0000675
Y0000676
Y0000513
Y0000514
New G0200000
G0300000
G0325000
G0325010
Catalogue No. 48-2006/4
10 mg
50 mg
n/a
2000 mg
2000 mg
50 mg
10 mg
0.952 mg
100 mg
10 mg
0.012 mg
50 mg
10 mg
1
1
1
1
1
1
1
2
1
1
1
1
1
25
0.952 mg pure human glucagon per vial
4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzene
sulphonamide
ethyl [2-[4-[(cyclohexylcarbamoyl)sulphamoyl]phenyl]ethyl]
carbamate
Information
Unit Sale
Quantity Unit
n/a
1
50 mg
1
60 mg
1 Batch 1 is valid until 31 August 2006
100 mg 1
50 mg
1
50 mg
1 99.9% C„HŒœClFœN–O÷
20 mg
1
5 mg
1
0.196 mg 1
25 mg
2 16500 IU per vial ; Batch 4 is valid until 31 March 2007
30 mg
1
100 mg 1
100 mg 1 4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulphonamide
10 mg
1 methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]
sulphonyl]carbamate
20 mg
1 Batch 1 is valid until 31 August 2006
25 mg
1 2-nitroso-octahydrocyclopenta[c]pyrrole
25 mg
1 1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(2-methylphenyl)
sulphonyl]urea
60 mg
1 99.4% Cœ÷H–÷N÷O—S
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
Leaflet Storage
a
j
l
a
a
a
a
c
a
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 l
79 a
79 a
79 a
79 a
79 g
79 g
79 a
79 a
79 c
79 a
79 a
79 a
For extra charges please see 2.2
0906
1635
0177,0178,0187,
0188,0204,0209,
1061,1215,1570
0750,0797,1445,
2076
1670
1291
0496,0497
1427
1428
0906
2223
2223
0906
0906
0718,1524
1524
1524
0718
0798,0848
1381
1215
0181
1070,1487
2306
2306
1694
1694
0331,20702
0078,0079,2168
0718
0718
Monograph
6 December 2006
Glycerol monolinoleate
Glycerol mono-oleate
Glycerol monostearate 40-55
Glyceryl trinitrate - reference spectrum
Glyceryl trinitrate solution
Glycine
Ammonium glycyrrhizate
Glycyrrhizate (monoammonium)
Gonadorelin
Goserelin
Gosereline - reference spectrum
4-D-Ser-goserelin
Goserelin validation mixture
Gramicidin
Granisetron hydrochloride
Granisetron impurity A
Reference Standard
2
2
1
2
© Council of Europe, all rights reserved 2006
Hepatitis B vaccine (rDNA) BRP method A (thiomersal free)
Hepatitis B vaccine (rDNA) BRP method B
Hepatitis C Virus RNA for NAT testing BRP
Heptadecanol
Y0000389
H0210010
H0215000
H0220000
1
n/a
4
1
3
1
2
1
1
1
1
1
2
Haloperidol decanoate
Halothane - reference spectrum
Heparin Low-Molecular-Mass for assay BRP
Heparin Low-Molecular-Mass for calibration CRS
Heparin sodium BRP
Granisetron impurity E
Griseofulvin
Guaiacol
Guaifenesin
Halofantrine hydrochloride
Halofantrine impurity C
Haloperidol
1
1
1
2
n/a
2
3
1
1
4
1
n/a
1
1
1
1
1
Batch
H0205010 Hepatitis A vaccine (inactivated, adsorbed) Type B BRP
H0100100
H0150000
H0185000
H0190000
H0200000
Y0000395
G0600000
New Y0000619
G0700000
Y0000117
Y0000118
H0100000
Y0000478 Granisetron impurity B
Order
Code
G0400006
G0400007
G0400008
G0400101
G0400100
New G0450000
Y0000433
G0460000
G0525000
Y0000125
Y0000126
Y0000019
Y0000194
G0550000
Y0000396
Y0000477
Catalogue No. 48-2006/4
0.5 ml
1 ml
40 mg
600 mg
0.5 ml
60 mg
n/a
1 ml
25 mg
2 ml
100 mg
125 mg
10 mg
50 mg
2
2
5
1
3
1
1
5
1
1
1
1
1
1
1695
0182
1978
0615
1979
1979
0616,0995,1178,
1503
1397,1431
0393
See leaflet,0828
0828
0332,0333,0569,
0686,20705
See leaflet,20714
1695
1429
1430
0495
1331
1331,1355
0614,0752
1772
0277,1536,1772
0827
1636
1636
1636
1636
0907,1662,20702
1695
1695
Monograph
26
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
Leaflet Storage
b
b
e
a
b
a
l
b
a
a
a
a
a
a
a
a
a
a
79 242 90 90 90 79 90 90 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 l
79 g
79 a
79 a
79 a
79 c
79 c
79 l
79 c
79 c
79 a
79 a
79 a
For extra charges please see 2.2
262 IU per ml; Please contact us for information on the type
needed for your use
16.6 micrograms per ml
See leaflet,20715
20 micrograms per ml
See leaflet,1056
HCV-RNA content 500 IU per vial; For plasma pool testing by NAT See leaflet,20621
0801,0802,0847
Anti-IIa activity : 33 IU per ml; Anti-Xa activity : 113 IU per ml.
Mn = 3700
1010 IU per ml ; Batch 2 is valid until 31 January 2007
99.6% CœÿH–ŒCl–F–NO
[1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol
Information
Unit Sale
Quantity Unit
2000 mg 1
2000 mg 1
2000 mg 1 Batch 1 is valid until 30 September 2006
n/a
1
0.5 ml
1 1% m/m in ethanol ; Batch 1 is valid until 28 February 2007
50 mg
1 Batch 2 is valid until 28 February 2007
70 mg
1
300 mg 1 80.6% C÷œHÿ—NOŒÿ
5.08 mg 1 5.08 mg per vial of C——HŸ—NŒŸOŒ–
4.93 mg 1 4.93 mg per vial of C—„H‡÷NŒ‡OŒ÷
n/a
1
0.1 mg
1
1 mg
1 Supplied with the Ph. Eur. reference chromatogram
250 mg 1 1081 IU per mg
120 mg 1 99.8% CŒ‡Hœ—ClN÷O
1 mg
1 2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2
H-indazole-3-carboxamide
1 mg
1 N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole
-3-carboxamide
10 mg
1 endo-3-amino-9-methyl-9-azabicyclo[3.3.1]nonane
50 mg
1 Batch 1 is valid until 30 June 2006
2200 mg 1 99.5% CŸH‡Oœ
6 December 2006
1
1
3
1
1
© Council of Europe, all rights reserved 2006
1
1
1
1
1
1
4
1
1
1
Y0000488 Human immunoglobulin (molecular size) BRP
Human Plasma Pools for NAT validation
Human rabies immunoglobulin BRP
Human tetanus immunoglobulin BRP
Human vaccinia immunoglobulin
Hyaluronidase BRP
Hydralazine hydrochloride
Hydrochlorothiazide
Hydrocodone hydrogen tartrate 2.5-hydrate - * narc
Hydrocodone for peak identification - * narc
2
H1000000 Human immunoglobulin for electrophoresis BRP
H1005000
H1100000
H1110000
Y0000502
H1115000
H1120000
H1200000
New Y0000646
New Y0000710
2
H0990000 Human immunoglobulin BRP
Human anti-D immunoglobulin BRP
Human coagulation factor VII concentrate BRP
Human coagulation factor VIII concentrate BRP
Human coagulation factor IX concentrate BRP
Human hepatitis A immunoglobulin BRP
Y0000219
Y0000667
H0920000
H0920500
H0950000
1
1
3
1
1
1
1
4
1
2
1
1
1
1
n/a
Batch
1
Reference Standard
Heptaminol hydrochloride
Heptaminol impurity A
alpha-Hexachlorocyclohexane
Hexamidine diisetionate
Hexetidine
Hexobarbital
Hexylresorcinol
Hide powder
Histamine dihydrochloride
Histamine phosphate
Histidine
Histidine hydrochloride monohydrate
Homatropine hydrobromide
Homatropine methylbromide
L-Homocysteine thiolactone hydrochloride - reference
spectrum
H0900000 Human albumin for electrophoresis BRP
Order
Code
Y0000063
Y0000057
H0250000
H0330000
H0325000
H0400000
H0420000
H0500000
H0600000
H0700000
H0750000
H0755000
H0800000
H0830000
H0837000
Catalogue No. 48-2006/4
3502 mg
170 mg
87 mg
1 ml
50 mg
20 mg
150 mg
10 mg
10 mg
700 mg
96 mg
1320 mg
1 uc
26 mg
34 mg
30 mg
10 mg
1000 mg
1
3
1
3
1
1
1
1
1
3
1
3
1
2
5
5
3
1
27
Batch 3 is valid until 30 November 2006
Set of 103 plasma pool samples
91 IU per vial
120 IU per vial
23 IU per vial
328 IU per mg
75.7% to 80.9% of the total protein is the main band (Ig),
protein content: 5%
Each vial contains 0.7 gram of immunoglobulin G
Contains 1.0 mg Immunoglobulin G per vial
96,7% to 98,7% of the total protein is the main band (albumin),
protein content : 5%
285 IU anti-D immunoglobulin per ampoule
8.2 IU per vial
8.6 IU per vial; Common standard with FDA
Common standard with FDA
10.2 IU per vial
Information
Unit Sale
Quantity Unit
150 mg 1
30 mg
1 (2RS)-6-methylhept-5-en-2-amine
10 mg
1
50 mg
1
100 mg 1
500 mg 1
100 mg 1
500 mg 1
250 mg 1
250 mg 1
100 mg 1
100 mg 1
100 mg 1
25 mg
1
n/a
1
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
-20°C
-20°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
c
c
b
a
a
a
k
k
a
a
a
c
c
c
c
c
a
79 79 79 79 79 270 90 90 400 90 79 90 90 90 90 79 90 79 Extra
Price
charges
79 a
79 a
79 a
79 g
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 l
For extra charges please see 2.2
See leaflet, 0338,
0918,1928
See leaflet,20621
See leaflet,0723
0398
See leaflet
0912
0829
0394,0546
1784
1784
See leaflet,20713
See leaflet,20710
See leaflet,20704
See leaflet,20711
See leaflet,0338,
0769
See leaflet,0338,
0918
0338,0918
0255
1980
1980
0772
1436
1221
0183
1437
20814
0143
0144
0911
0910
0500,0720
0720
1617
Monograph
6 December 2006
1
1
n/a
3
2
1
1
1
n/a
H1600000 Hyoscyamine sulphate
Y0000449 Hyoscyamine impurity E
H5000000 Hypromellose phthalate - reference spectrum
I0020000 Ibuprofen
B1220000 Ibuprofen impurity B
Y0000140
I0050000
I0060000
I0060100
© Council of Europe, all rights reserved 2006
Ibuprofen impurity F
Idoxuridine
Ifosfamide
Ifosfamide - reference spectrum
1
1
H1500000 Hyoscine hydrobromide
Y0000448 Hyoscine hydrobromide impurity B
2
1
1
n/a
1
1
1
2
1
1
2
1
1
1
1
1
1
1
Hydrocortisone hydrogen succinate
Hydrogenated wool fat
Hydromorphone hydrochloride - * narc
Hydrous benzoyl peroxide - reference spectrum
Hydroxocobalamin
Hydroxycarbamide
Hydroxyethyl salicylate
4-Hydroxyphenoxymethylpenicillin
D-alpha-(4-Hydroxy-phenyl)glycine
Hydroxypropylbetadex
Hydroxyzine hydrochloride
Hymecromone
Hymecromone impurity A
Hymecromone impurity B
Hyoscine
Hyoscine impurity A
8
7
Batch
H1450000 Hyoscine butylbromide
Y0000447 Hyoscine butylbromide impurity E
H1425000
H1426000
Y0000446
B0650000
H1428000
Y0000119
H1429400
H1429700
H1430000
Y0000186
H1435000
Y0000011
Y0000012
Y0000013
Y0000483
Y0000484
Order
Reference Standard
Code
New H1300000 Hydrocortisone
H1400000 Hydrocortisone acetate
Catalogue No. 48-2006/4
5 mg
50 mg
50 mg
n/a
n/a
100 mg
1.15 ml
100 mg
10 mg
50 mg
10 mg
25 mg
10 mg
100 mg
250 mg
10 mg
n/a
10 mg
175 mg
125 mg
50 mg
50 mg
10 mg
600 mg
100 mg
25 mg
25 mg
10 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
28
100.0% CŸHŒ—ClœNœOœP
solution of 0.06% m/V in acetonitrile
(2RS)-2-(4-Butylphenyl)propanoic acid - to be diluted as
appropriate.
3-[4-(2-methylpropyl)phenyl]propanoic acid
(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenyl
-propanoate
(1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl
(2S)-3-hydroxy-2-phenylpropanoate
(1R,2R,4S,5S,7S)-9-butyl -7-[[(2S)-3-hydroxy2-phenylpropanoyl]oxy]-3-oxa -9-azoni atricyclo
[3.3.1.02,4]nonane
(1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl
(2S)-3-hydroxy-2-phenylpropanoate (norhyoscine)
Resorcinol
7-hydroxy-2-methyl-4H-1-benzopyran-4-one.
98.8% CŒÿHŒ‡NœOÿ
99.9% CH÷NœOœ
Batch 1 is valid until 31 December 2005
Information
Unit Sale
Quantity Unit
100 mg 1 Batch 7 is valid until 31 March 2007
125 mg 1
0721
0669
1529
1529
0347
0721
0721
0501
0501
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
l
l
a
g
g
g
g
g
a
a
a
a
k
l
a
a
a
a
a
a
a
a
a
a
g
g
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
0106,0500
0106
0737
0737
0335,0353,0561
0321,0334,0734,
0767
0768,1131
0969
2099
0704
0913,0914,0915
1616
1225
0148,0149
0813
1804
0916,1086,1092
1786
1786
1786
2167
2167
Monograph
6 December 2006
1
3
2
3
1
2
1
1
1
1
1
1
1
1
1
1
Insulin (bovine)
Insulin (human)
Iohexol impurity J
I0310000
Y0000348 Insulin lispro
I0320000 Insulin (porcine)
Interferon alfa-2a
Interferon alfa-2b
Interferon gamma 1b
Interferon gamma-1b validation solution
Iobenguane sulphate
Iohexol
Iohexol impurity A
I0305000
I0320300
I0320301
I0320330
I0320331
I0328000
I0320800
I0320810
I0320820
Y0000672 Iohexol for peak identification
I0329000 Iopamidol
I0329010 Iopamidol impurity A
Y0000406 Iopamidol impurity H
I0330000
I0340000
© Council of Europe, all rights reserved 2006
Iopanoic acid
Iotalamic acid
3
Immunoglobulin panel for anti-D antibodies test BRP
Indapamide
Indapamide impurity B
Indometacin
Insulin aspart
3
1
3
2
1
1
1
1
1
1
1
1
2
Y0000540
I0150000
I0150020
I0200000
Y0000349
Batch
Ifosfamide impurity A
Ifosfamide impurity B
Ifosfamide impurity E
Ifosfamide impurity F
Imidazole
Imipenem
Imipramine hydrochloride
Reference Standard
Order
Code
I0060002
I0060004
I0060010
I0060012
I0086000
I0090000
I0100000
Catalogue No. 48-2006/4
100 mg
100 mg
10 mg
10 mg
50 mg
10 mg
125 mg
1 ml
0.2 ml
0.6 ml
0.2 ml
50 mg
150 mg
50 mg
5.93 mg
8.61 mg
7.03 mg
7.99 mg
2000 mg
150 mg
5 mg
50 mg
3.89 mg
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
29
0700
0751
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-80°C
-80°C
-80°C
-80°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
-20°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
d
d
d
d
a
a
a
c
c
c
c
a
a
a
g
c
79 79 79 79 79 79 79 79 79 79 79 90 90 90 90 90 90 90 90 79 79 79 90 Extra
Price
charges
79 a
79 a
79 a
79 b
79 a
79 c
79 g
For extra charges please see 2.2
1114
1115
1115, 1754
1114
0838,0854,1637,
1638
2085
0838,0854,1637,
1638
1110
1110
1440
1440
1111,1112,1113
1114
1114
0854,1637
1529
1529
1529
1529
1424
1226
0029,0408,0817,
0889,1787
See leaflet, 20626
1108
1108
0092,0922
2084
Monograph
N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-amino-2,4,6-triiodoisophthalamide
4-chloro-N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(2-hydro 1115
xypropanoyl)amino)2,6-diiodobenzenz-1,3-dicarboxamide
5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodo
benzene-1,3-dicarboxamide
5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,
3-dicarboxamide
About 1.46 mg per ml
about 7.19 mg per ml
about 1 mg per ml
about 1 mg per ml
3.89 mg [insulin aspart + B28isoAsp insulin aspart + A21Asp
insulin aspart + B3Asp insulin aspart + B3isoAsp insulin aspart]
per vial
7.99 mg insulin + A21 desamido per vial ; Batch 2 is valid until 28
February 2006
7.03 mg insulin + A21 desamido per vial ; Batch 2 is valid until 31
March 2006
5.93 mg insulin lispro per vial
8.61 mg [porcine insulin + A21-desamido porcine insulin] per vial
97.7% CŒÿHŒÿClN–O–S
4-chloro-3-sulphamoyl-N-(2-methyl-1H-indol-1-yl)-benzamide
Information
Unit Sale
Quantity Unit
30 mg
1 3-[(2-chloroethyl)amino]propyl dihydrogen phosphate
20 mg
1 bis[3-[(2-chloroethyl)amino]propyl] dihydrogen diphosphate
10 mg
1 3-chloro-N-(2-chloroethyl)propan-1-amine
10 mg
1 (RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide
100 mg 1
100 mg 1 92.8% CŒœHŒŸN–O÷S
50 mg
1 Batch 1 is valid until 30 June 2006
6 December 2006
1
1
2
Itraconazole
Ivermectin
I7000000
I8000010
Y0000041 Josamycin
Y0000042 Josamycin propionate
K0100000 Kanamycin B sulphate
© Council of Europe, all rights reserved 2006
2
1
Isoconazole
Isoconazole nitrate
Isoemetine hydrobromide
Isoflurane - reference spectrum
Isoleucine
Isomalt
Isomaltooligosaccharide
Isoniazid
Isoprenaline hydrochloride
Isoprenaline sulphate
Isopromethazine hydrochloride
Isopropyl hexadecanoate
Isopropyl tetradecanoate
Isosorbide dinitrate
Isosorbide mononitrate
Isosorbide-2-nitrate
Isotretinoin
Isoxsuprine hydrochloride
Isradipine
Isradipine impurity D
I0375000
I0380000
I0400000
Y0000037
I0460000
I0465000
Y0000070
I0500000
I0599990
I0600000
I0700000
I0725000
I0750000
I0775000
I0775010
I0775020
I0800000
I0900000
Y0000366
Y0000367
1
1
1
n/a
1
2
1
1
1
2
4
2
3
1
2
2
3
1
1
1
3
Ipratropium bromide impurity B
I0361000
1
1
1
1
Batch
5
1
Iotrolan
Iotrolan for system suitability
Ioxaglic acid
Ioxaglic acid impurity A
Reference Standard
I0360000 Ipratropium bromide
Y0000276 Ipratropium bromide impurity A
Order
Code
Y0000555
New Y0000658
Y0000141
Y0000142
Catalogue No. 48-2006/4
150 mg
150 mg
20 mg
150 mg
150 mg
200 mg
200 mg
25 mg
n/a
50 mg
3000 mg
0.9 mg
100 mg
50 mg
500 mg
50 mg
100 mg
2 ml
250 mg
100 mg
50 mg
60 mg
50 mg
125 mg
5 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
30
99.2% CŒ„HœŒN–O—
methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)
-2,6-dimethylpyridine-3,5-dicarboxylate
Batch 1 is valid until 31 January 2007
83.9% C÷‡HŸ÷OŒ÷ (compound HœBŒ´);
5.9% C÷ŸHŸœOŒ÷ (compound HœBŒÇ)
1000 Ph. Eur. units per mg
930 Ph. Eur. units per mg
Batch 1 is valid until 31 December 2006
Batch 3 is valid until 31 August 2006
94.3% CŒ„H–‡Oœ
98.8% CŒŸH–÷Oœ
24.5% CÿH‡NœO‡
99.9% CÿH„NOÿ; Isosorbide-5-nitrate
96.6% CŒœHœ÷OŒŒ ; Batch 1 is valid until 31 July 2006
Information
Unit Sale
Quantity Unit
100 mg 1
5 mg
1
125 mg 1
20 mg
1 3-amino-5[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-trioiodobenzoic acid
120 mg 1 Batch 4 is valid until 31 October 2006
5 mg
1 (1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane
10 mg
1 (1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
l
a
a
a
a
a
a
a
a
a
g
h
f
a
a
g
g
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
For extra charges please see 2.2
1982,1983,20702
1982,1983,20702
0032,0033,0645
1335
1336
1018
1017
0080,0081
1673
0770
1531
1506
0146
1332
0502
0524
0839
0725
1117,1118
1117,1118
1117,1118
0693,1019
1119
2110
2110
0919
0919
0772
1754
1754
2009
2009
Monograph
6 December 2006
Labetalol hydrochloride
Lactitol monohydrate
Lactobionic acid
Lactose (anhydrous)
Lactose
L0050000
L0129000
Y0000257
A1206000
L0100000
© Council of Europe, all rights reserved 2006
L0376001 Leuprorelin - reference spectrum
Lactulose
Lactulose for system suitability
Lamivudine
Lamivudine for system suitability 1
Lamivudine for system suitability 2
Leflunomide
Letrozole
Leflunomide impurity A
Leflunomide for peak identification
Leucine
Leuprorelin
3-Ketofusidic acid
Ketoprofen
Ketoprofen impurity A
Ketoprofen impurity C
Ketorolac trometamol
Ketorolac trometamol for peak identification
Ketotifen hydrogen fumarate - reference spectrum
Ketotifen impurity G
K1000000
K2000000
K2000010
K2000015
Y0000486
Y0000626
Y0000164
Y0000161
L0130000
Y0000188
Y0000425
Y0000518
Y0000426
New Y0000654
Y0000685
New Y0000487
New Y0000674
L0375000
L0376000
1
1
n/a
1
1
1
Ketamine hydrochloride - * narc
Ketamine impurity A
Ketobemidone hydrochloride - reference spectrum
Ketobemidone impurity B
Ketobemidone impurity C
Ketoconazole
Y0000450
K0551000
Y0000246
Y0000244
Y0000245
K0600000
n/a
2
2
1
1
1
1
1
1
1
2
4
1
2
1
1
1
3
2
3
2
1
1
n/a
2
2
Batch
Order
Reference Standard
Code
K0200000 Kanamycin monosulphate
Catalogue No. 48-2006/4
n/a
3000 mg
12 mg
150 mg
10 mg
10.3 mg
100 mg
70 mg
25 mg
1 mg
50 mg
0.925 mg
80 mg
60 mg
100 mg
100 mg
100 mg
10 mg
50 mg
5 mg
5 mg
10 mg
5 mg
n/a
3 mg
10 mg
50 mg
n/a
5 mg
5 mg
150 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Information
Monograph
31
1442
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
l
a
a
a
a
a
g
a
g
g
a
c
a
a
a
a
a
a
g
a
a
g
g
l
a
k
a
l
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0923
93.8% CŒœHœ÷OŒŒ
1337
1647
1061
0177,0178,0187,
0188,0204,0209,
1215,1570
99.7% CŒœHœœOŒŒ
0924,1230
0924,1230
99.7% C‡HŒŒN–O–S
2217
2217
2217
2330
99.7% CŒŸHŒŒN—
2334
4-(trifluoromethyl)aniline
2330
2330
0771,0874
0.925 mg per vial of pure leuprorelin peptide C—„H‡÷NŒÿOŒœ ; Batch 1442
3 is valid until 31 July 2006
0032,0033,0053,
0485,0645,1289,
1290,20702
1020
1-[(2-chlorophenyl)(methylimino)methyl]cyclopentanol
1020,1742
1746
1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidyl)ethanone
1746
1-(4-(3-hydroxyphenyl)-4-piperidyl)propan-1-one
1746
0921,1067,1270,
1335
Batch 2 is valid until 30 September 2006
0798,0848
Batch 1 is valid until 30 September 2006
0922,1157,1209
3-acetylbenzophenone
0922
2-(3-carboxyphenyl)propionic acid
0922
1755
1755
1592
4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b) 1592
thiophen-9,10-dione
Unit Sale
Quantity Unit
150 mg 1 799 IU per mg
6 December 2006
Lithocholic acid
Lobeline hydrochloride
Lomustine
Loperamide hydrochloride
Loperamide hydrochloride for system suitability
Loperamide oxide monohydrate
Loratadine
Loratadine for system suitability
Loratadine impurity F
Loratadine impurity H
Lorazepam - * psy
Lorazepam for system suitability
Lorazepam impurity D
Levomepromazine hydrochloride
Levomepromazine maleate
Levonorgestrel
Levothyroxine sodium
Lidocaine
Lidocaine hydrochloride
Lincomycin hydrochloride
Lindane
Liothyronine sodium
Lisinopril dihydrate
Lisinopril dihydrate for performance test
Lithium clavulanate
Levocarnitine
Levocarnitine impurity A
Levodopa
Levodropropizine
Levodropropizine impurity A
Levamisole for system suitability
Levamisole hydrochloride
Levamisole - reference spectrum
Levocabastine hydrochloride
Levocabastine impurity D
Reference Standard
© Council of Europe, all rights reserved 2006
L0720800
Y0000112
L0745000
L0750000
Y0000322
Y0000341
New Y0000688
Y0000603
Y0000604
Y0000605
L0750500
New Y0000576
New Y0000718
L0500000
L0505000
L0551000
L0570000
L0595000
L0600000
L0650000
L0655000
L0700000
L0702000
L0702100
L0720000
New L0399900
L0399905
L0400000
L0420000
L0420002
Order
Code
Y0000047
L0380000
Y0000048
L0390000
L0390008
Catalogue No. 48-2006/4
1
1
1
1
1
1
3
1
1
1
1
1
1
1
1
1
2
1
1
2
1
5
1
2
4
2
1
1
1
1
1
1
n/a
1
1
Batch
60 mg
50 mg
50 mg
150 mg
15 mg
20 mg
60 mg
20 mg
10 mg
50 mg
100 mg
0.8 mg
10 mg
100 mg
50 mg
30 mg
100 mg
50 mg
100 mg
250 mg
250 mg
50 mg
50 mg
2 mg
125 mg
100 mg
60 mg
20 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1339
1339
0038
1535
1535
0726,1728
0726
1728
1484
1484
Monograph
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 l
79 a
79 a
1189,1275
+5°C
a
1988
+5°C
a
0928
+5°C
a
0921,0929,1729
+5°C
g
0929
Yes
+5°C
g
1729
+5°C
g
2124
+5°C
a
2124
Yes
+5°C
a
2124
+5°C
a
2124
+5°C
a
1121
+5°C
j
1121
+5°C
j
(5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodia 1121
+5°C
a
zepine-2,3-dione
32
For extra charges please see 2.2
20303
0925,20303
0926
90.0% CŒ—HŒÕI÷NNaO÷
0401,0728
0727,1362
0227,1242,1363
87.4% CŒ‡H–÷NœOÿS
0582,0583,0996
0772
98.7% CŒ—HŒŒI–NNaO÷
0401,0728
1120
1120
98.8% C‡H‡LiNO—; 1 mg of CŸH‡LiNO— corresponds to 1.157 mg of 1140,1653
C‡H‡KNO—
(2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol
(dextrodropropizine)
Information
Unit Sale
Quantity Unit
80 mg
1
50 mg
1
n/a
1
125 mg 1
20 mg
1 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenyl-4-piperidine
carboxylic acid
125 mg 1 Batch 1 is valid until 30 April 2007
50 mg
1 4-(trimethylammonio)but-2-enoate
6 December 2006
1
n/a
2
4
M0100000
Y0000143
M0160000
M0200000
Measles vaccine (live) BRP
Mebendazole
Mebendazole for system suitability
Mebendazole - reference spectrum
Meclozine hydrochloride
Medronic acid
Medroxyprogesterone acetate
Medroxyprogesterone acetate for performance test
Medroxyprogesterone acetate for system suitability
Mefenamic acid
Mefloquine hydrochloride
Megestrol acetate
Megestrol acetate - reference spectrum
Meglumine - reference spectrum
Menadione
Menthol
Mepivacaine hydrochloride
Mepivacaine impurity B
Meprobamate - * psy
Mepyramine maleate
© Council of Europe, all rights reserved 2006
M0210000
M0215000
Y0000144
Y0000168
M0220000
M0240000
New M0250000
M0250010
Y0000598
M0252600
M0253000
M0260000
M0260100
Y0000267
M0300000
M0350000
M0370000
M0370020
M0400000
M0500000
M0206000 Maprotiline hydrochloride
M0206040 Maprotiline impurity D
1
1
1
n/a
1
1
2
2
1
1
1
2
n/a
n/a
1
4
1
1
1
1
1
1
2
M0120010 Malathion impurity B
Maleic acid
Malic acid - reference spectrum
Maltitol
Mannitol
1
1
2
M0088000 Magnesium aspartate dihydrate
M0120000 Malathion
M0120005 Malathion impurity A
Batch
2
1
2
2
Reference Standard
Lovastatin
Lynestrenol
Lysine acetate
Lysine hydrochloride
Order
Code
L0790000
L0800000
Y0000397
L0900000
Catalogue No. 48-2006/4
80 mg
20 mg
20 mg
n/a
150 mg
20 mg
100 mg
50 mg
10 mg
50 mg
100 mg
50 mg
n/a
n/a
100 mg
150 mg
100 mg
60 mg
100 mg
1000 mg
100 mg
25 mg
100 mg
n/a
1200 mg
1200 mg
10 mg
60 mg
250 mg
10 mg
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
33
(¢£)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
Batch 1 is valid until 31 March 2007
3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2en-1-amine; (dehydromaprotiline)
4.3 logŒÕ (ie 20000) infective viral units per vial
99.8% CŒœHœ÷OŒŒ ; Batch 1 is valid until 31 December 2006
98.6% CÿHŒ÷Oÿ
99.3% CŒÕHŒ„OÿPSœ
diethyl (2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl]
butane dioate (isomalathion)
diethyl (2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate
(maloxon)
Information
Unit Sale
Quantity Unit
40 mg
1 99.7% Cœ÷H–ÿO— ; Batch 1 is valid until 31 October 2006
50 mg
1
60 mg
1
50 mg
1 Batch 1 is valid until 30 September 2006
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
Leaflet Storage
c
a
a
l
a
a
a
a
c
a
a
a
l
l
a
a
a
a
j
a
a
a
a
l
a
a
c
a
a
c
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 90 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 c
79 a
79 a
79 a
For extra charges please see 2.2
1057,0213
1208,1254
0845
0845
0622
0641
0673,1094,1593
0673
0673
1240
1241
0673,1593
1593
2055
0507
0619,0623
1242
1242
0407,1689
0278
0365,0925
2080
1235,1236
0435,0559,1381,
1531
1237
1237
1343
1538,1563
0558
2114
0805,0806,0930,
1654
1445
1343
1343
Monograph
6 December 2006
n/a
n/a
n/a
n/a
50 mg
50 mg
100 mg
20 mg
10 mg
n/a
n/a
n/a
n/a
1
1
4
1
2
1
New Y0000664 Methotrexate impurity E
© Council of Europe, all rights reserved 2006
3
n/a
n/a
M1100000 3-Methoxymethyldopa
200 mg
n/a
1
n/a
20 mg
10 mg
n/a
n/a
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
34
4-[[(2-amino-4hydroxypteridin-6-yl)methyl]methyl-amino]
benzoic acid
4-[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid
(4-amino-N10-methylpteroic acid, APA)
88.6% CœÕHœœN‡O— ; Batch 3 is valid until 28 February 2006
Information
Unit Sale
Quantity Unit
10 mg
1 N-(4-methoxybenzyl)pyridin-2-amine
10 mg
1
125 mg 1
n/a
1
10 mg
1 2-(acetylsulphanyl)ethanesulphonic acid
10 mg
1 2,2'-disulphanediyl)bis(ethanesulphonic acid)
0.5 mg
1
60 mg
1 99.3% CœÕH–œOœ
30 mg
1 17ß-hydroxy-1alpha-methylandrost-4-en-3-one
100 mg 1
n/a
1
100 mg 1
100 mg 1 Batch 2 is valid until 30 April 2007
10 mg
1 4-formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3§-pyrazol3-one
50 mg
200 mg
n/a
1
1
1
n/a
1
1
1
1
1
1
n/a
3
3
2
Batch
2
1
n/a
Mepyramine impurity A
Mepyramine impurity C
Mesalazine
Mesna - reference spectrum
Mesna impurity C
Mesna impurity D
Meso-rich exametazime
Mesterolone
Mesterolone impurity A
Mestranol
Metacresol - reference spectrum
Metacycline hydrochloride
Metamizole sodium
Metamizole impurity A
Reference Standard
M0605000 Metformin hydrochloride
New Y0000770 Methacrylic acid-ethyl acrylate copolymer (1:1) - type A
M0610000 Methacrylic acid-ethylacrylate copolymer(1:1) - reference
spectrum
M0610030 Methacrylic acid-ethyl acrylate copolymer (1:1), dispersion
30%-ref.sp
Y0000323 Methacrylic acid-ethyl acrylate copolymer (1:1) - type B
M0620000 Methacrylic acid-methylmethacrylate copolymer(1:1)reference spectrum
M0630000 Methacrylic acid-methylmethacrylate copolymer(1:2)reference spectrum
M0800000 Methadone hydrochloride - reference spectrum
Y0000428 Methanol - reference spectrum
M0900000 Methaqualone - reference spectrum
M0920001 Methenamine - reference spectrum
M0950000 DL-Methionine
M0960000 Methionine
M1000000 Methotrexate
Y0000602 Methotrexate for peak identification
M1000008 Methotrexate impurity D
Order
Code
New Y0000679
New Y0000680
Y0000297
Y0000337
Y0000316
Y0000317
Y0000227
Y0000097
Y0000096
M0600000
Y0000301
M0600500
New M0600900
M0600905
Catalogue No. 48-2006/4
0045
0560
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
g
l
l
l
l
a
a
g
g
g
l
a
l
l
a
a
l
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 g
79 a
79 l
79 a
79 a
79 a
79 a
79 a
79 a
79 l
79 a
79 a
79 a
For extra charges please see 2.2
0408,1787
1989
0510
1545
0624
0788,1027
0560
0560
0560
1130
1128
1127
1129
0931
1128
1128
0278
0278
1699,1993
1674
1674
1674
1925
1730
1730
0509
2077
0272,0820
1346
1346
Monograph
6 December 2006
1
1
4
1
1
1
3
2
1
2
1
1
2
1
1
1
n/a
2
1
1
2
1
1
2
1
1
2
1
Methylatropine bromide
Methylatropine nitrate
Methylcarbidopa
Methyl 2-(4-chlorophenoxy)-2-methylpropionate
Methyldopa
Methylene chloride
2-(1-Methylethyl) pentanoic acid
Methyl 12-hydroxystearate
Methyl nicotinate
Methylnitrosoindoline
Methyl parahydroxybenzoate
Methylphenobarbital - * psy
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone hydrogen succinate
Methylprednisolone hydrogen succinate for performance test
N-Methylpyrrolidone - reference spectrum
Methyl ricinoleate
Methylrosanilinium chloride
Methylrosanilinium for system suitability
Methyl stearate
Methyltestosterone
Methylthioninium chloride
Methylthioninium impurity A
Metixene hydrochloride
Metoclopramide
Metoclopramide hydrochloride
Metoclopramide impurity A
Metoprolol succinate - reference spectrum
Metoprolol tartrate
Metrifonate
Metronidazole
Metronidazole benzoate
Metronidazole benzoate - reference spectrum
© Council of Europe, all rights reserved 2006
Y0000171
M1830000
M1845000
New M1850000
M1851000
Y0000069
n/a
1
1
2
1
n/a
1
1
Batch
Reference Standard
M1825010 Metoclopramide impurity E
Y0000145 Metoprolol impurity A
Order
Code
M1300000
M1400000
M1450000
M1470000
M1500000
M1550000
M1551000
M1556000
Y0000398
New M1625000
M1650000
M1700000
M1750000
M1755000
M1755200
M1755220
Y0000190
M1770180
Y0000418
Y0000407
M1770200
M1800000
M1800900
M1800902
M1808000
M1824990
M1825000
M1824995
Catalogue No. 48-2006/4
n/a
60 mg
100 mg
50 mg
50 mg
n/a
1
1
1
1
1
1
35
Batch 1 is valid until 31 March 2007
Information
Unit Sale
Quantity Unit
100 mg 1
100 mg 1
1 mg
1
0.5 ml
1
50 mg
1
2 ml
1
25 mg
1
100 mg 1 Batch 1 is valid until 31 January 2006
25 mg
1
100 mg 1 Batch 1 is valid until 30 April 2007
100 mg 1
500 mg 1
150 mg 1
100 mg 1
125 mg 1
50 mg
1
n/a
1
125 mg 1 Batch 1 is valid until 31 March 2006
40 mg
1
10 mg
1
100 mg 1
100 mg 1
50 mg
1 methylene blue
20 mg
1 3-(dimethylamino)-7-(methylamino)phenothiazin-5-ylium
75 mg
1
100 mg 1
50 mg
1
25 mg
1 4-(acetylamino)-5-chloro-N-(2-diethylaminoethyl)-2-methoxy
benzamide
20 mg
1 N,N-diethylethane-1,2-diamine
10 mg
1 (2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan2-ol
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
l
a
a
a
a
l
g
a
79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 j
79 a
79 a
79 a
79 a
79 l
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
For extra charges please see 2.2
1448
1028
1133
0675,0934
1424
0934
1575
1028,1448
0511,0919
0512
0755
0318
0045,0755
0932
0678,1378
1497
2129
1108
0409,1262,2134
0189
0312,0388,0561
0933
0768,1131
1131
1675
0051
1990
1990
0051,1497
0410
1132
1132
1347
1348
0674,0856,1303
1348
Monograph
6 December 2006
M3600000 Mumps vaccine (live) BRP
M3805000 Mupirocin - reference spectrum
M3805500 Mupirocin calcium - reference spectrum
M3806000 Mupirocin lithium
© Council of Europe, all rights reserved 2006
1
n/a
n/a
1
1
1
1
1
2
1
1
1
1
Modafinil
Modafinil for system suitability
Molgramostim
Mometasone furoate
Morantel hydrogen tartrate
Morphine hydrochloride (trihydrate) - * narc
Morphine sulphate - * narc
Moxonidine
Moxonidine impurity A
Y0000635
Y0000636
Y0000251
M2900000
Y0000028
Y0000451
Y0000452
Y0000226
Y0000222
2
1
1
2
1
1
1
1
2
3
Midazolam - * psy
Milk thistle standardised dry extract
Midazolam for system suitability - * psy
Minocycline hydrochloride
Minoxidil
Misoprostol
Misoprostol impurity A
M2200000
Y0000539
Y0000599
M2280000
M2300000
Y0000490
Y0000491
1
1
1
1
1
2
1
1
Batch
Y0000378 Mitomycin
M2305000 Mitoxantrone hydrochloride
M2305005 Mitoxantrone impurity A
Mexiletine impurity D
Mianserin hydrochloride
Miconazole
Miconazole nitrate
Midazolam impurity C
Y0000203
M1875000
M1880000
M1900000
Y0000562
Order
Reference Standard
Code
New Y0000087 Metronidazole impurity A
M1860000 Mexiletine hydrochloride
Y0000202 Mexiletine impurity C
Catalogue No. 48-2006/4
33 mg
n/a
n/a
100 mg
110 mg
0.1 mg
0.3 ml
100 mg
50 mg
10 mg
40 mg
50 mg
10 mg
120 mg
60 mg
5 mg
50 mg
120 mg
1 mg
125 mg
50 mg
30 mg
5 mg
50 mg
70 mg
100 mg
0.08 mg
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
36
95.4% CœÿH÷–O„Li
99.7% C„HŒœClN—O
4,6-dichloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2-methyl-5pyrimidinamine
4.6 logŒÕ (ie40000) infective viral units per vial
13.45 mg protein per ml
99.2% CœœH–‡O—
mixture of methyl 7-[(1RS,2SR,
3SR)-3-hydroxy-2-[(1E,4RS)-4-hydroxy-4-methyloct1-enyl]-5-ox
ocyclopentyl]heptanoate and methyl
7-[(1RS,2SR,3SR)-3-hydroxy-2-[(1E,4SR)-4-hydroxy4-methyloct
-1-enyl]-5-oxocyclopentyl]heptanoate (8-epimisoprostol),
99.1% CŒ—HŒ‡N÷O—
97.8% CœœH–ÕClœN÷Oÿ
1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl]
amino]anthracene-9,10-dione ; Batch 2 is valid until 31 March
2006
100.0% CŒ—HŒ—NOœS
90.8% Cœ–Hœ‡ClN–OŸ
27.5% of silibinin (A+B)
acide 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a]
[1,4]benzodiazepine-3-carboxylique
Information
Unit Sale
Quantity Unit
10 mg
1 2-methyl-4-nitroimidazole ; Batch 1 is valid until 30 April 2007
100 mg 1
2 mg
1 1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy]
dipropan-2-amine
2 mg
1 (2RS)-2-(2,6-dimethylphenoxy)propan-1-amine
Yes
+5°C
+5°C
-80°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
d
a
a
k
k
a
a
g
a
a
j
c
j
a
a
g
c
a
a
a
a
a
79 79 79 90 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
0538,1057
Yes
-80°C
d
1450
l
1451
l
1450,1451
+5°C
a
For extra charges please see 2.2
2307
2307
1641
1449
1546
0097
1244
1758
1758
1655
1243
1243
0936,1065
2071
0936
1030
0937
1731
1731
1029
0846
0935,1335
0513,1148
0936
0675
1029
1029
Monograph
6 December 2006
Naproxen
Naproxen (racemic)
Naproxen impurity L
Neamine
© Council of Europe, all rights reserved 2006
N0250000
Y0000399
Y0000631
N0300000
Nalidixic acid
Naloxone hydrochloride dihydrate
Naloxone impurity A
Naloxone for peak identification
Naltrexone hydrochloride
Naltrexone impurity C
Nandrolone decanoate
Nandrolone decanoate for peak identification
Nandrolone decanoate for system suitability
Naphazoline hydrochloride
Naphazoline hydrochloride - reference spectrum
Naphazoline nitrate
Naphazoline impurity A
1
1
1
3
1
1
2
1
1
1
1
1
1
3
n/a
2
3
1
Y0000331 Naftidrofuryl impurity F
N0050000
N0075000
N0075005
New Y0000695
Y0000400
Y0000410
Y0000542
Y0000547
Y0000548
N0080000
Y0000252
N0100000
N0200000
1
Y0000122 Naftidrofuryl impurity C
1
2
1
1
1
1
1
1
1
2
1
1
n/a
1
Batch
1
Mycophenolate mofetil
Mycophenolate mofetil for peak identification
Mycoplasma fermentans BRP
Mycoplasma hyorhinis BRP
Mycoplasma orale BRP
Mycoplasma synoviae BRP
Myo-inositol
Nabumetone
Nabumetone impurity D
Nabumetone impurity F
Nadolol
Nadroparin calcium
Naftidrofuryl - reference spectrum
Naftidrofuryl impurity A
Reference Standard
Y0000121 Naftidrofuryl impurity B
Order
Code
Y0000489
Y0000519
Y0000692
Y0000690
Y0000691
Y0000689
Y0000485
N0020000
N0020020
N0020030
Y0000146
N0025000
Y0000077
Y0000120
Catalogue No. 48-2006/4
100 mg
10 mg
10 mg
0.5 mg
100 mg
100 mg
10 mg
10 mg
50 mg
15 mg
5 mg
10 mg
10 mg
50 mg
n/a
10 mg
25 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1594
1594
1594
1700
1700
20607
20607
20607
20607
1805
1350
1350
1350
1789
0828,1134
1594
1594
Monograph
37
90.0% CŒŒHœÿN÷Oÿ
Yes
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-80°C
-80°C
-80°C
-80°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
c
c
c
a
l
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
120 d
120 d
120 d
120 d
79 a
79 a
79 a
79 a
79 a
79 a
79 l
79 a
For extra charges please see 2.2
0731
0731
1702
0180,0197
0701
0729,2099
4,5¶-epoxy-3,14-dihydroxymorphinan-6-one (noroxymorphone) 0729
0729
1790
N-(3-butenyl)-noroxymorphone
1790
1992
1992
1992
1162
0730
0147
N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide
0147,0730
(naphthylacetylethylenediamine)
Information
Unit Sale
Quantity Unit
30 mg
1
10 mg
1 Batch 1 is valid until 30 June 2006
1 ml
1
1 ml
1
1 ml
1
1 ml
1
1020 mg 1 99.8% CÿHŒœOÿ
60 mg
1 99.8% CŒ—HŒÿOœ
10 mg
1 (E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one
10 mg
1 6,6'-dimethoxy-2,2'-binaphthalenyl
100 mg 1
250 mg 1
n/a
1
10 mg
1 2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic
acid
25 mg
1 98% CœÕHœ–O–; ethyl 2-[(naphtalen-1-yl)methyl]3-(tetrahydrofuran-2-yl)propanoate
50 mg
1 97.5% C–ÕH––NOœ; 2-(diethylamino)ethyl 3-[(naphtalen-1-yl)2-[(naphtalen-1-yl)methyl]propanoate
10 mg
1 2-[(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3(tetrahydrofuran-2-yl)propanoate
6 December 2006
3
2
1
1
1
1
1
1
N0400000 Neomycin sulphate
N0401000
N0500000
N0550000
N0559000
Y0000520
Y0000521
Y0000388
1
1
n/a
2
1
1
1
N0560000
N0600000
N0590000
N0590200
N0700000
N0750000
N0750010
© Council of Europe, all rights reserved 2006
N0900000 Nitrazepam - * psy
N0900010 Nitrazepam impurity A
1
1
n/a
1
1
1
1
2
2
Y0000178
N0800000
N0845000
N0845006
N0845008
N0850000
N0850010
Nifuroxazide - reference spectrum
Nikethamide
Nimesulide
Nimesulide impurity C
Nimesulide impurity D
Nimodipine
Nimodipine impurity A
1
N0750015 Nifedipine impurity B
Niclosamide (anhydrous)
Nicotinamide
Nicotine - reference spectrum
Nicotine ditartrate
Nicotinic acid
Nifedipine
Nifedipine impurity A
n/a
1
Y0000287 Nicergoline - reference spectrum
Y0000283 Nicergoline impurity A
Neomycin sulphate for microbiological assay
Neostigmine bromide
Neostigmine metilsulfate
Netilmicin sulphate
Nevirapine (anhydrous)
Nevirapine for peak identification
Newcastle Disease Vaccine (inactivated) BRP
1
1
Batch
Order
Reference Standard
Code
N0399000 Neohesperidin-dihydrochalcone
N0399004 Neohesperidin-dihydrochalcone impurity B
Catalogue No. 48-2006/4
100 mg
25 mg
n/a
1 ml
100 mg
25 mg
20 mg
50 mg
1 ml
20 mg
50 mg
50 mg
n/a
20 mg
100 mg
50 mg
20 mg
n/a
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
38
3-amino-6-nitro-4-phenylquinol-2-one
2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl)
pyridine-3,5-dicarboxylate
2-phenoxyaniline
4-nitro-2-phenoxyaniline
Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5dicarboxylate
Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5dicarboxylate
92.6% CŒÕHŒ÷Nœ x 2 C÷HÿOÿ
[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10aoctahydroindol[4,3-fg]quinolin-9-yl]methyl
5-chloropyridine-3-carboxylate
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
-20°C
+5°C
+5°C
-20°C
-20°C
-20°C
+5°C
Leaflet Storage
j
a
l
a
a
a
a
a
a
a
a
a
l
a
a
a
a
l
a
a
a
a
a
g
g
c
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 180 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
0415,0898,1121
0415
1999
0233
1548
1548
1548
1245
1245
0627
0679,0680
0047
1452,1792
1452,1792
0459,0859
0627,1013
0627
1998
1998
Information
Unit Sale
Monograph
Quantity Unit
125 mg 1 89.9% Cœ‡H–ÿOŒ—
1547
10 mg
1 89% Cœ‡H–œOŒ—; 7-[[2-O-(6-deoxy-¶-L-mannopyranosyl)
1547
-ß-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyph
enyl)-4H-1-benzopyran-4-one (neodiosmin)
50 mg
1 Not to be used for microbiological assay
0032,0033,0053,
0180,0197,0485,
0645
19850
IU
per
vial
;
Batch
1
is
valid
until
31
December
2005
25 mg
1
0197,20702
50 mg
1
0046
50 mg
1
0626
25 mg
2 14656 IU per vial
1351,20702
99.8%
CŒ—HŒ÷N÷O
30 mg
1
2255
0.058 mg 1
2255
4 uc
1 The kit contains :1 vial BRP1 NDV reference antigen, 1 vial BRP1
0870
NDV control antigen, 1 vial BRP1 NDV coating antibody, 1 vial
BRP1 NDV conjugated, detection antibody
6 December 2006
Nomegestrol acetate
Nomegestrol acetate impurity A
Nonivamide
Nonoxinol 9 - reference spectrum
Noradrenaline tartrate
Noradrenaline impurity D
N1080000
N1080005
Y0000670
N1084000
N1100000
New Y0000681
Norgestrel
Norpseudoephedrine hydrochloride - * psy
Nortriptyline hydrochloride
Noscapine
Nystatin
Octoxinol 10
Octyl gallate
Octyldodecanol
Ofloxacin
Ofloxacin impurity A
© Council of Europe, all rights reserved 2006
N1250000
N1279000
N1280000
N1300000
N1400000
O0100900
Y0000368
O0101000
O0120000
O0120010
New Y0000682 Noradrenaline impurity E
New Y0000686 Noradrenaline impurity F
N1130000 Norcyclobenzaprine
N1140000 Nordazepam -* psy
New N1200000 Norethisterone
N1225000 Norethisterone acetate
Y0000522 Norethisterone for system suitability
N1230000 Norfloxacin
N1230010 Norfloxacin impurity A
n/a
1
1
n/a
1
1
Nitric oxide - reference spectrum
Nitrofural
Nitrosotriaminopyrimidine
Nitrous oxide - reference spectrum
Nizatidine
Nizatidine impurity F
N0930000
N0950000
N1000000
N1050000
N1090000
N1090060
1
2
2
1
4
2
1
4
1
1
1
1
1
1
2
1
1
1
1
1
1
1
n/a
4
1
2
2
Batch
Order
Reference Standard
Code
N0905000 Nitrendipine
N0905005 Nitrendipine impurity A
Catalogue No. 48-2006/4
30 mg
50 mg
10 mg
100 mg
300 mg
300 mg
30 mg
400 mg
50 mg
20 mg
10 mg
10 mg
25 mg
50 mg
100 mg
100 mg
10 mg
50 mg
20 mg
100 mg
50 mg
10 mg
n/a
200 mg
15 mg
n/a
100 mg
50 mg
n/a
250 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1246
1246
Monograph
39
(RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido
[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (FPA)
94.8% CœÕH÷œO
5600 IU per mg C÷ŸHŸ—NOŒŸ
Cathine
7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3carboxylic acid (corresponding also to pefloxacin impurity F)
Dipotassium clorazepate impurity B
Batch 1 is valid until 31 May 2007
Yes
Yes
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
j
a
a
c
a
a
a
a
a
a
a
a
j
a
a
c
a
a
a
a
g
l
g
g
l
a
a
l
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
0940
0683
0941
0102,0515,0516
0517,1292,20702
1553
2057
1136
1455
1455
0941
0898,1466
0234,1212
0850
0234
1248
1248,1460
1551
1551
2336,2337
1454
0254,0285,0732
4[(1R)-2-amino-1-methoxyethyl]benzene-1,2-diol (noradrenaline 0285,0732
methyl ether)
2-chloro-1-(3,4-dihydroxyphenyl)ethanone
0285,0732
N-benzyl-1-phenylmethanamine
0285,0732
17¶-acetoxy-6¶-methyl-19-norpregn-4-ene-3,20-dione
99.1% CŒŸHœŸNO–
1550
1135
0058
0416
99.3% CŒœHœŒN—OœSœ
1453
(EZ)-NÁ,NÁ'-[thiazole-2,4-diylbis(methylenesulphanediylethylene)] 1453
bis(N'-methyl-2-nitroethene-1,1-diamine)
99.8% CÿHÿN÷O÷
Information
Unit Sale
Quantity Unit
60 mg
1
20 mg
1 ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5dicarboxylate; (nitrophenylpyridine analogue)
6 December 2006
Oxfendazole for veterinary use
Oxfendazole impurity B
Oxfendazole with impurity D
Oxitropium bromide
© Council of Europe, all rights reserved 2006
O0225800
Y0000224
Y0000225
New Y0000709
2
1
1
1
1
1
1
1
1
O0225000
Y0000543
Y0000350
Y0000404
Y0000390
Oxazepam - * psy
Oxazepam for peak identification - * psy
Oxeladin hydrogen citrate
Oxeladin impurity C
Oxeladin impurity D
1
Y0000274 Oxaliplatin impurity D
1
1
1
2
3
2
Ouabain
Oxacillin sodium monohydrate
Oxacillin for peak identification
Oxaliplatin
Oxaliplatin impurity B
O0200000
Y0000638
Y0000560
Y0000271
Y0000272
1
1
2
2
2
1
1
2
2
1
1
1
2
Batch
Y0000273 Oxaliplatin impurity C
Olsalazine sodium
Olsalazine sodium for performance test
Omeprazole
Omeprazole impurity D
Ondansetron hydrochloride dihydrate
Ondansetron for LC system suitability
Ondansetron for TLC system suitability
Ondansetron impurity D
Orciprenaline sulphate
Orphenadrine citrate
Orphenadrine hydrochloride
Orphenadrine impurity E
O0146000
O0146010
O0150000
O0151000
Y0000218
Y0000197
Y0000196
Y0000195
O0180000
Y0000101
Y0000100
Y0000102
Order
Reference Standard
Code
New O0120050 Ofloxacin impurity E
Catalogue No. 48-2006/4
50 mg
10 mg
10 mg
50 mg
50 mg
0.008 mg
50 mg
10 mg
20 mg
5 mg
10 mg
150 mg
110 mg
10 mg
250 mg
20 mg
60 mg
60 mg
50 mg
5 mg
200 mg
10 mg
30 mg
10 mg
100 mg
100 mg
100 mg
30 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
40
methyl [5-(phenylsulphonyl)-1H-benzimidazole-2-yl]carbamate
2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate
2-(2-diethylaminoethoxy)ethyl 2-phenyl-butyrate dihydrogen
citrate
99.8 % C‡HŒ÷NœO÷Pt ; Batch 1 is valid until 28 February 2007
(SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2-diamine-kN,kN']
platinum (diaquodiaminocyclohexaneplatinum) ; Batch 2 is valid
until 31 October 2006
(OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-kOÁ,kOË]dihydroxyplatinum
; Batch 1 is valid until 31 July 2006
(SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-kOÁ,kOË]platinum (S,S-enantiomer of oxaliplatin)
(RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy]
ethanamine (meta-methylbenzyl isomer)
80.0% Cœ„H÷÷OŒœ
93.8% CŒ„HŒ‡N–NaO—S
9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one
Batch 1 is valid until 31 January 2007
Omeprazole sulphone
89.8% CŒ‡HœÕClN–O
Information
Unit Sale
Quantity Unit
20 mg
1 (RS)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
; Batch 1 is valid until 31 March 2007
1458
1458
1458
2170
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
j
j
g
g
g
g
g
a
a
a
g
g
a
a
c
c
g
g
g
g
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0778,1191
0778
1761
1761
1761
2017
2017
0048
2260
2260
2017
2017
1457
1457
0942,1032
0942,1032
2016
2016
2016
2016
1033,1332
1759
1760
1759,1760
1455
Monograph
6 December 2006
1
1
1
1
2
O0250000
O0260000
O0270000
O0288000
O0288005
Pancreas powder (protease) BRP
Pancuronium bromide
Pancuronium bromide for system suitability
Papaverine hydrochloride
Paracetamol
Paraffin, hard - reference spectrum
Paraffin, liquid - reference spectrum
Paraffin (white soft) - reference spectrum
Paraffin, yellow soft - reference spectrum
Parnaparin sodium
P0200000
P0250000
Y0000577
P0270000
P0300000
P0302000
Y0000058
Y0000293
P0302500
P0305000
© Council of Europe, all rights reserved 2006
Oxymetazoline hydrochloride
Oxyphenbutazone
Oxytetracycline
Oxytetracycline hydrochloride
Oxytocin
Oxytocin/Desmopressin validation mixture
Palmitic acid
Pamidronate disodium pentahydrate
Pancreas powder (amylase and lipase) BRP
O0290000
O0300000
O0400000
New O0500000
O0700000
O0770000
P0090000
Y0000524
P0100000
Y0000492 Oxycodone hydrochloride - * narc
Y0000453 Oxycodone impurity D
3
1
1
1
2
n/a
n/a
n/a
n/a
1
1
1
6
4
3
2
3
1
3
1
1
1
1
1
O0240000 Oxolinic acid
O0240005 Oxolinic acid impurity A
O0240010 Oxolinic acid impurity B
Oxprenolol hydrochloride
Oxybendazole
Oxybuprocaïne hydrochloride
Oxybutynin hydrochloride
Oxybutynin impurity A
1
1
Batch
Y0000713 Oxitropium bromide impurity D
Order
Reference Standard
Code
New Y0000715 Oxitropium bromide impurity B
Catalogue No. 48-2006/4
2000 mg
100 mg
20 mg
25 mg
100 mg
n/a
n/a
n/a
n/a
250 mg
80 mg
100 mg
100 mg
20 mg
41 mg
0.2 mg
100 mg
10 mg
2000 mg
100 mg
25 mg
50 mg
100 mg
150 mg
150 mg
10 mg
50 mg
20 mg
20 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0943
0418
0198,0199
0198,1030
0779,0780
0712,0779,0780
0229,0882,2058
1779
0350
1793
1793
0628,0876,1072
1386
1251
1354
1354
1353
1353
1353
41
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
g
g
a
a
l
l
l
l
a
a
a
a
a
c
c
a
a
a
k
a
a
a
a
a
a
a
a
a
g
79 79 79 79 79 79 79 79 79 79 79 79 79 79 90 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
41.4 Ph. Eur. U. lipolytic activity per mg; 56.3 Ph. Eur. U.
amylolytic activity per mg ; Batch 2 is valid until 31 October 2006
1.48 Ph. Eur. U. per mg ; Batch 2 is valid until 31 October 2006
0350
Vecuronium impurity B
0681,1769
0681
0102,0573
0049
1034
0239,0240
1799
1554
0828,1252
90.2% CœœHœ÷NœO„ ; Batch 5 is valid until 31 December 2005
Batch 3 is valid until 31 March 2007
1.24 mg per vial of C÷–HÿÿNŒœOŒœSœ
about 0.1 mg oxytocin + 0.1 mg desmopressin per vial
Batch 2 is valid until 31 March 2006
7,8-didehydro-4,5 alpha-epoxy-14-hydroxy-3-methoxy
-17-methylmorphinan-6-one (14-hydroxycodeinone)
4-(diethylamino)but-2-ynyl(¢£)-2-(cyclohex-3-enyl)-2cyclohexyl-2-hydroxyacetate
8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7carboxylate
Information
Unit Sale
Monograph
Quantity Unit
15 mg
1 (1R,2R,4S,5S,7s)-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9, 2170
9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane
(methylhyoscine)
10 mg
1 (1R,2R,4S,5S,7s,9r)-9-ethyl-9-methyl-7-[(2-phenylprop-2-enoyl) 2170
oxy]-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane
(apo-N-ethylhyoscine)
6 December 2006
1
2
1
1
1
1
1
Y0000579 Paroxetine hydrochloride (anhydrous) impurity C
Y0000256 Paroxetine impurity D
Y0000580 Paroxetine impurity E
Y0000581
Y0000630
P0309000
P0309020
1
1
1
1
n/a
n/a
n/a
1
1
n/a
1
1
Penicillamine
Penicillamine disulphide
Pentaerythrityl tetranitrate diluted
Pentamidine diisetionate
Pentazocine - reference spectrum
Pentazocine hydrochloride - reference spectrum
Pentazocine lactate - reference spectrum
Pentobarbital - * psy
Pentoxifylline
Pentoxyverine hydrogen citrate - reference spect.
Pentoxyverine impurity A
Pentoxyverine impurity B
Pepsin powder BRP
Pergolide mesilate
Perindopril impurity A
Perindopril for stereochemical purity
Perindopril for system suitability
P0310000
P0320000
P0400100
P0405000
P0405500
P0405510
Y0000417
P0500000
P0510000
Y0000076
Y0000098
Y0000099
P0525000
Y0000010
Y0000237
Y0000207
Y0000206
© Council of Europe, all rights reserved 2006
1
1
P0307000 Penbutolol sulphate
P0307005 Penbutolol impurity A
2
1
1
1
1
2
P0309030 Pefloxacin impurity C
Paroxetine hydrochloride (anhydrous) impurity H
Paroxetine for system suitability
Pefloxacin mesilate dihydrate
Pefloxacin impurity B
1
1
2
Batch
Order
Reference Standard
Code
Y0000578 Paroxetine hydrochloride (anhydrous)
Y0000281 Paroxetine hydrochloride hemihydrate
Y0000233 Paroxetine impurity A
Catalogue No. 48-2006/4
2000 mg
150 mg
10 mg
40 mg
30 mg
100 mg
100 mg
600 mg
30 mg
n/a
n/a
n/a
500 mg
100 mg
n/a
10 mg
10 mg
100 mg
20 mg
0.01 mg
5 mg
200 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
42
1-phenylcyclopentanecarboxylic acid
2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate
(caramiphen)
0.99 Ph. Eur. U. per mg
99.9% CœÕH–ÕNœO–Sœ
(2S,3aS,7aS)-octahydro-1Hindole-2-carboxylic acid
10.0% C—H‡N÷OŒœ
(2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1-dimethylethyl)
amino]propan-2-ol
1-ethyl-6-chloro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(chlorinated homologue of pefloxacin)
1-ethyl-6-fluoro-5-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (isopefloxacin)
Information
Unit Sale
Quantity Unit
100 mg 1
100 mg 1 97.4% CŒ„HœŒClFNO–
5 mg
1 (3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-phenylpiperidine
(desfluoroparoxetine)
10 mg
1 (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-1-benzyl-4-(4-fluorophenyl)piperidine (N-benzylparoxetine)
5 mg
1 (3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)
piperidine
((+)-trans-paroxetine) ; Batch 1 is valid until 31 July 2006
5 mg
1 (3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4fluorophenyl)piperidine (cis-paroxetine)
10 mg
1 [(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol
0682
1555
2019
2019
2019
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
h
a
l
l
l
j
a
l
a
a
a
a
a
g
g
a
a
g
g
g
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 g
79 g
79 g
For extra charges please see 2.2
0566
0566
1355
1137,1436
1462
1463
2000
0200,0419
0851
1621
1621
1621
1461
1461
1460
2283
2018
1460
1460
2283
2018,2283
2283
2283
2018,2283
2018,2283
Monograph
6 December 2006
Y0000123 Pidolic acid
P1650000 Pilocarpine hydrochloride
© Council of Europe, all rights reserved 2006
trans-Epoxyphytomenadione
Picotamide monohydrate
Picotamide impurity A
Pidolate impurity B
Phentolamine mesilate - reference spectrum
Phenylalanine
Phenylbutazone
Phenylbutazone impurity B
Phenylephrine
Phenylephrine hydrochloride
Phenylephrine hydrochloride for peak identification
Phenylmercuric acetate - reference spectrum
Phenylmercuric borate - reference spectrum
Phenylpropanolamine hydrochloride - * Drug Precursor
Phenytoin
Phenytoin sodium
Phloroglucinol (anhydrous)
Pholcodine - reference spectrum
Phthalylsulfathiazole
Physostigmine salicylate
Physostigmine sulphate
Phytomenadione
P1109000
P1150000
P1200000
Y0000147
P1240000
P1250000
New Y0000683
Y0000229
P1255100
P1260000
P1290000
P1300000
Y0000493
P1400000
P1500000
P1600000
P1605000
P1609000
P1609010
P1645000
P1645005
Y0000124
Perindopril tert-butylamine
Perphenazine
Pertussis toxin BRP
Pethidine hydrochloride - reference spectrum
Pethidine impurity A
Phenazone
Pheniramine maleate
Phenobarbital - * psy
Phenoxyethanol
Phenoxymethylpenicillin
Phenoxymethylpenicillin potassium
Reference Standard
Order
Code
Y0000238
P0550000
Y0000021
P0600000
P0600002
P0800000
New P0850000
New P0900000
P0950000
P1000000
P1100000
Catalogue No. 48-2006/4
1
1
2
1
1
1
n/a
3
1
1
1
2
1
n/a
n/a
1
1
1
1
n/a
1
1
1
3
2
1
1
n/a
1
1
2
3
2
2
3
Batch
125 mg
50 mg
10 mg
125 mg
25 mg
50 mg
n/a
60 mg
100 mg
20 mg
60 mg
50 mg
2 mg
n/a
n/a
50 mg
100 mg
250 mg
210 mg
n/a
100 mg
100 mg
100 mg
150 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
43
4-methoxybenzene-1,3-dicarboxylic acid
(2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentanedioic acid
87.0% trans-phytomenadione, 12.6% cis-phytomenadione,
0.09% trans-epoxyphytomenadione; Vitamin K1 ; Batch 2 is valid
until 28 February 2007
Norephedrin
(4-butyl-4-hydroxy-1,2-diphenyl-3,5)-pyrazolidinedione
Information
Unit Sale
Quantity Unit
40 mg
1
100 mg 1
0.05 mg 2
n/a
1
20 mg
1 1-methyl-4-phenylpiperidine (MPP)
50 mg
1
250 mg 1 Batch 1 is valid until 30 April 2007
250 mg 1 Batch 2 is valid until 30 April 2006
2 ml
1
250 mg 1
250 mg 1 99.0% CŒÿHŒŸKNœO—S
1619
0633
1036
1358
1358
1619
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
Leaflet Storage
a
a
a
a
l
a
a
a
a
a
a
l
l
i
a
a
a
l
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
90 f
79 l
79 a
79 a
79 a
79 j
79 a
79 a
79 a
79 +5°C
a
79 +5°C
a
For extra charges please see 2.2
2019
0629,0904
See leaflet,1356
0420
0420
0421
1357
0189,0201,0630
0781
0148
0113,0114,0148,
0149
1138
0782,0796,1161
0422,1574
0422
1035
0632,1205
0632,1035
2042
0103
0683
1253,1988
0521
2301,2302
0522
0352
0286
0684
1036
Monograph
6 December 2006
1
1
2
1
1
2
E0800000 Plastic additive 04
P2155005 Plastic additive 05
P2155008 Plastic additive 08
P2155009 Plastic additive 09
P2155010 Plastic additive 10
P2155011 Plastic additive 11
© Council of Europe, all rights reserved 2006
1
P2155003 Plastic additive 03
1
1
1
1
1
1
n/a
3
1
1
1
2
1
1
1
2
3
1
1
1
Batch
1
Pilocarpine nitrate
Pilocarpine nitrate for system suitability
Pimobendan
Pimobendan for system suitability
Pimozide
Pindolol
Pipemidic acid trihydrate - reference spectrum
Piperacillin
Piperazine adipate
Piperazine citrate
Piperazine hydrate
Piracetam
Pirenzepine dihydrochloride monohydrate
Piretanide
Piretanide impurity A
Piroxicam
Piroxicam for system suitability
Pivampicillin
Pivmecillinam hydrochloride
Pivmecillinam impurity C
Reference Standard
P2155001 Plastic additive 01
Order
Code
P1700000
Y0000106
Y0000525
Y0000401
P1750000
P1800000
Y0000061
P1890000
P1900000
P2000000
P2100000
Y0000288
Y0000038
P2120000
P2120002
P2130000
P2130100
P2150000
P2152000
P2152015
Catalogue No. 48-2006/4
500 mg
250 mg
250 mg
1
1
1
44
4,4',4''-[(2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene)]tris[2,6-bis(1,1-dimethylethyl)phenol]
Synonym:
2,2',2'',6,6',6''-hexatert-butyl-4,4',4''-[2,4,6-trtimethyl-1,3,5benzenetriyl)trismethylene]triphenol
Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate ;
Batch 1 is valid until 31 August 2006
Information
Unit Sale
Quantity Unit
50 mg
1
20 mg
1
10 mg
1
0.1 mg
1
150 mg 1
100 mg 1
n/a
1
100 mg 1 94.5% Cœ–HœŸN—OŸS
250 mg 1
250 mg 1
250 mg 1
120 mg 1 99.8% CÿHŒÕNœOœ ; Batch 1 is valid until 31 March 2006
250 mg 1
100 mg 1
20 mg
1 4-phenoxy-3(1H-pyrrol-1-yl)-5-sulphamoylbenzoic acid
100 mg 1
10 mg
1 Batch 2 is valid until 31 March 2007
50 mg
1 99,2% CœœHœ„N–OÿS
100 mg 1 99.0% CœŒH–÷ClN–O—S
10 mg
1 methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydo1H-azepin-1-yl)methylene]amino]methyl]-5,5-dimethylthiazolidin
-4-carboxylate
2 ml
1 (2RS)-2-ethylhexyl) benzene-1,2-dicarboxylate
Synonym: di(2-ethylhexyl)phthalate
100 mg 1 N,N'-ethylenedialcanamide
Synonym: N,N'-diacylethylenediamines
500 mg 1 Epoxidised soya oil
500 mg 1 Epoxidised linseed oil
500 mg 1 Ethylene bis [3,3-di(3-1,1-dimethylethyl-4-hydroxyphenyl)
butyrate] R
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 Extra
Price
charges
79 g
79 g
79 a
79 g
79 a
79 a
79 l
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
For extra charges please see 2.2
30103,30105,30106,
30107
30101
90001,30114
30103,30104,30105,
30106
30103,30105,30106,
30107
30103,30105,30106,
30107
90001,30114
90001,90002,30114
0104
0104,0633
2179
2179
1254
0634,0871,1789
1743
1168,1169
0423
0424
0425
1733
2001
1556
1556
0944
0944
0808,0852
1359
1359
Monograph
6 December 2006
1
1
1
1
1
1
1
1
1
1
3
1
1
1
1
1
n/a
4
P2155014 Plastic additive 14
P2155015 Plastic additive 15
Plastic additive 16
Plastic additive 17
Plastic additive 18
Plastic additive 20
E1260000 Plastic additive 21
P2155022 Plastic additive 22
P2155023 Plastic additive 23
P2160000 Poliomyelitis vaccine (inactivated) BRP
P2161000 Poliomyelitis vaccine (oral) BRP
Poloxamer 124
Poloxamer 188
Poloxamer 237
Poloxamer 338
Poloxamer 407
Polyacrylate - reference spectrum
Polymyxin B sulphate
Polymyxin B sulphate for microbiological assay
Polysorbate 20 - reference spectrum
Polysorbate 40 - reference spectrum
Polysorbate 60 - reference spectrum
Polysorbate 80 - reference spectrum
Poly(vinyl chloride)
Potassium clavulanate - reference spectrum
P2155016
P2155017
P2155018
O0140000
P2163920
P2164009
P2164020
P2164021
P2164030
P2170000
P2400000
Y0000355
Y0000289
Y0000290
Y0000291
Y0000007
P2600000
P2649610
© Council of Europe, all rights reserved 2006
1
P2155013 Plastic additive 13
1
n/a
n/a
n/a
n/a
1
n/a
2
Batch
Order
Reference Standard
Code
P2155012 Plastic additive 12
Catalogue No. 48-2006/4
25 mg
n/a
n/a
n/a
n/a
100 mg
n/a
30 mg
100 mg
100 mg
100 mg
100 mg
n/a
120 mg
1 ml
0.6 mg
200 mg
100 mg
100 mg
500 mg
500 mg
100 mg
100 mg
200 mg
500 mg
250 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
5
5
1
1
1
1
1
1
1
1
1
1
Monograph
45
67.4% polymyxin B1, 7.8% polymyxin, 2.6% polymyxin B3, 7.3%
polymyxin B1-I
203360 IU per vial
Yes
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
a
l
l
l
l
a
l
a
a
a
a
a
l
a
d
d
a
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 90 90 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
0426
1914
0427
0428
90001,90002,30114
1140
1464
1464
1464
1464
1464
0733
0203
-20°C
-80°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
30103,30105,30106,
30107
1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1, 30103,30105,30106
3,5-triazine-2,4,6-trione
2,2'-Di(octadecycloxy)-5,5'-spirobi(1,3,2-dioxaphosphorinane) R 30103,30105,30106
Dioctadecyl disulphide
30103,30104,30105,
30106
Didodecyl 3,3'-thiodipropionate R
30103,30105,30106
Dioctadecyl 3,3'-thiodipropionate R
30103,30105,30106
30103
Oleamide R
30103,30105,30106,
30107
Erucamide R
30103,30107
Copolymer of dimethyl butanedioate and
30103
1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidin-4-ol
Synonyms: copolymer of dimethyl succinate and
(4-hydroxy-2,2,6,6-tetramethylpiperidin-1-yl)ethanol
di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate
30110,30111
containing about 27% of (tri(isooctyl)2,2',2''- [monooctylstannylidyne)tris(thio)] triacetate.
Tin-content of 15.4%
430-95-285 Ph. Eur. D-Antigen Units per ml for types 1-2-3,
0214,2066,2065,
Yes
respectively
2328,2061,2067,
1934,2329,20720
log ŒÕ CCID50/ml for types 1,2,3 and total virus content: 6.99,
See leaflet,0215
Yes
6.06, 6.83 and 7.20, respectively
Information
Unit Sale
Quantity Unit
200 mg 1 Tris (2,4-di-1,1-dimethylethylphenyl) phosphite R
6 December 2006
© Council of Europe, all rights reserved 2006
Prednisolone acetate for peak identification
Prednisolone hexanoate
Prednisolone pivalate
Prednisolone sodium phosphate
Prednisone
Pregnenolone isobutyrate
Prekallikrein activator in albumin BRP
Prilocaine
Prilocaine hydrochloride
Prilocaine impurity E
Primaquine diphosphate
Primidone
Primidone for peak identification
Probenecid
Procainamide hydrochloride
Procaine benzylpenicillin
Procaine hydrochloride
Prochlorperazine maleate
1
1
1
3
3
4
1
1
1
1
2
1
1
1
1
2
1
1
1
1
1
5
Y0000582
P2804000
P2805000
P2810000
P2900000
P2920000
Y0000263
P2939000
P2939060
P2939025
P2940000
P2950000
Y0000369
P3000000
P3050000
P3090000
P3100000
P3200000
Prazosin hydrochloride
Prednicarbate
Prednicarbate impurity F
Prednisolone
P2680000
P2698000
P2698060
P2700000
1
1
2
2
3
Pravastatin 1,1,3,3-tetramethylbutylamine
Prazepam -* psy
Praziquantel
Praziquantel impurity A
Y0000204
P2669000
P2670000
P2675000
1
1
2
1
n/a
2
Batch
P2800000 Prednisolone acetate
Potassium hydrogen aspartate hemihydrate
Potassium sorbate
Povidone
Povidone (iodinated)
Pravastatin sodium - reference spectrum
Pravastatin impurity A
Reference Standard
Order
Code
Y0000315
P2650000
P2660000
Y0000466
Y0000215
Y0000223
Catalogue No. 48-2006/4
10 mg
10 mg
100 mg
150 mg
50 mg
100 mg
1 ml
150 mg
100 mg
25 mg
500 mg
150 mg
5 mg
100 mg
100 mg
250 mg
100 mg
100 mg
120 mg
50 mg
100 mg
10 mg
150 mg
50 mg
150 mg
10 mg
1
1
1
1
1
1
3
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
46
96.3% Cœ„H–‡N÷OÿS; 39.7% CŒ–HœÕNœOœ (procaine)
100% CŒœHŒ÷NœOœ
(¢£)-N-(methylphenyl)-2-(propylamino)propanamide
Batch 3 is valid until 28 February 2007
29 IU per vial
99.1% CœŸH–ÿO‡
1,2-dihydroprednicarbate
99.8% CŒ„Hœ÷NœOœ
(RS)-2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]
isoquinolin-4-one ; Batch 1 is valid until 28 February 2007
Information
Unit Sale
Quantity Unit
50 mg
1
100 mg 1
50 mg
1
10 mg
1
n/a
1
10 mg
1 (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl
-8-[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphtha
len-1-yl]heptanoic acid (6'-epipravastatin) ; Batch 1 is valid until
30 November 2006
30 mg
1 76.4% pravastatin
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
b
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
c
j
a
a
79 79 79 79 79 79 79 79 79 79 79 90 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 l
79 c
For extra charges please see 2.2
0856
1467
1467
0335,0353,0354,
0735
0734,0736,0933,
0975,1467
0734
1212
0734,0736
0549,0735,0810
0354
0993
See leaflet,20615
1362
1363
1362,1363
0635
0584
0584
0243
0567
0115
0050
0244,20303
2059
1466
0855
0855
2076
0618
0685
1142
2059
2059
Monograph
6 December 2006
Propanol - reference spectrum
Propofol
Propofol for peak identification
Propofol impurity J
Propranolol hydrochloride
Propranolol hydrochloride for performance test
Propylene glycol dilaurate
Propylene glycol monolaurate
Propyl gallate
Propyl parahydroxybenzoate
Propylthiouracil
Propyphenazone
Protirelin
D-His-Protirelin
Proxyphylline
Pseudoephedrine hydrochloride - * Drug Precursor
Pseudoisoeugenyl 2-methylbutyrate for peak identification
Purpureaglucoside A
Purpureaglucoside B
Pyrantel embonate
Pyrantel impurity A
© Council of Europe, all rights reserved 2006
P4050000 Pyrazinamide
P4099900 Pyridostigmine bromide
Y0000278
Y0000016
Y0000017
Y0000018
P3500000
P3600000
Y0000318
Y0000319
New P3640000
P3650000
P3700000
P3750000
P3760000
P3760020
P3800000
P3850000
Y0000387
P3900000
P4000000
Y0000402
Y0000403
1
2
n/a
3
2
2
2
3
1
1
2
2
1
3
3
2
1
2
1
1
1
1
1
1
2
n/a
1
1
P3390000
P3400000
P3490000
Y0000455
Y0000456
Promazine hydrochloride
Promethazine hydrochloride
Propacetamol hydrochloride - reference spectrum
Propafenone hydrochloride
Propafenone impurity B
2
P3350000 Proline
1
1
n/a
2
Batch
2
Progesterone
Progesterone impurity C
Proguanil hydrochloride - reference spectrum
Proguanil impurity C
Reference Standard
Y0000182 Proguanil impurity D
Order
Code
P3300000
Y0000148
Y0000179
Y0000181
Catalogue No. 48-2006/4
30 mg
50 mg
n/a
290 mg
0.1 ml
20 mg
30 mg
20 mg
100 mg
100 mg
50 mg
100 mg
100 mg
200 mg
5.03 mg
0.5 mg
100 mg
100 mg
100 mg
25 mg
25 mg
10 mg
20 mg
100 mg
50 mg
n/a
10 mg
10 mg
60 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0785,0910,0911,
1049
0475,1365,20303
0524,20303
1366
2103
2103
2002
0429
0429
2002
2002
Monograph
47
0859
1255
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
l
a
a
a
g
g
a
a
a
a
a
a
c
c
a
i
a
a
a
a
a
a
g
l
g
g
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 l
79 a
For extra charges please see 2.2
2036
99.9% CŒœHŒ‡O ; Batch 2 is valid until 31 October 2006
1558
1558
2,6-bis (1-methylethyl)-1,4-benzoquinone
1558
Batch 1 is valid until 30 April 2006
0568,0923
Batch 2 is valid until 30 September 2006
0568
2087
1915
Batch 1 is valid until 1 November 2006
1039
0431,0852,1263
0525
0636
5.03 mg per vial of pure protirelin peptide CŒÿHœœNÿO÷
1144
approx. 0.1 mg per vial ; Batch 1 is valid until 30 September 2006 1144
0526
0487,1367
Anise oil
2108
0117
0117
1680
1-methyl-2-[(Z)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyri 1680
midine
1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]
-3-phenylpropenone
Information
Unit Sale
Quantity Unit
250 mg 1
10 mg
1 (20R)-20-hydroxypregn-4-en-3-one
n/a
1
10 mg
1 1,5-bis(4-chlorophenyl)biguanide ; Batch 1 is valid until 31
December 2005
10 mg
1 1,5-bis(1-methylethyl)biguanide ; Batch 1 is valid until 30
November 2006
6 December 2006
2
2
1
1
1
1
3
2
5
1
R0150000 Ranitidine hydrochloride
Y0000416 Ranitidine impurity J
Ranitidine for system suitability
Repaglinide
Repaglinide for system suitability
Repaglinide impurity E
Y0000411
Y0000457
Y0000458
Y0000459
R0200000 Reserpine
R0250000 Residual solvents solution class 1
R0300000 Retinol acetate
R0290000 Retinol esters
1
1
1
3
1
1
2
R0145020 Ramipril impurity D
R0500500 Reviparin sodium
Y0000377 Ribavirin
Y0000353 Ribavirin for system suitability
R0600000 Riboflavin
R0630000 Riboflavin sodium phosphate
Y0000149 Rifabutin
© Council of Europe, all rights reserved 2006
2
R0145015 Ramipril impurity C
1
1
1
1
1
2
4
2
2
Batch
2
Pyridostigmine impurity A
Pyridoxine hydrochloride
Pyrimethamine
Pyrrolidone
Quinidine sulphate
Quinine sulphate
Rabies vaccine (inactivated) for veterinary use BRP
Ramipril
Ramipril impurity A
Reference Standard
R0145010 Ramipril impurity B
Order
Code
P4099910
P4100000
P4200000
Y0000659
Q0100000
Q0200000
R0100000
R0145000
R0145005
Catalogue No. 48-2006/4
250 mg
100 mg
1 mg
100 mg
250 mg
150 mg
100 mg
100 mg
1500 mg
1000 mg
100 mg
0.00025
mg
20 mg
20 mg
6 mg
5 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1368
1368
1255
0245
0288
2180
0017,0018,0019
0017,0018,0019
See leaflet,0451
1368
1368
Monograph
0946
2135
2135
2-ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl] 2135
amino]-2-oxoethyl]benzoic acid
99.8% C––H÷ÕNœO„
0528
Batch 1 is valid until 31 May 2006
20424
1044000 IU per g
0218,0219,0220,
1192,1193
0217,0218,0219,
0220
0828
100.0% C‡HŒœN÷O—
2109
2109
Vitamin B2 ; Batch 2 is valid until 31 October 2006
0292,0786
0786
96.3% C÷—HÿœN÷OŒŒ
1657
48
For extra
ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro
1368
-1H- cyclopenta[e]pyrrolo[1,2a]pyrazin-2-yl]-4-phenylbutanoate
(ramipril diketopiperazine) ; Batch 1 is valid until 31 May 2006
Batch 1 is valid until 30 April 2006
0946,1453
1,1'-N-[methylenebis(sulphanediylethylene)]bis(N'-methyl-2-nitro 0946
ethene-1,1-diamine)
Information
Unit Sale
Quantity Unit
20 mg
1 pyridin-3-yl-dimethylcarbamate
100 mg 1
250 mg 1
20 mg
1
300 mg 1
300 mg 1
86 mg
3 11 IU per vial
20 mg
1
10 mg
1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(methoxycarbonyl)-3phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2
-carboxylic acid (ramipril methylester)
10 mg
1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-[(methylethoxy)carbonyl]-3phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole2-carboxylic acid (ramipril isopropyl ester)
10 mg
1 (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-cyclohexylprop
yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic
acid (hexahydroramipril) ; Batch 1 is valid until 31 December 2005
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
a
a
g
c
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
90 c
79 a
79 a
+5°C
a
+5°C
a
+5°C
a
+5°C
a
+5°C
a
+5°C
a
charges please see 2.2
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
Leaflet Storage
6 December 2006
1
3
2
2
2
2
1
1
1
Rutoside trihydrate
Saccharin
Saccharin sodium
Salbutamol
Salbutamol impurity B
Y0000105
S0040000
S0050000
S0100000
Y0000030
Y0000071 Salbutamol impurity D
Y0000031 Salbutamol impurity F
Y0000034 Salbutamol impurity G
Y0000032 Salbutamol impurity I
S0150000
S0200000
Y0000405
Y0000422
Y0000423
© Council of Europe, all rights reserved 2006
Salbutamol sulphate
Salicylic acid
Salicylic acid impurity B
Salmeterol xinafoate
Salmeterol for system suitability
1
1
1
2
2
Rocuronium for peak identification
Rocuronium bromide - reference spectrum
Roxithromycin
Roxithromycin for system suitability
Rubella vaccine (live) BRP
Ruscogenins
1
n/a
4
1
1
1
1
1
3
1
1
3
n/a
1
1
1
1
Y0000527
Y0000594
R1500000
Y0000220
R2000000
Y0000494
Batch
Rifabutin impurity A
Rifampicin
Rifampicin quinone
Rifamycin B
Rifamycin S
Rifamycin sodium
Rilmenidine dihydrogenophosphate - reference spectrum
Rilmenidine for system suitability
Risperidone
Risperidone for system suitability
RK 13 cells
Reference Standard
Order
Code
Y0000184
R0700000
R0800000
R0900000
R0950000
R1000000
Y0000250
Y0000187
R1000600
Y0000370
R1300000
Catalogue No. 48-2006/4
50 mg
100 mg
10 mg
40 mg
25 mg
0.006 mg
5 mg
5 mg
10 mg
100 mg
30 mg
50 mg
50 mg
5 mg
10 mg
n/a
125 mg
5 mg
18 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
5
1
49
4-hydroxyisophthalic acid
99.6% C–ÿH÷—NOŸ
(1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol
(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzaldehyde
1,1'-[oxybis[methylene(4-hydroxy-1,3-phenylene)]]bis[2-[(1,1dimethylethyl)amino]ethanol]
91.3% salbutamol impurity G;
2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone
(1RS)-2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4benzyloxyphenyl]ethanol
3.6 logŒÕ (ie 4000) infective viral units per vial
38.2% ruscogenin
60.4% neoruscogenin
96.8% C÷ŒHŸÿNœOŒ—
Information
Unit Sale
Quantity Unit
20 mg
1 (N-(2-methylpropyl)-4-piperidone)
500 mg 1
100 mg 1
50 mg
1
50 mg
1
300 mg 1 856 IU per mg
n/a
1
30 mg
1
100 mg 1
20 mg
1
1 ml
2 cell lines (kidney, rabbit) titration of live measles, mumps and
rubella vaccines
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-80°C
+5°C
-20°C
+5°C
+5°C
+5°C
-180°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
Leaflet Storage
a
a
a
a
a
a
a
a
a
a
a
a
a
a
g
l
a
a
d
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 90 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 c
79 l
79 a
79 g
79 g
100 d
For extra charges please see 2.2
0687
0366,1156
0366
1765
1765
0529,0687
0529,0687
0529,0687
0529,0687
1795
0947
0787
0529,1033
0529,0687
1764
1764
1146
1146
1057,0162
1847
1657
0052
0052
0432
0432
0432,20702
2020
2020
1559
1559
0162,1057
Monograph
6 December 2006
© Council of Europe, all rights reserved 2006
New Y0000711 Somatropin/desamidosomatropin resolution mixture
S0950000 Sorbic acid
S0930000 Sodium valproate
S0945000 Somatostatin
S0947000 Somatropin
1
1
3
2
2
1
1
1
1
1
3
1
2
1
n/a
1
1
1
2
2
2
n/a
2
1
1
n/a
n/a
1
1
1
1
2
S0450000
S0460000
Y0000371
S0500000
S0600000
S0650000
S0660000
Y0000014
S0695000
Y0000300
Y0000039
S0700000
S0710000
S0750000
S0760000
S0765000
S0781000
S0780000
Y0000620
S0785000
Y0000210
Y0000268
S0800000
Y0000662
S0808000
S0808060
S0900000
Serine
Sertaconazole nitrate
Sestamibi labelling kit
Silicone elastomer
Silicone oil
Simvastatin
Sisomicin sulphate
Sodium alendronate
Sodium amidotrizoate
Sodium aminosalicylate dihydrate - reference spectrum
Sodium ascorbate
Sodium calcium edetate
Sodium cetostearylsulphate
Sodium cromoglicate
Sodium cyclamate
Sodium diclofenac
Sodium hyaluronate - reference spectrum
Sodium hyaluronate BRP
Sodium laurilsulfate
Sodium picosulphate
Sodium polystyrene sulphonate - reference spectrum
Sodium propionate - reference spectrum
Sodium salicylate
Ribonucleic acid
Sodium stearyl fumarate
Sodium stearyl maleate
Sodium taurocholate BRP
1
1
1
Batch
Order
Reference Standard
Code
S0360000 Selegiline hydrochloride
S0360090 (RS)-Selegiline hydrochloride
S0400000 Senna extract
Catalogue No. 48-2006/4
33 mg
100 mg
50 mg
125 mg
1 uc
2000 mg
1 ml
100 mg
50 mg
150 mg
125 mg
n/a
50 mg
100 mg
100 mg
10 mg
100 mg
100 mg
n/a
300 mg
40 mg
100 mg
n/a
n/a
100 mg
100 mg
50 mg
10 mg
10000
mg
150 mg
2.55 mg
35 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Unit Sale
Quantity Unit
50 mg
1
25 mg
1
50 mg
1
50
2.55 mg somatostatin peptide per vial
1.69 mg somatropin monomer per vial ; Batch 1 is valid until 31
October 2006
1.7 mg somatropin per vial
Batch 1 is valid until 31 March 2006
100.0 %
99.4% Cœ—H–‡O— ; Batch 2 is valid until 30 September 2006
83.4% C–‡H‡÷NŒÕO–÷S—
83.4% C÷HŒœNNaOŸPœ
Information
Yes
Yes
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
Room
temp.
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
c
a
a
a
a
a
a
c
a
a
a
l
a
a
a
a
a
a
l
a
a
a
l
l
a
a
a
a
a
79 150 150 90 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
For extra charges please see 2.2
0678
0949
See leaflet,0950,
0951,0952
0950,0951,0952
0592
1260
1260
0206,0207,0208,
1261
0788,1027
1148
1926
30109
30108
1538,1563
1351
1564
1150
1993
1791
0231
0847
0562
0774
1002,1281
1472
0912
0802
1031
1909
2041
0413
2090
1567
1567
0350
Monograph
6 December 2006
n/a
1
1
n/a
n/a
1
1
1
1
S1400000 Streptomycin sulphate
S1500000 Succinylsulfathiazole
S1600000 Sucrose
S1608100
S1609000
Y0000529
Y0000528
Y0000550
S1700000
© Council of Europe, all rights reserved 2006
Sufentanil - reference spectrum
Sufentanil citrate - reference spectrum
Sulbactam sodium
Sulbactam
Sulbactam for peak identification
Sulfacetamide sodium
1
S1350000 Stearyl alcohol
1
1
1
1
1
1
3
1
1
2
Spirapril hydrochloride monohydrate
Spirapril for system suitability
Spironolactone
Squalane
Stanozolol
Stanozolol impurity A
Starch BRP
Y0000381
Y0000332
S1200000
Y0000185
S1250000
S1250010
S1300000
2
1
1
4
Y0000408 Stavudine
Y0000421 Stavudine for system suitability
S1340000 Stearic acid
Spectinomycin hydrochloride
Spectinomycin for system suitability
Spectinomycin sulphate tetrahydrate
Spiramycin
Y0000597
Y0000549
New Y0000655
S1100000
1
1
Y0000114 Sotalol hydrochloride
Y0000115 Sotalol impurity B
Batch
1
3
Reference Standard
Order
Code
Y0000385 1,4-Sorbitan
S1000000 Sorbitol
Catalogue No. 48-2006/4
n/a
n/a
10 mg
150 mg
20 mg
50 mg
100 mg
100 mg
100 mg
250 mg
60 mg
15 mg
100 mg
0.25 ml
125 mg
10 mg
50000
mg
100 mg
10 mg
100 mg
100 mg
20 mg
10 mg
200 mg
25 mg
20 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Monograph
51
99.7% C‡HŒŒNO—S
78 500 IU per ampoule; International standard provided for an
interim period
100% CŒ‡H–‡O
Plastic additive 19
99.6% CŒÕHŒœNœO÷
(5¶,17ß)-17-hydroxy-17-methylandrostan-3-one
Batch 2 is valid until 30 September 2006
99.7% C–ÕHÿœ
4530 IU per mg
Spiramycin I: 87.9%, Spiramycin II: 0.2%, Spiramycin III: 5.3%
95.9% CœœH–ŒClNœO—Sœ
Yes
Yes
l
l
a
b
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
c
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
For extra charges please see 2.2
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
2130
2130
Yes
0229,0882,2058,
30103,30105,30106,
30107
0702,0753,0801,
0802,0847,0969,
1123,1340,1411
0032,0033,0053,
0485,20702
0357
0177,0178,0187,
0188,0204,0209,
1061,1570
1569
1269
2209
2209
2209
Yes
0107
1152
1658
0179,0293,1982,
1983,20702
1766
1766
0688
1630
1568
1568
0350
2048
0435,0436,0437,
1235,1236,1337,
1381,1531,2048
2004
N-[4-[[(1-methylethyl)amino]acetyl]phenyl]methanesulphonami- 2004
de
81.3% CŒ÷HœÿClœNœOŸ and CŒ÷Hœ‡ClœNœOŸ
1152
Information
Unit Sale
Quantity Unit
50 mg
1 99.2% CÿHŒœO—
1200 mg 1 97.9 % CÿHŒ÷Oÿ ; Batch 2 is valid until 28 February 2007
6 December 2006
2
1
1
1
© Council of Europe, all rights reserved 2006
Sumatriptan for system suitability
Suxamethonium chloride
Suxibuzone
Suxibuzone impurity B
Y0000027
S2200000
S2400000
S2400004
1
1
2
3
1
2
2
2
1
1
1
1
1
2
3
Sulfathiazole
Sulfinpyrazone
Sulfinpyrazone impurity A
Sulfinpyrazone impurity B
Sulfisomidine
Sulindac
Sulpiride
Sulpiride impurity A
Sulpiride impurity B
Sultamicillin
Sultamicillin tosilate
Sultamicillin for peak identification
Sumatriptan succinate
Sumatriptan impurity C
S2158000
S2159000
S2159010
S2159015
S2160000
S2180000
S2190000
S2191000
S2192000
Y0000530
Y0000531
Y0000532
Y0000022
Y0000025
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
Batch
Y0000026 Sumatriptan impurity mixture
Sulfadiazine
Sulfadimidine
Sulfadoxine
Sulfafurazole
Sulfaguanidine
Sulfamerazine
Sulfamethizole
Sulfamethoxazole
Sulfamethoxazole impurity A
Sulfamethoxazole impurity F
Sulfamethoxypyridazine
Sulfanilamide
Sulfapyridine
Sulfasalazine
Sulfasalazine derivative for resolution
Reference Standard
Order
Code
S1800000
S1900000
S1950000
S1975000
S1975600
S2000000
S2050000
S2100000
Y0000412
Y0000413
S2150000
S2151000
S2159100
S2155000
S2155010
Catalogue No. 48-2006/4
2 mg
1000 mg
50 mg
10 mg
3 mg
100 mg
30 mg
20 mg
20 mg
50 mg
50 mg
100 mg
20 mg
30 mg
10 mg
200 mg
10 mg
50 mg
5 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0294
0295
0740
0741
1476
0358,1571
0637
0108
0108
0108
0638
1571
0863
0863,1457
0863
Monograph
52
(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl
butanedioate
1573
0248
1574
1574
Yes
Yes
Yes
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
c
a
a
a
c
a
a
a
a
a
a
a
a
a
a
a
a
c
c
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 g
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
For extra charges please see 2.2
0742
0790
1,2-diphenyl-4-[2-(phenylsulphonyl)ethyl)pyrazolidine-3,5-dione 0790
1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dione
0790
0639
Contains 0.3% m/m of E-isomer
0864
1045,1348
2-aminomethyl-1-ethylpyrrolidine
1045
methyl 5-sulphamoyl-2-methoxybenzoate
1045
2211
68.5% Cœ—H–ÕN÷O„Sœ
2212
2211
98.8% CŒ‡HœŸN–OÿS
1573
[3-[2-(dimethylamino)ethyl]-1-(hydroxymethyl)-1Hindol-5-yl]-N- 1573
methylmethanesulphonamide
Batch 2 is valid until 31 December 2006
1573
Batch 1 is valid until 30 June 2006
Information
Unit Sale
Quantity Unit
100 mg 1
100 mg 1
100 mg 1
100 mg 1
60 mg
1
100 mg 1
100 mg 1
50 mg
1
5 mg
1 N-(4-(5-methyl)-isoxazol-3-ylsulphamoyl)phenylacetamide
5 mg
1 4-amino-N-(3-methylisoxazol-5-yl)benznesulphonamide
50 mg
1
100 mg 1
20 mg
1
250 mg 2 99.9 % CŒ‡HŒ÷N÷O—S
20 mg
1 2-hydroxy-5-[[4-[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]
azo]benzoic acid
6 December 2006
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
T0040000 Temazepam - * psy
Y0000344 Temazepam impurity C
Y0000345 Temazepam impurity D
Y0000346 Temazepam impurity F
Y0000347 Temazepam impurity G
T0040800
Y0000621
Y0000666
Y0000622
Y0000665
Y0000623
Y0000624
Y0000535
T0050000
T0050015
1
T0100000 Testosterone
© Council of Europe, all rights reserved 2006
1
1
1
T0060000 Terconazole
T0071000 Terfenadine
T0080000 Terfenadine impurity A
Tenoxicam
Terazosin hydrochloride dihydrate
Terazosin for system suitability
Terazosin impurity A
Terazosin impurity E
Terazosin impurity L
Terazosin impurity N
Terbinafine hydrochloride
Terbutaline sulphate
Terbutaline impurity C
1
New Y0000652 Tamsulosin impurity H
New
New
New
New
New
New
50 mg
80 mg
50 mg
10 mg
10 mg
10 mg
1
1
2
1
1
1
250 mg
250 mg
100 mg
30 mg
100 mg
40 mg
0.5 mg
10 mg
10 mg
10 mg
10 mg
10 mg
100 mg
15 mg
5 mg
5 mg
5 mg
50 mg
5 mg
10 mg
1 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
See leaflet,0064
See leaflet,0064
1574
Monograph
0954
0954
0954
0879
0954
53
1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl)
piperidin-1-yl]butan-1-one (ketone)
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
g
a
a
a
a
a
a
a
a
a
a
a
a
g
a
a
a
j
a
a
a
g
a
a
A
a
f
f
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 90 90 Extra
Price
charges
79 a
6 December 2006
For extra charges please see 2.2
0410,1373
1270
0955
0955
1156
2021
2021
2-chloro-6,7-dimethoxyquinazolin-4-amine
2021
2,2'-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine) 2021
1-(furan-2-ylcarbonyl)piperazine
2021
1-[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine
2021
1734
0690
1-(3,5-dihydroxyphenyl)-2-[(1,1-dimethylethyl)amino]-ethanone 0690
; Batch 2 is valid until 30 April 2006
(3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4benzodiazepin-3-yl acetate
(3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H1,4-benzodiazepin-2-one
(5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4benzodiazepine-2,3-dione
(5RS)-7-chloro-1,4-methyl-5-phenyl-4,5-dihydro-1H-1,4benzodiazepine-2,3-dione
0808,0852
1046
1046
2131
2131
(2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan- 2131
2-amine
(2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan- 2131
2-amine
2.6 x10Ï Cfu per vial
Information
Unit Sale
Quantity Unit
10 mg
1 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4Hpyrazole-3,5-dione
1 mg
1 6.5 x10Ì Cfu per vial
1
1
1
Batch
S5000001 Swine erysipelas bacteria, serotyp 1 (for vaccines - vet.
use) BRP
S5000002 Swine erysipelas bacteria, serotyp 2 (for vaccines - vet.
use) BRP
T0010000 Talampicillin hydrochloride
T0014000 Tamoxifen citrate
T0015000 Tamoxifen citrate for performance test
New Y0000650 Tamsulosin hydrochloride
New Y0000653 Tamsulosin racemate
New Y0000651 Tamsulosin impurity D
Order
Reference Standard
Code
S2400006 Suxibuzone impurity C
Catalogue No. 48-2006/4
1
1
1
n/a
1
1
1
2
1
Tetryzoline hydrochloride
Theobromine
Theophylline
Theophylline - reference spectrum
Thiamazol
Thiamazol impurity A
Thiamazol impurity C
Thiamine hydrochloride
Thiamine impurity E
Thiamine nitrate - reference spectrum
Thiamphenicol
Thioctic acid
Thioctic acid for system suitability
Thioctic acid containing impurity B
Thiomersal
Thiopental
Thioridazine - reference spectrum
Thioridazine hydrochloride
Y0000460
T0700000
T0800000
Y0000294
Y0000336
Y0000372
Y0000373
Y0000467
Y0000059
Y0000060
T1100000
Y0000546
Y0000592
Y0000545
Y0000109
T1200000
Y0000150
T1300000
© Council of Europe, all rights reserved 2006
n/a
1
Y0000015 Tetrazepam - reference spectrum
Y0000008 Tetrazepam impurity C
n/a
1
1
1
1
1
1
n/a
1
100 mg
0.365 mg
100 mg
1
2
2
n/a
125 mg
110 mg
10 mg
30 mg
30 mg
500 mg
n/a
50 mg
10 mg
100 mg
100 mg
n/a
125 mg
10 mg
20 mg
10 mg
10 mg
n/a
20 mg
n/a
n/a
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
0057
0644
0173,0198,0199,
0210,0211,1654
1738
1738
1325
0297
1048
1048
1048
1373
1373
1048
1048
0297
See leaflet,20708
Monograph
54
99.8% C‡HŒ÷OœSœ
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
-20°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
l
a
a
a
a
a
a
l
g
a
a
a
l
a
a
a
a
a
l
a
g
c
a
l
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 c
79 a
79 a
79 a
79 a
79 l
90 c
6 December 2006
For extra charges please see 2.2
0531
0109
1648
1648
1648
1625
0212
2005
0586,20303
2101
0298
0300,0301
0299,0302
1706
1706
1706
0303
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)- 0303,0531
4-methyl-4-thiazolidine-2-thione
7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
365 μg per vial of pure tetracosactide peptide CŒ–ÿHœŒÕN÷ÕO–ŒS
96.7% CœœHœ—ClNœO‡ ; Batch 1 is valid until 31 March 2006
Information
Unit Sale
Quantity Unit
10 mg
1
50 mg
1
25 mg
1
100 mg 1
15 mg
1
15 mg
1
25 mg
1
250 mg 1
n/a
1
11 mg
1 469 IU per ampoule for assays in guinea pig
496 IU per ampoule for assays in mice
T0499000 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethane-sulphonyl-ß - ref
spectrum
T0500000 Tetracaine hydrochloride
T0550000 Tetracosactide
T0600000 Tetracycline hydrochloride
Batch
2
1
1
1
1
1
1
1
n/a
2
Reference Standard
Testosterone acetate
Testosterone caproate
Testosterone decanoate
Testosterone enantate
Testosterone for impurity D identification
Testosterone for system suitability
Testosterone isocaproate
Testosterone propionate
Testosterone propionate - reference spectrum
Tetanus vaccine (adsorbed) BRP
Order
Code
T0200000
T0210000
T0240000
T0250000
Y0000342
Y0000343
T0260000
T0300000
Y0000170
T0400000
Catalogue No. 48-2006/4
Thioridazine for system suitability
Thioxanthene
Thioxanthone
Threonine
Thymol
Tiabendazole
Tiamulin for peak identification
Tiamulin hydrogen fumarate
Tiamulin - reference spectrum
Tianeptine sodium - reference spectrum
Tianeptine for system suitability
Tianeptine impurity A
Tiapride hydrochloride
Tiapride N-oxide
Tiaprofenic acid
Tiaprofenic acid impurity C
Tibolone - reference spectrum
Tibolone for system suitability
Ticarcillin monosodium
Reference Standard
T1423000 Ticlopidine hydrochloride
T1423025 Ticlopidine impurity F
Y0000325 Tilidine hydrochloride hemihydrate - reference spectrum
T1450000 Timolol maleate
Y0000644 (R)-timolol
T1470000 Tinidazole
T1471000 Tinidazole impurity B
T1490000 Tinzaparin sodium
Y0000292 Tioconazole - reference spectrum
Y0000282 Tioconazole for system suitability
T1500000 Tobramycin
Y0000383 All-rac-alpha-tocopherol for peak identification
Y0000384 All-rac-alpha-tocopheryl acetate for peak identification
T1550000 alpha-Tocopherol
T1600000 alpha-Tocopheryl acetate
© Council of Europe, all rights reserved 2006
T1420010 Ticarcillin impurity A
Order
Code
Y0000541
T1305100
T1305000
T1340000
T1350000
T1410000
Y0000414
Y0000333
Y0000379
Y0000151
Y0000152
Y0000153
T1405000
T1405050
T1410900
T1410910
New Y0000748
New Y0000668
Y0000465
Catalogue No. 48-2006/4
3
2
n/a
2
1
1
3
1
n/a
1
2
1
1
5
6
1
1
2
2
1
1
1
1
1
n/a
n/a
1
1
1
1
1
1
n/a
1
1
Batch
50 mg
10 mg
n/a
50 mg
20 mg
100 mg
20 mg
250 mg
n/a
50 mg
250 mg
15 mg
15 mg
250 mg
250 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
97.7% Cœ„H—ÕOœ; Vitamin E
98.9% C–ŒH—œO–
55
91.6% CŒ‡H–ŸN—O„
1-(2-ethylsulphonylethyl)-2-methyl-4-nitroimidazole
6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
Information
Unit Sale
Quantity Unit
0.21 mg 1
20 mg
1
10 mg
1
50 mg
1
50 mg
1
50 mg
1
10 mg
1
450 mg 1 99.1% C–œH—ŒNO‡S
n/a
1
n/a
1
30 mg
1
20 mg
1 ethyl 7-bromoheptanoate
60 mg
1
20 mg
1
50 mg
1
20 mg
1 (¢£)-2-(5-benzoyl-3-thienyl)propanoic acid
n/a
1
10 mg
1
250 mg 1 93.2% CŒ—HŒ—NœNaOÿSœ
Correction factor 1.054
50 mg
1 89.8%;
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(thiophen-3-yl)acetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(decarboxyticarcillin)
1050
1050
1767
0572
0572
1051
1051
0828
2074
2074
0645
0692
0439
0692,1256,20432
0439,0691,1257
For extra
0956
0586
1347
1347
0785,1049
0791
0866
1659
1659,1660
1660
2022
0505
2022
1575
1575
1157
1157
1739
1739
0956
Monograph
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 g
79 g
79 l
79 l
79 a
79 a
79 a
79 a
79 a
79 a
79 l
79 b
79 a
a
a
l
+5°C
g
Yes
+5°C
g
+5°C
a
+5°C
a
+5°C
a
l
Yes
+5°C
a
+5°C
a
Yes
+5°C
a
Yes
+5°C
a
+5°C
a
+5°C
a
charges please see 2.2
Yes
Yes
Yes
Leaflet Storage
6 December 2006
T1975000 Triazolam - * psy
Y0000165 Tribenoside
Y0000166 Tribenoside impurity A
Y0000330 Tributyl acetylcitrate - reference spectrum
© Council of Europe, all rights reserved 2006
1
1
2
n/a
3
2
1
1
1
1
n/a
n/a
1
3
1
1
T1810000
T1810030
T1820000
T1820002
T1820004
T1850000
T1899000
G0400010
T1899990
T1900000
T1950000
Y0000050
Tranexamic acid
Tranexamic acid impurity C
Trapidil
Trapidil impurity A
Trapidil impurity B
Tretinoin
3,4,6-Tri-O-acetyl-D-glucal - reference spectrum
Triacetin - reference spectrum
Triamcinolone
Triamcinolone acetonide
Triamcinolone hexacetonide
Triamcinolone impurity C
1
Y0000496 Trandolapril impurity D
2
1
1
1
1
1
Tramadol impurity E
Tramazoline hydrochloride monohydrate
Tramazoline impurity A
Tramazoline impurity B
Y0000157
Y0000072
Y0000065
Y0000066
1
1
1
1
1
1
2
2
Batch
Y0000501 Trandolapril
Y0000495 Trandolapril impurity C
RRR-alpha-Tocopheryl hydrogen succinate
Tolbutamide
Tolfenamic acid
Tolnaftate
Torasemide anhydrous
Torasemide for system suitability
Tramadol hydrochloride
Tramadol impurity A
Reference Standard
Order
Code
T1610000
T1700000
Y0000154
T1707000
Y0000461
Y0000462
Y0000155
Y0000156
Catalogue No. 48-2006/4
10 mg
150 mg
30 mg
n/a
50 mg
10 mg
50 mg
20 mg
20 mg
100 mg
n/a
n/a
150 mg
100 mg
100 mg
10 mg
10 mg
10 mg
10 mg
20 mg
10 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1681
1597
1597
1597
1258,1259
0304
2039
1158
2132
2132
1681
1681
Monograph
1065
98.9% Cœ„H–÷Oÿ
1740
3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)-¶-D-glucofuranose 1740
1770
56
9-fluoro-11ß-16alpha,17,21-tetrahydroxypregn-4-ene-3,20dione (pretriamcinolone)
5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol
1,2,4-triazol-3-amine
(4-(aminomethyl) cyclohex-1-enecarboxylic acid)
Yes
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
a
a
l
l
a
a
a
a
a
a
a
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 a
79 a
79 a
79 a
79 a
79 a
79 a
j
a
c
l
For extra charges please see 2.2
0875
0875
1576
1576
1576
0693,1019,1385
1325
1106
1376
0533,0867,1075
0533,0867
1376
2245
(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)pr 2245
opyl]amino]propanoyl]octahydro-1H-indole-2-carboxylic acid
(hexahydrotrandolapril)
ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydro
2245
pyrazino[1,2-a]indol-2(1H)-yl]-4-phenylbutanoate (trandolapril
diketopiperazine)
N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine
75% CŒ—HŒ„N–ÕO; mixture of 1-acetyl-2-[(5,6,7,8-tetrahydronaphthalen-1-yl) amino]-4,5- dihydro-1H-imidazole and
N-(4,5-dihydro-1H-imidazol-2-yl)-N-(5,6,7,8- tetrahydronaphthalen-1-yl)acetamide
Information
Unit Sale
Quantity Unit
125 mg 1 98.6% C––H—÷O—
100 mg 1
100 mg 1
60 mg
1
10 mg
1
0.4 mg
1
75 mg
1
15 mg
1 (1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol
10 mg
1 (2RS)-2-[(dimethylamino)methyl]cyclohexanone
6 December 2006
Trimethoprim impurity B
Trimethoprim impurity E
Trimethyltetradecylammonium bromide
Trimipramine maleate
Trimyristin
Tristearin
Trolamine
Trometamol
Tropicamide
Tropisetron hydrochloride
Tropisetron impurity B
Tropine
Trospium chloride
Trospium impurity A
Trospium impurity B
Trospium impurity C
T2200010
T2200025
New T2450000
T2500000
T2500100
T2501200
T2545000
T2550000
T2580000
Y0000616
Y0000618
T2580300
Y0000429
Y0000432
Y0000431
Y0000430
© Council of Europe, all rights reserved 2006
Y0000497 Troxerutin
Trihexyphenidyl hydrochloride
Trihexyphenidyl impurity A
Trilaurin
Trimetazidine dihydrochloride - reference spectrum
Trimetazidine for system suitability
Trimethadione
Trimethoprim
Trimethoprim for system suitability
Tri-n-butyl phosphate
Tricaprin
Tricaproin
Tricaprylin
Trichloroacetic acid - reference spectrum
Trichlorotrifluoroethane
Triethyl citrate - reference spectrum
Trifluoperazine hydrochloride
Triflusal
Triflusal impurity B
Reference Standard
Y0000108
Y0000068
T2009000
Y0000092
Y0000093
T2100000
T2200000
New Y0000684
Order
Code
Y0000279
T1977990
T1977995
T1978000
Y0000111
T1985000
T1986000
T2000000
T2005000
T2005010
Catalogue No. 48-2006/4
1
3
2
2
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
n/a
1
1
1
1
1
1
1
1
n/a
1
n/a
1
1
1
Batch
30 mg
100 mg
20 mg
1250 mg
n/a
50 mg
250 mg
50 mg
0.00075
mg
10 mg
20 mg
200 mg
100 mg
500 mg
100 mg
1000 mg
100 mg
50 mg
40 mg
10 mg
50 mg
10 mg
20 mg
15 mg
5 mg
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1626
1626
1410
1741
1741
0440
0060
0060
1682
1410
1410
1410
1967
0393
1479
0059,20303
1377
1377
Monograph
57
2133
Yes
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
Leaflet Storage
a
a
a
a
g
c
c
a
a
a
g
a
a
g
a
g
g
a
a
c
l
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
79 c
79 c
79 c
79 l
79 a
79 l
79 a
79 a
79 a
For extra charges please see 2.2
0060
0060
0378
0534
1410
1410
1577
Batch 1 is valid until 30 September 2006
1053
1159,1197
2102
2102
1308
1798
hydroxydiphenylacetic acid (benzilic acid)
1798
(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate
1798
(1R,3r,5S)-3-hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyr 1798
rolidinium]
(2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone
4-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol
Batch 1 is valid until 30 April 2007
100% CÿH„NO–
1-phenyl-3-(piperidin-1-yl)propan-1-one
Information
Unit Sale
Quantity Unit
300 μl
1
150 mg 1
40 mg
1
225 mg 1
n/a
1
2.5 ml
2
n/a
1
100 mg 1
50 mg
1
25 mg
1 2-hydroxy-4-(trifluoromethyl)benzoic acid;
(4-(trifluoromethyl)salicylic acid)
6 December 2006
Valproic acid
Vancomycin hydrochloride
Vanillin
Vecuronium bromide
Vecuronium for peak identification
Venlafaxine hydrochloride
Venlafaxine for system suitability
Verapamil hydrochloride
Verapamil impurity I
V0033000
V0045000
V0050000
Y0000561
Y0000625
Y0000587
Y0000588
V0100000
V0100018
© Council of Europe, all rights reserved 2006
V0100026 Verapamil impurity M
Uracil arabinoside
Urea
Ursodeoxycholic acid
Valerian standardised dry extract
Valine
Valnemulin hydrochloride
Valnemulin hydrogen tartrate
Valnemulin for peak identification
Valnemulin impurity E
Tyrothricin
Ubidecarenone
Ubidecarenone for system suitability
Ubidecarenone impurity D
T3000000
U0020000
U0020001
U0020008
U0100000
U0600000
U0800000
New Y0000583
V0030000
Y0000584
Y0000533
Y0000585
Y0000586
2
1
n/a
1
Tylosin D
Tylosin phosphate for peak identification
Tylosin tartrate - reference spectrum
Tyrosine
T2880100
Y0000498
T2880200
T2900000
2
2
2
1
1
1
1
1
1
2
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
T2610000 Tryptophan
T2800000 Tubocurarine chloride
T2880000 Tylosin
Batch
2
Reference Standard
Order
Code
T2600000 Trypsin BRP
Catalogue No. 48-2006/4
20 mg
100 mg
100 mg
100 mg
10 mg
10 mg
50 mg
1 mg
100 mg
5 mg
30 mg
100 mg
60 mg
400 mg
50 mg
10 mg
120 mg
10.25 mg
10 mg
10 mg
50 mg
10 mg
5 mg
5 mg
10 mg
n/a
50 mg
100 mg
100 mg
150 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0760
0743
1189,1275
0453,1898,1899
0770,0771,0796
2137
2137
2137
2137
0476,0579,0580,
0694
1272
0305
1273,1274,1661,
20702
1273,1274,1661
1273,1274,1661
1274
0782,0895,1161,
1272,1384
0907,1662
1578
1578
1578
Monograph
58
Yes
Yes
Yes
Yes
Yes
Yes
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
Leaflet Storage
a
a
a
a
g
g
a
a
a
a
a
a
a
c
a
a
a
a
a
a
a
a
a
a
a
l
a
a
a
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
For extra charges please see 2.2
1378
102500 IU per vial
1058,20702
0747
1769
1769
2119
2119
0573
(2¢£)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4)dimethoxyphenyl)- 0573
ethyl](methyl)amino]ethyl]-3-methylbutanenitrile
5,5'-[[2-(3,4)dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxy 0573
-phenyl)-2-(1-methylethyl)pentanenitrile
(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-te
tramethyl-1-oxodecahydro-3a,9-propano-3aH-cyclopenta[8]ann
ulen-8-yl 2-hydroxyacetate (pleuromulin)
98.7% C–—H—‡NœOŒŒS
5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]
benzene-1,4-dione (ubiquinone-9)
87.75% C–ŸH÷œClœNœOÿ
1035 IU per mg
Information
Unit Sale
Quantity Unit
100 mg 1 0.707 microkatal per mg
6 December 2006
4
n/a
4
n/a
2
n/a
1
1
1
1
1
1
1
1
1
1
1
2
3
Zinc acexamate
Zinc acexamate impurity A
Zolpidem tartrate - * psy
Zolpidem impurity A
Zopiclone -* psy
Zopiclone oxide
Zuclopenthixol decanoate - reference spectrum
Zuclopenthixol for system suitability
Zuclopenthixol impurity B
Z2000000
Z2000010
Z2500000
Z2500010
Z3000000
Z3001000
Y0000062
Y0000534
Y0000083
© Council of Europe, all rights reserved 2006
1
Z1904000 Zidovudine impurity B
1
2
n/a
1
1
1
1
2
X0200000 Xylose
Z1900000 Zidovudine
Z1902000 Zidovudine impurity A
Vinblastine sulphate
Vinblastine sulphate - reference spectrum
Vincristine sulphate
Vincristine sulphate - reference spectrum
Vindesine sulphate
Vindesine sulphate - reference spectrum
Vinorelbine tartrate
Vinorelbine impurity B
Warfarin sodium
Xylazine hydrochloride
Xylazine impurity C
Xylazine impurity E
Xylitol
Xylometazoline hydrochloride
Xylometazoline impurity A
V0300000
V0305000
V0400000
V0405000
V0500000
V0500010
Y0000463
Y0000464
W0100000
X0075000
Y0000158
Y0000159
X0080000
X0100000
X0101000
Batch
1
1
Reference Standard
Order
Code
Y0000661 Verbenalin
V0180000 VERO cells
Catalogue No. 48-2006/4
60 mg
20 mg
n/a
0.1 mg
10 mg
50 mg
50 mg
150 mg
10 mg
10 mg
100 mg
60 mg
10 mg
1
1
1
1
1
1
1
1
1
1
1
1
1
59
2-chloro-9H-thioxanthen-9-one
N,N'-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazol[1,2-a]
pyridin-3-yl]acetamide ; Batch 2 is valid until 31 January 2007
6-[[6-(acetylamino)hexanoyl]amino]hexanoic acid
1060
1060
1707
1707
1707
1279
1279
1280
1280
1278
99.7% CŒÕHŒ–N—O÷
1059
1-[(2¢,5£)-5-hydroxymethyl-2,5-dihydro-2-furyl]-5-methyl
1059
pyrimidine-2,4(1§,3§)-dione
1-(3-chloro-2,3-dideoxy-ß-D-ribofuranosyl)-5-methylpyrimidine- 1059
2,4(1§,3§)-dione
Yes
Yes
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
+5°C
-20°C
-20°C
-20°C
+5°C
-180°C
Leaflet Storage
j
a
l
c
a
a
a
j
a
a
a
a
a
c
l
c
l
c
l
c
c
g
a
a
a
a
g
a
79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 79 Extra
Price
charges
79 a
100 d
For extra charges please see 2.2
Information
Unit Sale
Monograph
Quantity Unit
11 mg
1 0.97 mg CŒŸHœ÷OŒÕ
1854
1 ml
2 Cell lines (kidney, african green monkey, Cercopithecus aethiops) 0213,0538,1057
titration of live measles, mumps and rubella vaccines
5 mg
1 5.01 mg per vial of C÷ÿHÿÕN÷OŒ–S
0748,0749
n/a
1
0748
4.98 mg 1 4.98 mg per vial of C÷ÿH—‡N÷OŒ÷S
0748,0749
n/a
1
0749
5 mg
1 5.11 mg of C÷–H—ŸN—OŒŒS
1276
n/a
1
1276
40 mg
1
2107
4-O-deacetylvinorelbine
7 mg
1
2107
100 mg 1
0698,0699
125 mg 1
1481
50 mg
1 2,6-dimethylphenyl isothiocyanate
1481
87.5%
CŒÕHŒ–NSœ;
N-(2,6-dimethylphenyl)-S-methyldithiourea
50 mg
1
1481
500 mg 1 99.2% C—HŒœO—
1381
100 mg 1
0972,1162
10 mg
1 N-(2-aminoethyl)-2-(4-1,1-dimethylethyl-2,6-dimethylphenyl)
1162
acetamide
6 December 2006

Documents pareils

European Pharmacopoeia - courtage analyses services

European Pharmacopoeia - courtage analyses services For reference substances and preparations supplied in sealed glass ampoules the following technique is suitable for opening the ampule: tap gently to collect the material at the lower end, score th...

Plus en détail

Le Loup-Garou - jean

Le Loup-Garou - jean # œ n n œœ # n œœ # œ b œ n œ nœ 74 n n œœ n œ b n œœ n œ b b œœ b n œœ # œ n # œœ n œ p ƒ #œ #œ 74 # œ n œ n œ # œ n n œœ # œ n b œœ

Plus en détail